Cancer	Gene	PMID	Sentence
Prostate Adenocarcinoma	PDGFRL	9197531	Although loss of heterozygosity at the PRLTS gene locus is a relatively common abnormality, mutation of this gene is rare in prostate cancer.
Prostate Adenocarcinoma	SRD5A2	18780294	The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
Prostate Adenocarcinoma	TP53	9649454	Because others have reported p53 mutations and overexpression of p53 protein in Barrett's esophagus, we studied p53 antibodies in plasma of 88 serially endoscoped patients: 36 with Barrett's metaplasia, 23 with esophageal squamous cell carcinoma, 10 with esophageal adenocarcinoma, and 19 with esophagitis or normal esophagus.
Prostate Adenocarcinoma	PSCA	19822092	High expression of prostate stem cell antigen (PSCA) has been shown to be associated with adverse prognostic features in clinically-diagnosed prostate cancer.
Prostate Adenocarcinoma	BRCA1	21520156	Moreover, to better elucidate whether deleterious BRCA1 mutations are involved in the development of prostate cancer, we performed a systematic review and a meta-analysis of BRCA1 studies on prostate cancer.
Prostate Adenocarcinoma	TIMP1	19747478	Inhibition of TSP-1 induced TIMP-1 levels increased tumor cell invasion.
Prostate Adenocarcinoma	THBS1	19747478	Inhibition of TSP-1 induced TIMP-1 levels increased tumor cell invasion.
Prostate Adenocarcinoma	CAV1	23729330	These findings suggest that loss of Cav-1 in the tumour microenvironment contributes to the metastatic behaviour of tumour cells by a mechanism that involves up-regulation of TGF-beta1 and SNCG through Akt activation.
Prostate Adenocarcinoma	TGFB1	23729330	These findings suggest that loss of Cav-1 in the tumour microenvironment contributes to the metastatic behaviour of tumour cells by a mechanism that involves up-regulation of TGF-beta1 and SNCG through Akt activation.
Prostate Adenocarcinoma	AKT1	23729330	These findings suggest that loss of Cav-1 in the tumour microenvironment contributes to the metastatic behaviour of tumour cells by a mechanism that involves up-regulation of TGF-beta1 and SNCG through Akt activation.
Prostate Adenocarcinoma	SNCG	23729330	These findings suggest that loss of Cav-1 in the tumour microenvironment contributes to the metastatic behaviour of tumour cells by a mechanism that involves up-regulation of TGF-beta1 and SNCG through Akt activation.
Prostate Adenocarcinoma	TP53	9649454	Six antibody-positive cancer patients had p53 mutations, whereas 2 patients with cancer and 1 with Barrett's esophagus with antibodies had p53 protein overexpressed in esophageal tissues.
Prostate Adenocarcinoma	PTEN	15492994	We therefore conclude that, in contrast to prostate cancer, mutations in the PTEN gene seem not to affect cellular distribution of the beta-catenin protein in endometrial carcinomas.
Prostate Adenocarcinoma	CTNNB1	15492994	We therefore conclude that, in contrast to prostate cancer, mutations in the PTEN gene seem not to affect cellular distribution of the beta-catenin protein in endometrial carcinomas.
Prostate Adenocarcinoma	CNBP	12238242	EGF, for instance, is also able to activate lipogenesis via the SREBP pathway and activation of the P13 kinase system by inactivation of PTEN (a phenomenon observed in some 50% of the prostate cancers) also causes increased lipogenesis.
Prostate Adenocarcinoma	PTEN	12238242	EGF, for instance, is also able to activate lipogenesis via the SREBP pathway and activation of the P13 kinase system by inactivation of PTEN (a phenomenon observed in some 50% of the prostate cancers) also causes increased lipogenesis.
Prostate Adenocarcinoma	COX2	10579801	Aberrant or increased expression of cyclooxygenase (COX)-2 has been implicated in the pathogenesis of many diseases including carcinogenesis.
Prostate Adenocarcinoma	ID1	14688027	Previously, we reported that over-expression of the helix-loop-helix protein Id-1 was associated with progression of prostate cancer and ectopic expression of Id-1 induced serum-independent proliferation in prostate cancer cells.
Prostate Adenocarcinoma	RB1	8834174	These results suggest alterations of RB1 mRNA expression occur more frequently in higher stages and grades of prostate cancer and, thus, may be contributing to the malignant progression of a subset of human prostate cancer.
Prostate Adenocarcinoma	AR	10428464	The ligand specificity of the induction reflects the altered specificity of the mutated androgen receptor in LNCaP.
Prostate Adenocarcinoma	ERBB2	25871401	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Prostate Adenocarcinoma	AR	25871401	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Prostate Adenocarcinoma	YBX1	25871401	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Prostate Adenocarcinoma	SRD5A2	18780294	METHODS: Thirty-three men with early onset prostate cancer (PCa) were genotyped for the SRD5A2 V89L substitution and other polymorphisms in genes encoding receptors or enzymes that play important roles in pathways of steroid metabolism to ascertain if they were associated with standard clinical measures of disease progression at the time of diagnosis.
Prostate Adenocarcinoma	AMACR	17067752	BACKGROUND: High-throughput gene expression profiling has recently shown that the mRNA for alpha-methylacyl CoA racemase (AMACR or P504S) is overexpressed in prostate carcinomas (PCa).
Prostate Adenocarcinoma	ALOX12	14669797	Alteration in 12-LOX expression or activity has been reported in various carcinomas including prostate carcinoma.
Prostate Adenocarcinoma	PRB2	12060621	Interestingly, one specimen in which we also found a high-grade prostatic intraepithelial neoplasia showed the progressive loss of pRb2/p130 from normal prostatic cells to prostatic intraepithelial neoplasia cells, suggesting that in prostatic cancer, lack of expression of the tumor suppressor gene pRb2/p130 could be involved in the progression of the disease, from an early stage.
Prostate Adenocarcinoma	RBL2	12060621	Interestingly, one specimen in which we also found a high-grade prostatic intraepithelial neoplasia showed the progressive loss of pRb2/p130 from normal prostatic cells to prostatic intraepithelial neoplasia cells, suggesting that in prostatic cancer, lack of expression of the tumor suppressor gene pRb2/p130 could be involved in the progression of the disease, from an early stage.
Prostate Adenocarcinoma	BACH1	28889753	Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression.
Prostate Adenocarcinoma	HSD3B1	17826523	CONCLUSIONS: These results suggest that the HSD3B1 N367T and UGT2B17 null polymorphisms may modify the risk of prostate cancer, particularly among men with a family history of the disease.
Prostate Adenocarcinoma	UGT2B17	17826523	CONCLUSIONS: These results suggest that the HSD3B1 N367T and UGT2B17 null polymorphisms may modify the risk of prostate cancer, particularly among men with a family history of the disease.
Prostate Adenocarcinoma	TGFB1	21757379	Surprisingly, T cell- but not Treg cell-specific ablation of TGF-beta1 was sufficient to augment T cell cytotoxic activity and blocked tumor growth and metastases.
Prostate Adenocarcinoma	AR	11304731	Examination of CWR22R cells, which express the AR but are androgen-independent, identified an in-frame duplication of exon 3, which resulted in insertion of 39 amino acids in the DNA-binding domain.
Prostate Adenocarcinoma	CXCR2	25512615	The molecular etiology of this prostate cancer variant is not well understood; however, mutation of the p53 (TP53) tumor suppressor in prostate neuroendocrine cells inactivates the IL8-CXCR2-p53 pathway that normally inhibits cellular proliferation, leading to the development of SCNC.
Prostate Adenocarcinoma	TP53	25512615	The molecular etiology of this prostate cancer variant is not well understood; however, mutation of the p53 (TP53) tumor suppressor in prostate neuroendocrine cells inactivates the IL8-CXCR2-p53 pathway that normally inhibits cellular proliferation, leading to the development of SCNC.
Prostate Adenocarcinoma	AURKA	25512615	Therefore, the relationship of these two molecular events was studied, and we show that p53 mutation leads to increased expression of miR-25 and downregulation of the E3 ubiquitin ligase FBXW7, resulting in elevated levels of Aurora kinase A.
Prostate Adenocarcinoma	TP53	25512615	Therefore, the relationship of these two molecular events was studied, and we show that p53 mutation leads to increased expression of miR-25 and downregulation of the E3 ubiquitin ligase FBXW7, resulting in elevated levels of Aurora kinase A.
Prostate Adenocarcinoma	MIR25	25512615	Therefore, the relationship of these two molecular events was studied, and we show that p53 mutation leads to increased expression of miR-25 and downregulation of the E3 ubiquitin ligase FBXW7, resulting in elevated levels of Aurora kinase A.
Prostate Adenocarcinoma	FBXW7	25512615	Therefore, the relationship of these two molecular events was studied, and we show that p53 mutation leads to increased expression of miR-25 and downregulation of the E3 ubiquitin ligase FBXW7, resulting in elevated levels of Aurora kinase A.
Prostate Adenocarcinoma	KLK2	27819754	In prostate adenocarcinoma, besides mutations in BRCA1 and BRCA2 genes that are known to increase the incidence of high-risk cancer in young patients, new studies have shown mutation in other gene such as HOXB13 and also polymorphisms in MYC, MSMB, KLK2 and KLK3 that can be related to hereditary prostate cancer.
Prostate Adenocarcinoma	MSMB	27819754	In prostate adenocarcinoma, besides mutations in BRCA1 and BRCA2 genes that are known to increase the incidence of high-risk cancer in young patients, new studies have shown mutation in other gene such as HOXB13 and also polymorphisms in MYC, MSMB, KLK2 and KLK3 that can be related to hereditary prostate cancer.
Prostate Adenocarcinoma	KLK3	27819754	In prostate adenocarcinoma, besides mutations in BRCA1 and BRCA2 genes that are known to increase the incidence of high-risk cancer in young patients, new studies have shown mutation in other gene such as HOXB13 and also polymorphisms in MYC, MSMB, KLK2 and KLK3 that can be related to hereditary prostate cancer.
Prostate Adenocarcinoma	MYC	27819754	In prostate adenocarcinoma, besides mutations in BRCA1 and BRCA2 genes that are known to increase the incidence of high-risk cancer in young patients, new studies have shown mutation in other gene such as HOXB13 and also polymorphisms in MYC, MSMB, KLK2 and KLK3 that can be related to hereditary prostate cancer.
Prostate Adenocarcinoma	HOXB13	27819754	In prostate adenocarcinoma, besides mutations in BRCA1 and BRCA2 genes that are known to increase the incidence of high-risk cancer in young patients, new studies have shown mutation in other gene such as HOXB13 and also polymorphisms in MYC, MSMB, KLK2 and KLK3 that can be related to hereditary prostate cancer.
Prostate Adenocarcinoma	BRCA1	27819754	In prostate adenocarcinoma, besides mutations in BRCA1 and BRCA2 genes that are known to increase the incidence of high-risk cancer in young patients, new studies have shown mutation in other gene such as HOXB13 and also polymorphisms in MYC, MSMB, KLK2 and KLK3 that can be related to hereditary prostate cancer.
Prostate Adenocarcinoma	BRCA2	27819754	In prostate adenocarcinoma, besides mutations in BRCA1 and BRCA2 genes that are known to increase the incidence of high-risk cancer in young patients, new studies have shown mutation in other gene such as HOXB13 and also polymorphisms in MYC, MSMB, KLK2 and KLK3 that can be related to hereditary prostate cancer.
Prostate Adenocarcinoma	TP53	8078807	Mutations and overexpression of p53 gene in prostate carcinoma have been found but their significance in the development and progression of cancer is so far unknown.
Prostate Adenocarcinoma	SRC	12642901	Moreover, homotypic aggregation of the mutant src transfectant cells was not enhanced by KAI1/CD82 ligation with anti- CD82 antibody.
Prostate Adenocarcinoma	CD82	12642901	Moreover, homotypic aggregation of the mutant src transfectant cells was not enhanced by KAI1/CD82 ligation with anti- CD82 antibody.
Prostate Adenocarcinoma	MLH1	27013479	Prostate cancer was associated with mutations in MSH2, MLH1 and MSH6 with loss of the respective mismatch repair protein in 69 % of the tumors, though a MSI-high phenotype was restricted to 13 % of the tumors.
Prostate Adenocarcinoma	RBBP4	27013479	Prostate cancer was associated with mutations in MSH2, MLH1 and MSH6 with loss of the respective mismatch repair protein in 69 % of the tumors, though a MSI-high phenotype was restricted to 13 % of the tumors.
Prostate Adenocarcinoma	MSH2	27013479	Prostate cancer was associated with mutations in MSH2, MLH1 and MSH6 with loss of the respective mismatch repair protein in 69 % of the tumors, though a MSI-high phenotype was restricted to 13 % of the tumors.
Prostate Adenocarcinoma	MSH6	27013479	Prostate cancer was associated with mutations in MSH2, MLH1 and MSH6 with loss of the respective mismatch repair protein in 69 % of the tumors, though a MSI-high phenotype was restricted to 13 % of the tumors.
Prostate Adenocarcinoma	AR	20173765	The AR (T559S) mutation may contribute to the disease by altering AR DNA-binding affinity and/or its response to androgens, non-androgenic steroids or anti-androgens.
Prostate Adenocarcinoma	KLK3	7522415	In conclusion, 3 months of neoadjuvant androgen ablation for localized prostatic carcinoma significantly lowers serum PSA and prostatic volume and produces involutional changes in residual carcinomas that mimic high-grade disease.
Prostate Adenocarcinoma	AURKA	25512615	This study demonstrates an intracellular pathway by which p53 mutation leads to Aurora kinase A expression, which is critically important for the rapid proliferation and aggressive behavior of prostatic SCNC.
Prostate Adenocarcinoma	TP53	25512615	This study demonstrates an intracellular pathway by which p53 mutation leads to Aurora kinase A expression, which is critically important for the rapid proliferation and aggressive behavior of prostatic SCNC.
Prostate Adenocarcinoma	BRCA1	21520156	Moreover, the result of the meta-analysis also discards the involvement of BRCA1 mutations in the development of prostate cancer.
Prostate Adenocarcinoma	ETV1	19465903	Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas.
Prostate Adenocarcinoma	TMPRSS2	19465903	Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas.
Prostate Adenocarcinoma	ETV5	19465903	Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas.
Prostate Adenocarcinoma	ETV4	19465903	Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas.
Prostate Adenocarcinoma	ERG	19465903	Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas.
Prostate Adenocarcinoma	POU2F1	19058140	EMSA revealed that Oct1 bound the motif, and that the mutations that abolished DHT responsiveness in the transfection assays augmented Oct1 binding.
Prostate Adenocarcinoma	GPX1	23363810	However, the GPx1 rs1050450 allele T in association with prostate cancer recorded a significantly higher GPx activity compared to the controls.
Prostate Adenocarcinoma	VDR	32918214	It seems probable that other factors such as ethnicity, phenotype, 25(OH)D plasma levels, and UV radiation exposure play a role as confounding factors and introduce heterogeneity.To conclude, there is some indication that VDR polymorphisms may modulate the risk of some cancer sites and in future studies VDR genetic variation should be integrated also with assessment of vitamin D status and stratified by ethnicity.
Prostate Adenocarcinoma	TP53	8610059	In conclusion, this study may indicate that either p53 gene mutation or the presence of HPV's oncogenic protein E6 is involved in the development of prostate cancer.
Prostate Adenocarcinoma	PDGFRA	20442296	Our studies show that this truncated PDGFRalpha is able to restore bone-metastatic potential of prostate cancer cells as effectively as the full-length form of the receptor.
Prostate Adenocarcinoma	XRCC1	23684781	BACKGROUND: We assessed the effect of excision repair cross-complementing group 1 (ERCC1) and x-ray cross-complementing group 1 (XRCC1) gene polymorphisms on treatment outcomes with satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Prostate Adenocarcinoma	ERCC1	23684781	BACKGROUND: We assessed the effect of excision repair cross-complementing group 1 (ERCC1) and x-ray cross-complementing group 1 (XRCC1) gene polymorphisms on treatment outcomes with satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Prostate Adenocarcinoma	GPX1	23363810	Three SNPs, namely GPx1 rs1050450, SEL15 rs5845 and CAT rs1001179, were significantly associated with prostate disease risk.
Prostate Adenocarcinoma	IL6	19965896	Genetic variants in the interleukin-6 (IL6) and prostaglandin-endoperoxide synthase-2 (PTGS2, encoding for the COX-2 enzyme) genes, in particular, have been related to several cancer types, including breast and prostate cancers.
Prostate Adenocarcinoma	PTGS2	19965896	Genetic variants in the interleukin-6 (IL6) and prostaglandin-endoperoxide synthase-2 (PTGS2, encoding for the COX-2 enzyme) genes, in particular, have been related to several cancer types, including breast and prostate cancers.
Prostate Adenocarcinoma	COX2	19965896	Genetic variants in the interleukin-6 (IL6) and prostaglandin-endoperoxide synthase-2 (PTGS2, encoding for the COX-2 enzyme) genes, in particular, have been related to several cancer types, including breast and prostate cancers.
Prostate Adenocarcinoma	AR	29530944	Recent findings implicate AR signaling in control of DNA repair and show that alterations in DNA damage repair pathways are strongly associated with disease progression and poor outcome.
Prostate Adenocarcinoma	LAMB3	30850586	Inhibition of LAMB3 abrogated the tumorigenic outcomes of PI3K/Akt signaling pathway activation, including those involving cell cycle arrest, cell apoptosis, proliferation, invasion and migration in vitro, and tumor growth and liver metastasis in vivo.
Prostate Adenocarcinoma	TP53	8688333	Mutations in the p53 tumour-suppressor gene are among the most common genetic alterations in human cancers.
Prostate Adenocarcinoma	CCND1	10939590	Similarly, ectopic expression of CDK4/cyclin D1, which stimulated RB phosphorylation in the presence of androgen, was incapable of inactivating RB or driving cell cycle progression in the absence of androgen.
Prostate Adenocarcinoma	CDK4	10939590	Similarly, ectopic expression of CDK4/cyclin D1, which stimulated RB phosphorylation in the presence of androgen, was incapable of inactivating RB or driving cell cycle progression in the absence of androgen.
Prostate Adenocarcinoma	MAP3K7	30656528	Lower ERG expression in dural and intraparenchymal metastases suggests a possibility that ERG-negative tumors with loss of MAP3K7 may become resistant to standard therapies and diffusely metastasize.
Prostate Adenocarcinoma	ERG	30656528	Lower ERG expression in dural and intraparenchymal metastases suggests a possibility that ERG-negative tumors with loss of MAP3K7 may become resistant to standard therapies and diffusely metastasize.
Prostate Adenocarcinoma	BRCA2	18288683	Mutations in BRCA2 have been associated with increased prostate cancer risk and account for around 2% of young onset (&lt;56 years) prostate cancer cases.
Prostate Adenocarcinoma	EDNRB	12499435	CONCLUSIONS: EDNRB hypermethylation at CpG sites upstream of the transcription start site can be detected in a high proportion of prostate adenocarcinomas.
Prostate Adenocarcinoma	TP53	24324286	The results show that clinical characteristics were not determinant on the developing of radiation sensitivity in prostate cancer patients, and intronic TP53 polymorphisms would be associated with increased acute and chronic radiation toxicities.
Prostate Adenocarcinoma	PIK3CA	11830512	As part of our efforts to elucidate the mechanisms responsible for FAS overexpression, we have addressed the question whether overexpression of FAS may be linked to the frequently observed inactivation of PTEN and subsequent activation of the phosphatidylinositol 3'-kinase (PI3k) pathway.
Prostate Adenocarcinoma	PTEN	11830512	As part of our efforts to elucidate the mechanisms responsible for FAS overexpression, we have addressed the question whether overexpression of FAS may be linked to the frequently observed inactivation of PTEN and subsequent activation of the phosphatidylinositol 3'-kinase (PI3k) pathway.
Prostate Adenocarcinoma	FASN	11830512	As part of our efforts to elucidate the mechanisms responsible for FAS overexpression, we have addressed the question whether overexpression of FAS may be linked to the frequently observed inactivation of PTEN and subsequent activation of the phosphatidylinositol 3'-kinase (PI3k) pathway.
Prostate Adenocarcinoma	BRCA2	27197191	We also identified a known breast cancer locus CASP8/ALS2CR12 associated with prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated with lung adenocarcinoma and prostate cancer, and confirmed the associations of a breast BRCA2 locus with lung and serous ovarian cancer.
Prostate Adenocarcinoma	FLACC1	27197191	We also identified a known breast cancer locus CASP8/ALS2CR12 associated with prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated with lung adenocarcinoma and prostate cancer, and confirmed the associations of a breast BRCA2 locus with lung and serous ovarian cancer.
Prostate Adenocarcinoma	CASP8	27197191	We also identified a known breast cancer locus CASP8/ALS2CR12 associated with prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated with lung adenocarcinoma and prostate cancer, and confirmed the associations of a breast BRCA2 locus with lung and serous ovarian cancer.
Prostate Adenocarcinoma	CDKN2B-AS1	27197191	We also identified a known breast cancer locus CASP8/ALS2CR12 associated with prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated with lung adenocarcinoma and prostate cancer, and confirmed the associations of a breast BRCA2 locus with lung and serous ovarian cancer.
Prostate Adenocarcinoma	ALK	29559559	Alterations in anaplastic lymphoma kinase (ALK) gene are involved in neuroblastoma, lung cancer, and other malignancies, but its role in SCCP has not been documented.
Prostate Adenocarcinoma	ERG	24516518	ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
Prostate Adenocarcinoma	TMPRSS2	19396154	In conclusion, we found that TMPRSS2-ERG gene fusion is associated with the zonal origin of prostate cancer.
Prostate Adenocarcinoma	ERG	19396154	In conclusion, we found that TMPRSS2-ERG gene fusion is associated with the zonal origin of prostate cancer.
Prostate Adenocarcinoma	TMPRSS2	16983328	Considering the high incidence of prostate cancer and the high frequency of this gene fusion, the TMPRSS2-ETS gene fusions are the most common genetic aberration so far described in human malignancies.
Prostate Adenocarcinoma	SATB1	23308245	Consequently, knockdown of SATB1 in highly aggressive human prostate cancer PC-3M cells inhibited invasiveness and tumor growth in vivo along with increase in E-cadherin protein expression.
Prostate Adenocarcinoma	CDH1	23308245	Consequently, knockdown of SATB1 in highly aggressive human prostate cancer PC-3M cells inhibited invasiveness and tumor growth in vivo along with increase in E-cadherin protein expression.
Prostate Adenocarcinoma	AR	14618630	Androgen receptor (AR) mutations that modify both the ligand binding and the transactivation capacities of the AR represent one of the mechanisms involved in the transition of prostate cancer (PCa) from androgen-dependent to androgen-independent growth.
Prostate Adenocarcinoma	XRCC1	18582155	Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Prostate Adenocarcinoma	XRCC3	18582155	Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Prostate Adenocarcinoma	SOD2	18582155	Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Prostate Adenocarcinoma	AR	12941814	In addition, activation of a common tumor-derived AR allele by 17 beta-estradiol and progesterone was inhibited through ectopic expression of cyclin D1.
Prostate Adenocarcinoma	CCND1	12941814	In addition, activation of a common tumor-derived AR allele by 17 beta-estradiol and progesterone was inhibited through ectopic expression of cyclin D1.
Prostate Adenocarcinoma	PCAT5	26282172	Genome-wide expression analysis of a PCAT5-positive prostate cancer after PCAT5 silencing highlighted alterations in cell proliferation pathways.
Prostate Adenocarcinoma	LMO2	17167821	Immunohistochemical analysis on a tissue microarray consisting of 91 human prostate specimens, including normal, prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, and invasive carcinoma, revealed that overexpression of LMO2 was significantly associated with advanced tumour stage, as measured by Gleason score (p = 0.012), as well as with the development of distant metastasis (p = 0.018).
Prostate Adenocarcinoma	IL1B	23880210	The aims of this study were 1) to evaluate whether polymorphisms and haplotypes of the inflammation-related genes COX-2, Il1B, NFKB1, and PPARG are associated with risk of PC; 2) to investigate gene-environment interactions between polymorphisms and NSAID use; and 3) to examine whether the studied polymorphisms were associated with the aggressiveness of PC.
Prostate Adenocarcinoma	NFKB1	23880210	The aims of this study were 1) to evaluate whether polymorphisms and haplotypes of the inflammation-related genes COX-2, Il1B, NFKB1, and PPARG are associated with risk of PC; 2) to investigate gene-environment interactions between polymorphisms and NSAID use; and 3) to examine whether the studied polymorphisms were associated with the aggressiveness of PC.
Prostate Adenocarcinoma	COX2	23880210	The aims of this study were 1) to evaluate whether polymorphisms and haplotypes of the inflammation-related genes COX-2, Il1B, NFKB1, and PPARG are associated with risk of PC; 2) to investigate gene-environment interactions between polymorphisms and NSAID use; and 3) to examine whether the studied polymorphisms were associated with the aggressiveness of PC.
Prostate Adenocarcinoma	PPARG	23880210	The aims of this study were 1) to evaluate whether polymorphisms and haplotypes of the inflammation-related genes COX-2, Il1B, NFKB1, and PPARG are associated with risk of PC; 2) to investigate gene-environment interactions between polymorphisms and NSAID use; and 3) to examine whether the studied polymorphisms were associated with the aggressiveness of PC.
Prostate Adenocarcinoma	ADSL	29467457	Knockdown of ADSL in endometrial cancer cells decreased cell proliferation, migration, and invasive capability, and caused the cells to adopt a more rounded shape.
Prostate Adenocarcinoma	AR	14618630	Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.
Prostate Adenocarcinoma	CASP3	21229607	Additionally, DIM induced increases in the levels of cleaved caspase-8, truncated Bid, Fas, and Fas ligand, and the caspase-8 inhibitor Z-IETD-FMK was shown to mitigate DIM-induced apoptosis and the cleavage of caspase-3, PARP, and Bid.
Prostate Adenocarcinoma	CASP8	21229607	Additionally, DIM induced increases in the levels of cleaved caspase-8, truncated Bid, Fas, and Fas ligand, and the caspase-8 inhibitor Z-IETD-FMK was shown to mitigate DIM-induced apoptosis and the cleavage of caspase-3, PARP, and Bid.
Prostate Adenocarcinoma	BID	21229607	Additionally, DIM induced increases in the levels of cleaved caspase-8, truncated Bid, Fas, and Fas ligand, and the caspase-8 inhibitor Z-IETD-FMK was shown to mitigate DIM-induced apoptosis and the cleavage of caspase-3, PARP, and Bid.
Prostate Adenocarcinoma	FASLG	21229607	Additionally, DIM induced increases in the levels of cleaved caspase-8, truncated Bid, Fas, and Fas ligand, and the caspase-8 inhibitor Z-IETD-FMK was shown to mitigate DIM-induced apoptosis and the cleavage of caspase-3, PARP, and Bid.
Prostate Adenocarcinoma	PARP1	21229607	Additionally, DIM induced increases in the levels of cleaved caspase-8, truncated Bid, Fas, and Fas ligand, and the caspase-8 inhibitor Z-IETD-FMK was shown to mitigate DIM-induced apoptosis and the cleavage of caspase-3, PARP, and Bid.
Prostate Adenocarcinoma	KDM1A	32403054	Recently, a neural-specific transcript variant of LSD1-LSD1+8a-was discovered and demonstrated to activate neuronal gene expression in neural cells.
Prostate Adenocarcinoma	PAQR3	29122400	We hypothesized that promoter methylation could be responsible for PAQR3 silencing in prostate cancer tissues.
Prostate Adenocarcinoma	DEFB1	16951166	Previously, we showed that cancer-specific loss of hBD-1 was found in 90% of renal clear cell carcinomas and in 82% of prostate cancers.
Prostate Adenocarcinoma	PCAT1	31464517	Our results suggested that polymorphisms in lncRNA-PCAT1 might be associated with lung cancer susceptibility in a northeastern Chinese population.
Prostate Adenocarcinoma	NPEPPS	29315911	SOX11 hypermethylation was associated with adverse clinicopathological characteristics of prostate cancer, including higher PSA level (P &lt; 0.01), Gleason score &gt;= 7 (P = 0.03) and perineural invasion (P = 0.03).
Prostate Adenocarcinoma	SOX11	29315911	SOX11 hypermethylation was associated with adverse clinicopathological characteristics of prostate cancer, including higher PSA level (P &lt; 0.01), Gleason score &gt;= 7 (P = 0.03) and perineural invasion (P = 0.03).
Prostate Adenocarcinoma	KLK3	11791186	While wild type p53 strongly repressed, dominant negative p53 mutants stimulated PSA promoter-driven transcription and secretion of PSA in transient transfection experiments.
Prostate Adenocarcinoma	TP53	11791186	While wild type p53 strongly repressed, dominant negative p53 mutants stimulated PSA promoter-driven transcription and secretion of PSA in transient transfection experiments.
Prostate Adenocarcinoma	CYP19A1	19952760	This study examined whether the genetic polymorphisms of estrogen receptors (ESR-alpha and ESR-beta) and cytochrome P450 19A1 (CYP19A1) modified the protective effect of isoflavones against prostate cancer.
Prostate Adenocarcinoma	ESR1	19952760	This study examined whether the genetic polymorphisms of estrogen receptors (ESR-alpha and ESR-beta) and cytochrome P450 19A1 (CYP19A1) modified the protective effect of isoflavones against prostate cancer.
Prostate Adenocarcinoma	ESR2	19952760	This study examined whether the genetic polymorphisms of estrogen receptors (ESR-alpha and ESR-beta) and cytochrome P450 19A1 (CYP19A1) modified the protective effect of isoflavones against prostate cancer.
Prostate Adenocarcinoma	CD44	10344738	Hypermethylation of the 5' CpG island of CD44 gene was observed in 31 of 40 primary prostate cancer specimens, 3 of 4 distant organ site metastases obtained at autopsy from men who died of prostate cancer, and 4 of the 40 matched normal tissues.
Prostate Adenocarcinoma	BRCA2	28067867	Germline mutations in the BRCA2 tumour suppressor are associated with both an increased lifetime risk of developing prostate cancer (PCa) and increased risk of aggressive disease.
Prostate Adenocarcinoma	NODAL	25456955	High Nodal expression was associated with older age and BRAF mutation in PTC.
Prostate Adenocarcinoma	BRAF	25456955	High Nodal expression was associated with older age and BRAF mutation in PTC.
Prostate Adenocarcinoma	KLK3	15241826	CONCLUSIONS: Prostate carcinoma screening identified abnormal PSA values in 3.2% of the HIV-positive cohort, many associated with prostatitis.
Prostate Adenocarcinoma	PAQR3	29122400	PAQR3 hypermethylation was associated with perineural invasion (p=0.03), an adverse clinicopathological feature of prostate cancer.
Prostate Adenocarcinoma	AR	26311513	This study revealed that an EMT inducer (TGF-beta) induced full-length androgen receptor (AR) and AR variant expression.
Prostate Adenocarcinoma	VEGFA	15905202	In this study, we have demonstrated that overexpression of Id-1 (inhibitor of differentiation/DNA synthesis), a member of the helix-loop-helix family proteins, is a key factor in promoting angiogenesis through activation of the vascular endothelial growth factor (VEGF) in prostate cancer cells.
Prostate Adenocarcinoma	ID1	15905202	In this study, we have demonstrated that overexpression of Id-1 (inhibitor of differentiation/DNA synthesis), a member of the helix-loop-helix family proteins, is a key factor in promoting angiogenesis through activation of the vascular endothelial growth factor (VEGF) in prostate cancer cells.
Prostate Adenocarcinoma	AR	18007998	Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
Prostate Adenocarcinoma	ESR2	18007998	Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
Prostate Adenocarcinoma	BRCA2	28067867	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
Prostate Adenocarcinoma	SOD2	18582155	In addition, patients who had the SOD2 rs4880 T/C (Val16Ala) genotype exhibited a significant increase in grade 2 late rectal bleeding compared to patients who had either the C/C or T/T genotype for this SNP (8% compared to 0%; P=0.02).
Prostate Adenocarcinoma	XRCC1	18582155	Patients with the XRCC1 rs25489 G/A (Arg280His) genotype were more likely to develop erectile dysfunction after irradiation than patients who had the G/G genotype (67% compared to 24%; P=0.048).
Prostate Adenocarcinoma	GSTP1	12576869	CONCLUSIONS: Quantitation of GSTP1 hypermethylation accurately detects the presence of cancer even in small, limited tissue samples.
Prostate Adenocarcinoma	KLK3	11791186	By using cDNA microarray gene expression profiling, we found a fourfold increase in the PSA mRNA level in prostatic carcinoma cell line LNCaP, in which the p53 pathway was suppressed by a dominant negative p53 mutant.
Prostate Adenocarcinoma	TP53	11791186	By using cDNA microarray gene expression profiling, we found a fourfold increase in the PSA mRNA level in prostatic carcinoma cell line LNCaP, in which the p53 pathway was suppressed by a dominant negative p53 mutant.
Prostate Adenocarcinoma	AR	33664492	Irrespective of treatment exposure, adenocarcinoma cells pervasively coexpressed multiple androgen receptor isoforms, including truncated isoforms hypothesized to mediate resistance to androgen-targeting therapies2,3.
Prostate Adenocarcinoma	PPARG	12609711	Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study.
Prostate Adenocarcinoma	AR	15350307	The presence of short AR alleles and the G allele of the PSA gene may contribute to the development of prostate cancer in a 47,XXY patient.
Prostate Adenocarcinoma	KLK3	15350307	The presence of short AR alleles and the G allele of the PSA gene may contribute to the development of prostate cancer in a 47,XXY patient.
Prostate Adenocarcinoma	EPB41L3	17640904	Down-regulation of 4.1B increased the metastatic propensity of poorly metastatic cells in an orthotopic model of prostate cancer.
Prostate Adenocarcinoma	PVT1	30808975	A long-range interaction of genetic variants with c-MYC or long non-coding PVT1 at this locus contributes to the genetic risk of prostate cancer.
Prostate Adenocarcinoma	MYC	30808975	A long-range interaction of genetic variants with c-MYC or long non-coding PVT1 at this locus contributes to the genetic risk of prostate cancer.
Prostate Adenocarcinoma	MMP14	18196535	Inhibition of IGF-1R in PC-3N cells decreased MT1-MMP expression and treatment of LNCaP cells with a synthetic androgen and IGF-1 increased MT1-MMP expression.
Prostate Adenocarcinoma	IGF1R	18196535	Inhibition of IGF-1R in PC-3N cells decreased MT1-MMP expression and treatment of LNCaP cells with a synthetic androgen and IGF-1 increased MT1-MMP expression.
Prostate Adenocarcinoma	SMARCA4	17075831	CONCLUSIONS: We provide the first evidence that aberrant expression of BRG1 and BRM genes is associated with disease development and progression in prostate cancers and increased BRG1 expression may promote tumor growth and invasion.
Prostate Adenocarcinoma	SMARCA2	17075831	CONCLUSIONS: We provide the first evidence that aberrant expression of BRG1 and BRM genes is associated with disease development and progression in prostate cancers and increased BRG1 expression may promote tumor growth and invasion.
Prostate Adenocarcinoma	PEBP1	25327941	To determine if loss of RKIP alone promotes metastasis, RKIP was knocked down in the low metastatic LNCaP prostate cancer cell line.
Prostate Adenocarcinoma	KIF20A	31565099	Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer.
Prostate Adenocarcinoma	BRCA2	19064968	Consistent with previous reports, BRCA2 mutations are associated with an increased risk of PAC.
Prostate Adenocarcinoma	ARID1A	22009941	Mutations in the chromatin remodeling gene ARID1A have recently been identified in the majority of ovarian clear cell carcinomas (OCCCs).
Prostate Adenocarcinoma	SOX11	29315911	We hypothesized that hypermethylation may be responsible for SOX11 silencing in human prostate cancer.
Prostate Adenocarcinoma	GSTP1	11795433	When cells with defective GSTP1 genes appear amongst the PIA cells, such cells become vulnerable to oxidants and electrophiles that inflict genome damage that tends to promote neoplastic transformation to PIN and PCA cells.
Prostate Adenocarcinoma	NCOA1	19305643	SRC-1 and SRC-3 are overexpressed in multiple human endocrine cancers and knockdown of either one of them in prostate cancer cell lines impedes cellular proliferation.
Prostate Adenocarcinoma	NCOA3	19305643	SRC-1 and SRC-3 are overexpressed in multiple human endocrine cancers and knockdown of either one of them in prostate cancer cell lines impedes cellular proliferation.
Prostate Adenocarcinoma	H3P16	21796649	The expression of mutant (mt-p53) and p21 protein in PC-3 and DU-145 tumors was significantly decreased by treatment with MZ-J-7-138, whereas wild type wt-p53 expression in MDA-PCA-2b tumors was up regulated by treatment with Cetrorelix.
Prostate Adenocarcinoma	TP53	21796649	The expression of mutant (mt-p53) and p21 protein in PC-3 and DU-145 tumors was significantly decreased by treatment with MZ-J-7-138, whereas wild type wt-p53 expression in MDA-PCA-2b tumors was up regulated by treatment with Cetrorelix.
Prostate Adenocarcinoma	AR	32313227	Localization specific delta-catenin mutants influenced p120ctn-dependent Rho GTPase phosphorylation and shifted cells towards differential bFGF-responsive growth and motility, a known signal to bypass androgen receptor dependence.
Prostate Adenocarcinoma	FGF2	32313227	Localization specific delta-catenin mutants influenced p120ctn-dependent Rho GTPase phosphorylation and shifted cells towards differential bFGF-responsive growth and motility, a known signal to bypass androgen receptor dependence.
Prostate Adenocarcinoma	CTNND1	32313227	Localization specific delta-catenin mutants influenced p120ctn-dependent Rho GTPase phosphorylation and shifted cells towards differential bFGF-responsive growth and motility, a known signal to bypass androgen receptor dependence.
Prostate Adenocarcinoma	NQO1	12018106	BACKGROUND: NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T was reportedly associated with leukemia, lung cancer, colorectal cancer, and urological malignancies.
Prostate Adenocarcinoma	CD274	30958600	Programmed death-ligand 1 (PD-L1) is associated with the prognosis of several cancer types, and blockade of PD-1/PD-L1 signaling increases the amplitude of anti-tumor immunity.
Prostate Adenocarcinoma	TMPRSS2	23447416	TMPRSS2-ERG rearrangements occur in approximately 50% of prostate cancers and therefore represent one of the most frequently observed structural rearrangements in all cancers.
Prostate Adenocarcinoma	ERG	23447416	TMPRSS2-ERG rearrangements occur in approximately 50% of prostate cancers and therefore represent one of the most frequently observed structural rearrangements in all cancers.
Prostate Adenocarcinoma	PTEN	23545904	BACKGROUND: ERG rearrangements and PTEN (phosphatase and tensin homolog deleted on chromosome 10) loss are two of the most common genetic alterations in prostate cancer.
Prostate Adenocarcinoma	ERG	23545904	BACKGROUND: ERG rearrangements and PTEN (phosphatase and tensin homolog deleted on chromosome 10) loss are two of the most common genetic alterations in prostate cancer.
Prostate Adenocarcinoma	XRCC3	18582155	Finally, patients with the combination of the SOD2 rs4880 C/T genotype and XRCC3 rs861539 T/C (Thr241Met) genotype experienced a significant increase in grade 2 late rectal bleeding compared to patients without this particular genotypic arrangement (14% compared to 1%; P=0.002).
Prostate Adenocarcinoma	SOD2	18582155	Finally, patients with the combination of the SOD2 rs4880 C/T genotype and XRCC3 rs861539 T/C (Thr241Met) genotype experienced a significant increase in grade 2 late rectal bleeding compared to patients without this particular genotypic arrangement (14% compared to 1%; P=0.002).
Prostate Adenocarcinoma	MYB	26089205	The MYB rearrangement was detected in 2 (29%) of 7 ACC-like carcinomas but in none (0%) of the 5 PBCCs with a prominent solid pattern.
Prostate Adenocarcinoma	PTEN	19396168	Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
Prostate Adenocarcinoma	HOTTIP	29802154	Our study also demonstrated that other SNPs were correlated with overall cancer risk, namely, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1, rs619586 A/G), HOXA distal transcript antisense RNA (HOTTIP, rs1859168 A/C), and highly up-regulated in liver cancer (HULC, rs7763881 A/C).
Prostate Adenocarcinoma	MALAT1	29802154	Our study also demonstrated that other SNPs were correlated with overall cancer risk, namely, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1, rs619586 A/G), HOXA distal transcript antisense RNA (HOTTIP, rs1859168 A/C), and highly up-regulated in liver cancer (HULC, rs7763881 A/C).
Prostate Adenocarcinoma	HOXA@	29802154	Our study also demonstrated that other SNPs were correlated with overall cancer risk, namely, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1, rs619586 A/G), HOXA distal transcript antisense RNA (HOTTIP, rs1859168 A/C), and highly up-regulated in liver cancer (HULC, rs7763881 A/C).
Prostate Adenocarcinoma	CDH1	8339265	Dysfunction of E-cadherin-dependent cell-cell adhesion has been demonstrated to contribute to the acquisition of invasive potential of malignant adenocarcinoma cells.
Prostate Adenocarcinoma	HSPB1	22362414	METHODS: HSP27 protein concentrations in LNCaP and PC-3 cells were modulated by over-expression or silencing of HSP27.
Prostate Adenocarcinoma	NOTCH1	19147749	Because Notch1 was found to be overexpressed in prostate cancer (PCa) cells and human PCa tissue, we therefore tested our hypothesis that overexpression of Notch1 in PCa promotes tumor invasion.
Prostate Adenocarcinoma	CDKN2A	29802154	In the lncRNA antisense non-coding RNA (ncRNA) in the INK4 locus (ANRIL), the rs1333048 A/C, rs4977574 A/G, and rs10757278 A/G polymorphisms, but not rs1333045 C/T, were correlated with overall cancer risk.
Prostate Adenocarcinoma	CDKN2B-AS1	29802154	In the lncRNA antisense non-coding RNA (ncRNA) in the INK4 locus (ANRIL), the rs1333048 A/C, rs4977574 A/G, and rs10757278 A/G polymorphisms, but not rs1333045 C/T, were correlated with overall cancer risk.
Prostate Adenocarcinoma	MAPK14	32313227	Mutant delta-catenin promoted Myc-induced prostate tumorigenesis while increasing bFGF-p38 MAP kinase signaling, beta-catenin-HIF-1alpha expression, and the nuclear size.
Prostate Adenocarcinoma	HIF1A	32313227	Mutant delta-catenin promoted Myc-induced prostate tumorigenesis while increasing bFGF-p38 MAP kinase signaling, beta-catenin-HIF-1alpha expression, and the nuclear size.
Prostate Adenocarcinoma	FGF2	32313227	Mutant delta-catenin promoted Myc-induced prostate tumorigenesis while increasing bFGF-p38 MAP kinase signaling, beta-catenin-HIF-1alpha expression, and the nuclear size.
Prostate Adenocarcinoma	MYC	32313227	Mutant delta-catenin promoted Myc-induced prostate tumorigenesis while increasing bFGF-p38 MAP kinase signaling, beta-catenin-HIF-1alpha expression, and the nuclear size.
Prostate Adenocarcinoma	CTNNB1	32313227	Mutant delta-catenin promoted Myc-induced prostate tumorigenesis while increasing bFGF-p38 MAP kinase signaling, beta-catenin-HIF-1alpha expression, and the nuclear size.
Prostate Adenocarcinoma	MAOA	28402333	Emerging reports showed that overexpression MAOA is associated with prostate cancer (PCa).
Prostate Adenocarcinoma	VEGFA	30195633	However, subgroup analysis based on cancer types demonstrated that significantly increased association was found between VEGF rs699947 polymorphism and the risk of bladder cancer (BCa) under heterozygous genetic model (OR = 1.48, 95%CI = 1.17-1.89).
Prostate Adenocarcinoma	PTEN	30614821	Deletion of phosphatase and tensin homolog (PTEN) in prostate cancer has been associated with early biochemical recurrence, increased metastatic potential, and androgen independence.
Prostate Adenocarcinoma	HOXB13	31264434	Prostate cancer has the strongest degree of heritability, with BRCA1/2 and HOXB13 mutations playing a role in familial disease.
Prostate Adenocarcinoma	MYD88	23235763	Recent studies revealed MYD88 mutation in hematological malignancies and MYD88 overexpression in some solid cancers.
Prostate Adenocarcinoma	AR	24177177	Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.
Prostate Adenocarcinoma	STAT3	24177177	Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.
Prostate Adenocarcinoma	AR	16461912	Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.
Prostate Adenocarcinoma	AR	18007998	In tumors with specific AR mutations, BPA promotes therapeutic bypass, suggesting significant negative impact to the clinical management of prostate cancer.
Prostate Adenocarcinoma	TP53	20953142	RCC cell lines with reduced p53, either by mutation or through ectopic expression of p53 shRNA, demonstrated enhanced sensitivity to cell death following sequential treatment with DNA damage and G2/M checkpoint abrogation.
Prostate Adenocarcinoma	AR	24177177	Here, we demonstrate that loss of AR expression results in STAT3 activation in prostate cancer cells.
Prostate Adenocarcinoma	STAT3	24177177	Here, we demonstrate that loss of AR expression results in STAT3 activation in prostate cancer cells.
Prostate Adenocarcinoma	GSTP1	12475696	RESULTS: In tissue samples, GSTP1 hypermethylation was detected in 63 (91.3%) of the 69 patients with cancer and in 9 (29%) of the 31 patients with benign prostatic hyperplasia.
Prostate Adenocarcinoma	ID1	15905202	Since increased Id-1 has been reported in many types of advanced human cancers, our results indicate that downregulation of Id-1 may be a novel target to inhibit the growth of metastatic cancers through the suppression of angiogenesis.
Prostate Adenocarcinoma	CNN2	28915602	Knockdown of calponin 2 facilitated pancreatic cancer cell proliferation and metastasis.
Prostate Adenocarcinoma	KLK14	18497543	High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.
Prostate Adenocarcinoma	RNASEL	16609730	Mutations or variants that impair function of RNase L, particularly R462Q, have been proposed as susceptibility factors for prostate cancer.
Prostate Adenocarcinoma	BAP1	29061454	BACKGROUND: Germline pathogenic variants in BRCA1-associated protein-1 (BAP1), a nuclear ubiquitin carboxy-terminal hydrolase with evidence suggestive of independent tumor suppressor function, predispose affected families to uveal melanoma, cutaneous melanoma, renal cell carcinoma, malignant mesothelioma, and possibly a range of other tumors and malignancies as part of the BAP1 tumor predisposition syndrome, a recently recognized hereditary cancer syndrome.
Prostate Adenocarcinoma	ERG	24516518	In summary, we reported that ERG rearrangement was associated with cancer-related death in Chinese PCa patients.
Prostate Adenocarcinoma	RILP	33128214	Demethylation treatment enhanced RILP expression in lung cancer cells, suggesting hypermethylation is responsible for RILP silencing in lung cancer.
Prostate Adenocarcinoma	S100A6	15280928	Our data suggest that loss of S100A6 protein expression is common in prostate cancer development and may occur at an early stage.
Prostate Adenocarcinoma	AR	12860943	Mutations of the androgen receptor (AR) gene that broaden ligand specificity have been implicated.
Prostate Adenocarcinoma	SMARCA4	17075831	Consistently, overexpression of exogenous wild-type BRG1 and BRM but not mutant BRG1 enhanced cancer cell invasion in an in vitro cell invasion assay.
Prostate Adenocarcinoma	SMARCA2	17075831	Consistently, overexpression of exogenous wild-type BRG1 and BRM but not mutant BRG1 enhanced cancer cell invasion in an in vitro cell invasion assay.
Prostate Adenocarcinoma	VEGFA	30195633	CONCLUSIONS: In summary, our study showed evidence that the VEGF rs699947 polymorphism was obviously associated with an increased risk of bladder cancer and renal cell carcinoma, particularly in Asian population, while no significant association was observed in overall urologic neoplasms.
Prostate Adenocarcinoma	TENM1	29650325	RESULTS: Mutations in KIT gene are related to aggressive PC: TNM stages II to III, Gleason score &gt;= 7 and D'Amico risk (P = 0.037, 0.040, and 0.017).
Prostate Adenocarcinoma	GSTP1	12475696	GSTP1 hypermethylation was detected by both MSP methods in only one urine sample (3.2%) from a patient with benign prostatic hyperplasia.
Prostate Adenocarcinoma	CDK2	32606936	Furthermore, knockdown of ELL2 caused S-phase cell cycle arrest, inhibition of CDK2 phosphorylation and cyclin D1 expression, and increased expression of cyclin E. Conclusion: ELL2 knockdown in PC-3 and DU145 cells induced S-phase cell cycle arrest and profound apoptosis, which was accompanied by the induction of genes associated with cell death and survival pathways.
Prostate Adenocarcinoma	ELL2	32606936	Furthermore, knockdown of ELL2 caused S-phase cell cycle arrest, inhibition of CDK2 phosphorylation and cyclin D1 expression, and increased expression of cyclin E. Conclusion: ELL2 knockdown in PC-3 and DU145 cells induced S-phase cell cycle arrest and profound apoptosis, which was accompanied by the induction of genes associated with cell death and survival pathways.
Prostate Adenocarcinoma	CCND1	32606936	Furthermore, knockdown of ELL2 caused S-phase cell cycle arrest, inhibition of CDK2 phosphorylation and cyclin D1 expression, and increased expression of cyclin E. Conclusion: ELL2 knockdown in PC-3 and DU145 cells induced S-phase cell cycle arrest and profound apoptosis, which was accompanied by the induction of genes associated with cell death and survival pathways.
Prostate Adenocarcinoma	CYP17A1	32945940	CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
Prostate Adenocarcinoma	MTOR	31264434	Genomic alterations in clear cell renal cell carcinoma can inform prognosis and mutations in mTOR pathways predict response to mTOR inhibitors.
Prostate Adenocarcinoma	TMPRSS2	18500259	TMPRSS2:ERG gene fusions and PTEN deletions are the most common genomic aberrations in prostate cancer.
Prostate Adenocarcinoma	PTEN	18500259	TMPRSS2:ERG gene fusions and PTEN deletions are the most common genomic aberrations in prostate cancer.
Prostate Adenocarcinoma	ERG	18500259	TMPRSS2:ERG gene fusions and PTEN deletions are the most common genomic aberrations in prostate cancer.
Prostate Adenocarcinoma	RHOA	22504159	Consistent with these observations, cAMP elevation triggered the PKA-dependent phosphorylation of RhoA on serine 188, and a non-phosphorylatable Ser188Ala RhoA mutant functioned as a dominant-negative inhibitor of cAMP-mediated neuroendocrine phenotype formation.
Prostate Adenocarcinoma	SPOP	25274033	Somatic missense mutations in the substrate-binding pocket of the E3 ubiquitin ligase adaptor SPOP are present in up to 15% of human prostate adenocarcinomas, but are rare in other malignancies, suggesting a prostate-specific mechanism of action.
Prostate Adenocarcinoma	TLR4	15087412	We found an association between a sequence variant (11381G/C) in the 3'-untranslated region of the TLR4 gene and prostate cancer risk.
Prostate Adenocarcinoma	AR	14618630	This type of mutation, which leads to a c-terminal truncated AR, has not been described yet in PCa.
Prostate Adenocarcinoma	ARID1A	22009941	These findings suggest that the aberrant chromatin remodeling consequent to ARID1A inactivation contributes to a variety of different types of neoplasms.
Prostate Adenocarcinoma	PTEN	19165235	In this study we evaluated whether reintroducing P53 using non-viral gene transfer enhances PTEN-mediated inhibition of PI3K/AKT signaling by cetuximab in PC3 prostate adenocarcinoma cell line bearing p53 and pten mutations.
Prostate Adenocarcinoma	TP53	19165235	In this study we evaluated whether reintroducing P53 using non-viral gene transfer enhances PTEN-mediated inhibition of PI3K/AKT signaling by cetuximab in PC3 prostate adenocarcinoma cell line bearing p53 and pten mutations.
Prostate Adenocarcinoma	ALK	29559559	Prostate cancer databases were queried for alterations in ALK gene, mRNA, and its impact in clinical outcomes.
Prostate Adenocarcinoma	MIR499A	24278149	For miR-499, a significant association was found between the rs3746444 polymorphism and cancer risk in pooled analysis.
Prostate Adenocarcinoma	PTEN	15492994	PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
Prostate Adenocarcinoma	CTNNB1	15492994	PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
Prostate Adenocarcinoma	PTEN	27080984	PTEN protein loss, odds ratio=4.99, P=0.033; MYC/8q gain, odds ratio=5.36, P=0.010; and LPL/8p loss, odds ratio=3.96, P=0.003 were significantly more common in G3 cores derived from Gleason 7 vs Gleason 6 tumors.
Prostate Adenocarcinoma	MYC	27080984	PTEN protein loss, odds ratio=4.99, P=0.033; MYC/8q gain, odds ratio=5.36, P=0.010; and LPL/8p loss, odds ratio=3.96, P=0.003 were significantly more common in G3 cores derived from Gleason 7 vs Gleason 6 tumors.
Prostate Adenocarcinoma	AR	12860943	CONCLUSION: These data suggest that AR mutations are present in approximately 10% of patients with prostate cancer who experience treatment failure with hormone therapy that included an antiandrogen.
Prostate Adenocarcinoma	S100A4	12506178	CONCLUSION: Loss of S100A2 and increased expression of S100A4 may be an important event during progression of prostate cancer in humans.
Prostate Adenocarcinoma	S100A2	12506178	CONCLUSION: Loss of S100A2 and increased expression of S100A4 may be an important event during progression of prostate cancer in humans.
Prostate Adenocarcinoma	HDAC6	29383752	Cell proliferation assay with crystal violet, cell migration assay, cell invasion assay, Western blot analysis, and confocal fluorescent microscopy were conducted to test the impact of altered levels of P62 on the growth, migration, invasion, epithelial-to-mesenchymal transition, autophagy flux, HDAC6 activity, and microtubular acetylation of cancer cells.
Prostate Adenocarcinoma	SQSTM1	29383752	Cell proliferation assay with crystal violet, cell migration assay, cell invasion assay, Western blot analysis, and confocal fluorescent microscopy were conducted to test the impact of altered levels of P62 on the growth, migration, invasion, epithelial-to-mesenchymal transition, autophagy flux, HDAC6 activity, and microtubular acetylation of cancer cells.
Prostate Adenocarcinoma	ALK	29559559	Analysis of prostate cancer datasets showed that ALK amplification was associated with poor outcome.
Prostate Adenocarcinoma	PCNA	12820390	RESULTS: Our data confirmed that: 1) PCNA expression could be related to the grade of progression of cancer; and that 2) p53 mutation could be a late event in prostate carcinogenesis.
Prostate Adenocarcinoma	TP53	12820390	RESULTS: Our data confirmed that: 1) PCNA expression could be related to the grade of progression of cancer; and that 2) p53 mutation could be a late event in prostate carcinogenesis.
Prostate Adenocarcinoma	AR	19642730	Numerous mechanisms contribute to the development of resistance to androgen ablation therapy, resulting in ligand-independent reactivation of the androgen receptor, including amplification, mutation, phosphorylation, and activation of coreceptors.
Prostate Adenocarcinoma	SRPK1	25381816	Our study suggests that modulation of SRPK1 and subsequent inhibition of tumour angiogenesis by regulation of VEGF splicing can alter prostate tumour growth and supports further studies for the use of SRPK1 inhibition as a potential anti-angiogenic therapy in PCa.
Prostate Adenocarcinoma	VEGFA	25381816	Our study suggests that modulation of SRPK1 and subsequent inhibition of tumour angiogenesis by regulation of VEGF splicing can alter prostate tumour growth and supports further studies for the use of SRPK1 inhibition as a potential anti-angiogenic therapy in PCa.
Prostate Adenocarcinoma	NPEPPS	11254449	We investigated whether these polymorphisms could be informative in the prediction of the presence of prostate cancer in men undergoing prostatic biopsy for the evaluation of an elevated serum-PSA level (&gt; or = 4.0 ng/ml).
Prostate Adenocarcinoma	ZNRD2	9815624	These results indicate that frequent loss of the cyclin-dependent kinase inhibitor p27(Kip1) in human prostate cancer cells correlates with advancing histological aggressiveness, implicating deregulation of p27(Kip1) in prostate tumor progression.
Prostate Adenocarcinoma	CDKN1B	9815624	These results indicate that frequent loss of the cyclin-dependent kinase inhibitor p27(Kip1) in human prostate cancer cells correlates with advancing histological aggressiveness, implicating deregulation of p27(Kip1) in prostate tumor progression.
Prostate Adenocarcinoma	CYP1A1	15381379	These gene polymorphisms may play a role in the development prostate cancer (PCa) in Turkish populations; we therefore assessed the association of CYP1A1 and GSTM1 polymorphisms in patients with PCa in our population through a case-control study.
Prostate Adenocarcinoma	GSTM1	15381379	These gene polymorphisms may play a role in the development prostate cancer (PCa) in Turkish populations; we therefore assessed the association of CYP1A1 and GSTM1 polymorphisms in patients with PCa in our population through a case-control study.
Prostate Adenocarcinoma	PDGFRL	9197531	Since loss of heterozygosity on 8p22-p21.3 has been found frequently in prostate cancer, the status of a candidate tumor suppressor gene named PRLTS gene, recently cloned from the same region in some human malignancies, was examined in the present study.
Prostate Adenocarcinoma	MAPK1	26786102	Reciprocally, loss of either PKCdelta or c-Fos activates p38(MAPK) while suppressing the activation of ERK1/2.
Prostate Adenocarcinoma	PRKCD	26786102	Reciprocally, loss of either PKCdelta or c-Fos activates p38(MAPK) while suppressing the activation of ERK1/2.
Prostate Adenocarcinoma	FOS	26786102	Reciprocally, loss of either PKCdelta or c-Fos activates p38(MAPK) while suppressing the activation of ERK1/2.
Prostate Adenocarcinoma	TNF	12881706	In addition, inactivation of Id-1 by its antisense oligonucleotide and retroviral construct in DU145 cells resulted in the decrease of nuclear level of p65 and p50 proteins, which was associated with increased sensitivity to TNFalpha-induced apoptosis.
Prostate Adenocarcinoma	NFKB1	12881706	In addition, inactivation of Id-1 by its antisense oligonucleotide and retroviral construct in DU145 cells resulted in the decrease of nuclear level of p65 and p50 proteins, which was associated with increased sensitivity to TNFalpha-induced apoptosis.
Prostate Adenocarcinoma	ID1	12881706	In addition, inactivation of Id-1 by its antisense oligonucleotide and retroviral construct in DU145 cells resulted in the decrease of nuclear level of p65 and p50 proteins, which was associated with increased sensitivity to TNFalpha-induced apoptosis.
Prostate Adenocarcinoma	RELA	12881706	In addition, inactivation of Id-1 by its antisense oligonucleotide and retroviral construct in DU145 cells resulted in the decrease of nuclear level of p65 and p50 proteins, which was associated with increased sensitivity to TNFalpha-induced apoptosis.
Prostate Adenocarcinoma	RHOA	22504159	These results suggest that PKA-mediated inhibition of RhoA via its phosphorylation on serine 188 and the subsequent inhibition of ROCK activity plays a key role in determining initial changes in cellular morphology during LNCaP cell differentiation to a neuroendocrine phenotype.
Prostate Adenocarcinoma	AR	16461912	AR-negative prostate cancer cells were nonresponsive to cyclin D1 (a or b) expression, indicating that defects in AR corepressor function yield a growth advantage specifically in AR-dependent cells.
Prostate Adenocarcinoma	CCND1	16461912	AR-negative prostate cancer cells were nonresponsive to cyclin D1 (a or b) expression, indicating that defects in AR corepressor function yield a growth advantage specifically in AR-dependent cells.
Prostate Adenocarcinoma	KRAS	29650325	We show that KIT, KRAS, and TP53 genes have a higher presence among patients with PC and that mutations in KIT gene are related to an aggressive PC.
Prostate Adenocarcinoma	TP53	29650325	We show that KIT, KRAS, and TP53 genes have a higher presence among patients with PC and that mutations in KIT gene are related to an aggressive PC.
Prostate Adenocarcinoma	LZTS2	17351128	Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle.
Prostate Adenocarcinoma	KATNB1	17351128	Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle.
Prostate Adenocarcinoma	PRNCR1	33226844	In conclusion, rs13252298 and rs1456315 in PRNCR1 may be genetic susceptibility factors for LC in Chinese population.
Prostate Adenocarcinoma	BMI1	16963837	Quantitative immunofluorescence colocalization analysis and expression profiling experiments documented increased BMI1 and Ezh2 expression in clinical prostate carcinoma samples and demonstrated that high levels of BMI1 and Ezh2 expression are associated with markedly increased likelihood of therapy failure and disease relapse after radical prostatectomy.
Prostate Adenocarcinoma	EZH2	16963837	Quantitative immunofluorescence colocalization analysis and expression profiling experiments documented increased BMI1 and Ezh2 expression in clinical prostate carcinoma samples and demonstrated that high levels of BMI1 and Ezh2 expression are associated with markedly increased likelihood of therapy failure and disease relapse after radical prostatectomy.
Prostate Adenocarcinoma	KRAS	29650325	The most prevalent mutations among patients with PC are c.1621A&gt;C (rs3822214) in KIT, c.38G&gt;C (rs112445441) in KRAS and c.733G&gt;A (rs28934575) in TP53 genes.
Prostate Adenocarcinoma	TP53	29650325	The most prevalent mutations among patients with PC are c.1621A&gt;C (rs3822214) in KIT, c.38G&gt;C (rs112445441) in KRAS and c.733G&gt;A (rs28934575) in TP53 genes.
Prostate Adenocarcinoma	LMTK2	20569440	Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer.
Prostate Adenocarcinoma	MSMB	20569440	Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer.
Prostate Adenocarcinoma	HNF1B	20569440	Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer.
Prostate Adenocarcinoma	TWSG1	9309116	Such nonrandom AI is commonly associated with the presence of a tumor suppressor gene (TSG) at or near the tested locus.
Prostate Adenocarcinoma	DUSP6	25241655	The results showed that the overexpression of DUSP6 suppressed the invasion and growth of DU-145 human prostate cancer cells, whereas knockdown of DUSP6 promoted the invasion and proliferation of LNCap human prostate adenocarcinoma cells.
Prostate Adenocarcinoma	AKT1	11830512	Taken together, these results demonstrate that inactivation of PTEN and subsequent activation of the PI3k/Akt kinase pathway may play an important role in the overexpression of the FAS protein in cancer cells.
Prostate Adenocarcinoma	PTEN	11830512	Taken together, these results demonstrate that inactivation of PTEN and subsequent activation of the PI3k/Akt kinase pathway may play an important role in the overexpression of the FAS protein in cancer cells.
Prostate Adenocarcinoma	FASN	11830512	Taken together, these results demonstrate that inactivation of PTEN and subsequent activation of the PI3k/Akt kinase pathway may play an important role in the overexpression of the FAS protein in cancer cells.
Prostate Adenocarcinoma	MBD2	21747116	Whereas MBD2 depletion in normal liver cells had little or no effect, we found that its depletion in human HCC and adenocarcinoma cells resulted in suppression of cell growth, anchorage-independent growth and invasiveness as well as an increase in promoter methylation and silencing of several of the genes that are hypomethylated in tumors.
Prostate Adenocarcinoma	PTEN	19165235	These results highlight the interest of the analysis of signaling phosphoproteins expression as molecular predictive markers for response to cetuximab and show that p53 and pten mutations could be key determinants of cell response to cetuximab through the functional impact of these mutations on cell signaling.
Prostate Adenocarcinoma	TP53	19165235	These results highlight the interest of the analysis of signaling phosphoproteins expression as molecular predictive markers for response to cetuximab and show that p53 and pten mutations could be key determinants of cell response to cetuximab through the functional impact of these mutations on cell signaling.
Prostate Adenocarcinoma	LZTS2	17351128	These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.
Prostate Adenocarcinoma	KATNB1	17351128	These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.
Prostate Adenocarcinoma	CD44	8839552	Expression of both standard form and variant isoforms of CD44 protein has been associated with aggressive behavior and metastasis in various tumors, but has not been characterized in prostate adenocarcinoma (PAC).
Prostate Adenocarcinoma	EZR	15028477	Our results indicate that aberrant expression of ezrin might be involved in the pathogenesis of prostate cancer, and ezrin expression may be useful for the diagnosis of HGPIN.
Prostate Adenocarcinoma	AR	25274033	Indeed, we found that wild-type (wt) but not prostate adenocarcinoma-associated mutants of SPOP promoted AR ubiquitination and degradation, acting directly through a SPOP-binding motif in the hinge region of AR.
Prostate Adenocarcinoma	SPOP	25274033	Indeed, we found that wild-type (wt) but not prostate adenocarcinoma-associated mutants of SPOP promoted AR ubiquitination and degradation, acting directly through a SPOP-binding motif in the hinge region of AR.
Prostate Adenocarcinoma	ERG	21914348	Among the 11 cases with SCC features, a rearrangement of ERG gene was present in 5 cases, of which a deletion of the 5' ERG gene and increased copy number were seen in 3 cases.
Prostate Adenocarcinoma	NOTCH1	19147749	CONCLUSIONS: Our data show the involvement of Notch1 in human PCa invasion and that silencing of Notch1 inhibits invasion of human PCa cells by inhibiting the expression of MMP9 and uPA.
Prostate Adenocarcinoma	MMP9	19147749	CONCLUSIONS: Our data show the involvement of Notch1 in human PCa invasion and that silencing of Notch1 inhibits invasion of human PCa cells by inhibiting the expression of MMP9 and uPA.
Prostate Adenocarcinoma	RAD51	26339569	Our results indicate that the RAD51 gene rs1801320 polymorphism may contribute to prostate cancer susceptibility in Poland.
Prostate Adenocarcinoma	ALOX15B	11014584	These data show that in contrast to the uniform expression of 15-LOX-2 in differentiated secretory cells of benign prostate, reduced 15-LOX-2 is a common alteration in prostate carcinoma, and this correlates with tumor cell differentiation.
Prostate Adenocarcinoma	PCNT	18701509	PKCbetaII inhibition reduced the level and mislocalization of pericentrin and normalized microtubule organization in the tumor endothelial cells.
Prostate Adenocarcinoma	HPCX	20564318	CONCLUSIONS: Results suggest that variants in RNASEL contribute to susceptibility to early onset and familial forms of prostate cancer, whereas HPCX variants are associated with prostate cancer risk and tumor aggressiveness.
Prostate Adenocarcinoma	RNASEL	20564318	CONCLUSIONS: Results suggest that variants in RNASEL contribute to susceptibility to early onset and familial forms of prostate cancer, whereas HPCX variants are associated with prostate cancer risk and tumor aggressiveness.
Prostate Adenocarcinoma	TSPO	19789311	CONCLUSION: These data suggest that blocking TSPO function in tumor cells induces cell death and denotes a survival role for TSPO in prostate cancer and provides the first evidence for the use of benzodiazepines in prostate cancer therapeutics.
Prostate Adenocarcinoma	AKT1	18024597	The mutations hinder Rac and R-Ras binding and R-RasGAP activity, resulting in an increase in cell motility, invasion, adhesion, and lamellipodia extension.
Prostate Adenocarcinoma	BAP1	29061454	We report a case of malignant peripheral nerve sheath tumor in a patient affected by a BAP1 mutation.
Prostate Adenocarcinoma	BAP1	29528717	In an unselected study population with respect to BAP1 status, the prevalence of several tumor types described in BAP1 mutation carriers, including lung carcinoma, clear cell renal cell carcinoma, breast carcinoma, meningioma, pleomorphic undifferentiated sarcoma, and ocular melanoma, was increased.
Prostate Adenocarcinoma	PSCA	21681742	The T allele of rs2294008 in PSCA was found to be a highly significant risk factor for GC (per allele OR = 1.42, 95% CI: 1.23-1.66, p-value = 6.5 x 10(-6) ), particularly of the noncardia-type (per allele OR = 1.47, 95% CI: 1.19-1.81, p-value = 3 x 10(-4) ).
Prostate Adenocarcinoma	TP53	9253117	A role of genetic alterations in the p53 tumor suppressor gene has been implicated in many types of human malignancies.
Prostate Adenocarcinoma	RB1	8834174	The loss or mutational inactivation of the RB1 tumor suppressor gene has been implicated in the development of a diverse group of human malignancies.
Prostate Adenocarcinoma	TGFBR1	11707452	Similarly, DHT inhibits the activation of Smad-binding element (SBE)4(BV)-luciferase by either constitutively activated TbetaRI (T204D) or constitutively activated Smad3 (S3*).
Prostate Adenocarcinoma	SMAD3	11707452	Similarly, DHT inhibits the activation of Smad-binding element (SBE)4(BV)-luciferase by either constitutively activated TbetaRI (T204D) or constitutively activated Smad3 (S3*).
Prostate Adenocarcinoma	EGFR	1712471	We suggest that loss of blood group antigens may be correlated with elevated v-erbB oncoprotein expression (related to epidermal growth factor receptor) and increasing grade of prostatic malignancy.
Prostate Adenocarcinoma	CAV1	23729330	Silencing of Cav-1 by shRNA in WPMY-1 prostate fibroblasts resulted in up-regulation of Akt phosphorylation, and significantly altered expression of genes involved in angiogenesis, invasion, and metastasis, including a &gt; 2.5-fold increase in TGF-beta1 and gamma-synuclein (SNCG) gene expression.
Prostate Adenocarcinoma	TGFB1	23729330	Silencing of Cav-1 by shRNA in WPMY-1 prostate fibroblasts resulted in up-regulation of Akt phosphorylation, and significantly altered expression of genes involved in angiogenesis, invasion, and metastasis, including a &gt; 2.5-fold increase in TGF-beta1 and gamma-synuclein (SNCG) gene expression.
Prostate Adenocarcinoma	AKT1	23729330	Silencing of Cav-1 by shRNA in WPMY-1 prostate fibroblasts resulted in up-regulation of Akt phosphorylation, and significantly altered expression of genes involved in angiogenesis, invasion, and metastasis, including a &gt; 2.5-fold increase in TGF-beta1 and gamma-synuclein (SNCG) gene expression.
Prostate Adenocarcinoma	SNCG	23729330	Silencing of Cav-1 by shRNA in WPMY-1 prostate fibroblasts resulted in up-regulation of Akt phosphorylation, and significantly altered expression of genes involved in angiogenesis, invasion, and metastasis, including a &gt; 2.5-fold increase in TGF-beta1 and gamma-synuclein (SNCG) gene expression.
Prostate Adenocarcinoma	STEAP4	15897894	Furthermore, ectopic expression of STAMP2 in prostate cancer cells significantly increases cell growth and colony formation suggesting that STAMP2 may have a role in cell proliferation.
Prostate Adenocarcinoma	SLC39A9	30262433	Silencing ZIP9 expression by means of siRNA does not affect the responsiveness of the classical AR to testosterone; however, it prevents all of the testosterone effects described above: formation of lamellipodia cannot be induced, stimulation of FAK or paxillin phosphorylation or MMP-2 expression is prevented, and cell migration does not take place in the absence of ZIP9.
Prostate Adenocarcinoma	AR	30262433	Silencing ZIP9 expression by means of siRNA does not affect the responsiveness of the classical AR to testosterone; however, it prevents all of the testosterone effects described above: formation of lamellipodia cannot be induced, stimulation of FAK or paxillin phosphorylation or MMP-2 expression is prevented, and cell migration does not take place in the absence of ZIP9.
Prostate Adenocarcinoma	MMP2	30262433	Silencing ZIP9 expression by means of siRNA does not affect the responsiveness of the classical AR to testosterone; however, it prevents all of the testosterone effects described above: formation of lamellipodia cannot be induced, stimulation of FAK or paxillin phosphorylation or MMP-2 expression is prevented, and cell migration does not take place in the absence of ZIP9.
Prostate Adenocarcinoma	PTK2	30262433	Silencing ZIP9 expression by means of siRNA does not affect the responsiveness of the classical AR to testosterone; however, it prevents all of the testosterone effects described above: formation of lamellipodia cannot be induced, stimulation of FAK or paxillin phosphorylation or MMP-2 expression is prevented, and cell migration does not take place in the absence of ZIP9.
Prostate Adenocarcinoma	CYP1A1	12767526	These finding suggested that CYP1A1 polymorphisms has an association with prostate cancer risk, especially with progression of prostate cancer.
Prostate Adenocarcinoma	ID1	12881706	Our findings also suggest a potential therapeutic strategy in which inactivation of Id-1 may lead to sensitization of prostate cancer cells to chemotherapeutic drug-induced apoptosis.
Prostate Adenocarcinoma	PARP1	33517260	More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in the outcome of patients with metastatic prostate cancer who harbor certain genetic mutations.
Prostate Adenocarcinoma	KLK3	16322300	PURPOSE: We examined a panel of 13 polymorphisms in 13 different genes to determine whether specific genotypes can help predict prostate cancer at the time of biopsy among men prescreened with prostate-specific antigen and digital rectal exam.
Prostate Adenocarcinoma	PTEN	12717346	PTEN (phosphatase and tensin homologue deleted on chromosome-10), a dual specificity phosphatase, is a tumor suppressor gene whose inactivation has been associated with many different types of cancer including prostate cancer.
Prostate Adenocarcinoma	UBE2I	20561671	In line with increasing evidence that sumoylation plays an important role in tumorigenesis, we recently demonstrated that Ubc9 is expressed at high levels in advanced melanomas and that blocking expression of Ubc9 sensitizes melanomas to the cytotoxic effects of chemotherapeutic drugs.
Prostate Adenocarcinoma	PSCA	21538952	We studied five proteins overexpressed in pancreatic adenocarcinoma, namely, prostate stem cell antigen, fascin, 14-3-3 sigma, mesothelin and S100P utilizing immunohistochemistry on paraffin sections from cellblocks obtained by EUS-FNA.
Prostate Adenocarcinoma	MSLN	21538952	We studied five proteins overexpressed in pancreatic adenocarcinoma, namely, prostate stem cell antigen, fascin, 14-3-3 sigma, mesothelin and S100P utilizing immunohistochemistry on paraffin sections from cellblocks obtained by EUS-FNA.
Prostate Adenocarcinoma	FSCN1	21538952	We studied five proteins overexpressed in pancreatic adenocarcinoma, namely, prostate stem cell antigen, fascin, 14-3-3 sigma, mesothelin and S100P utilizing immunohistochemistry on paraffin sections from cellblocks obtained by EUS-FNA.
Prostate Adenocarcinoma	PEBP1	17030190	Loss of RKIP function promotes tumor metastasis in prostate cancer and melanoma.
Prostate Adenocarcinoma	CYP1A1	15381379	These data suggest that the CYP1A1 gene polymorphism may be associated with PCa susceptibility in Turkish men and that further studies will be needed to clarify the role of such variations in determining susceptibility to PCa.
Prostate Adenocarcinoma	IL10	15711248	An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma.
Prostate Adenocarcinoma	PTEN	12717346	The frequency of PTEN inactivation appears to increase during the progression of prostatic cancer.
Prostate Adenocarcinoma	BIRC6	31935634	MALAT1 or BIRC6 knockdown inhibited cell proliferation, migration and invasion and induced cell apoptosis in PCa.
Prostate Adenocarcinoma	MALAT1	31935634	MALAT1 or BIRC6 knockdown inhibited cell proliferation, migration and invasion and induced cell apoptosis in PCa.
Prostate Adenocarcinoma	CD82	12088206	Thus, KAI1 overexpression may restrain onset and early stage prostate cancer development, whilst its loss may predispose the patient to more aggressive cancer behaviour.
Prostate Adenocarcinoma	PEBP1	17030190	Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells.
Prostate Adenocarcinoma	CAV1	23729330	Pharmacological inhibition of Akt caused down-regulation of TGF-beta1 and SNCG, suggesting that loss of Cav-1 in the stroma can influence Akt-mediated signalling in the tumour microenvironment.
Prostate Adenocarcinoma	TGFB1	23729330	Pharmacological inhibition of Akt caused down-regulation of TGF-beta1 and SNCG, suggesting that loss of Cav-1 in the stroma can influence Akt-mediated signalling in the tumour microenvironment.
Prostate Adenocarcinoma	AKT1	23729330	Pharmacological inhibition of Akt caused down-regulation of TGF-beta1 and SNCG, suggesting that loss of Cav-1 in the stroma can influence Akt-mediated signalling in the tumour microenvironment.
Prostate Adenocarcinoma	SNCG	23729330	Pharmacological inhibition of Akt caused down-regulation of TGF-beta1 and SNCG, suggesting that loss of Cav-1 in the stroma can influence Akt-mediated signalling in the tumour microenvironment.
Prostate Adenocarcinoma	ILK	11448915	Inhibition of ILK in prostatic adenocarcinoma (CaP) cells elicits cell cycle arrest and induces apoptosis.
Prostate Adenocarcinoma	TP53	22448262	Our results demonstrate that cadmium can induce p53-dependent apoptosis in human prostate epithelial cells and suggest p53 mutation as a possible contributing factor for the acquisition of apoptotic resistance in cadmium prostatic carcinogenesis.
Prostate Adenocarcinoma	KLK3	9382999	Although we did not find a statistical correlation between the PSA-PCR results and clinical-histopathological parameters, the presence of circulating prostate cells was strongly correlated with an elevated Gleason score of primary tumor (P&lt;0.01).
Prostate Adenocarcinoma	CDH1	12796649	CONCLUSIONS: We noted that bcl-2 and aberrant E-cadherin expression are independent factors predicting biochemical relapse in stage pT2 prostatic cancers.
Prostate Adenocarcinoma	BIRC6	31935634	Moreover, MALAT1 knockdown inhibited BIRC mRNA and protein expression through upregulating miR-140 in PCa cells.
Prostate Adenocarcinoma	MALAT1	31935634	Moreover, MALAT1 knockdown inhibited BIRC mRNA and protein expression through upregulating miR-140 in PCa cells.
Prostate Adenocarcinoma	MIR140	31935634	Moreover, MALAT1 knockdown inhibited BIRC mRNA and protein expression through upregulating miR-140 in PCa cells.
Prostate Adenocarcinoma	EPB41L3	18554153	BACKGROUND: Loss of erythrocyte membrane protein band 4.1-like 3 (EPB41L3; aliases: protein 4.1B, differentially expressed in adenocarcinoma of the lung-1 (Dal-1)) expression has been implicated in tumor progression.
Prostate Adenocarcinoma	OGG1	16322300	CONCLUSIONS: Of the 13 polymorphisms, two were found to be positively associated with prostate cancer (TNF308 and KLK2) and two were negatively associated with prostate cancer (GSTT1 and HOGG1-326).
Prostate Adenocarcinoma	GSTT1	16322300	CONCLUSIONS: Of the 13 polymorphisms, two were found to be positively associated with prostate cancer (TNF308 and KLK2) and two were negatively associated with prostate cancer (GSTT1 and HOGG1-326).
Prostate Adenocarcinoma	KLK2	16322300	CONCLUSIONS: Of the 13 polymorphisms, two were found to be positively associated with prostate cancer (TNF308 and KLK2) and two were negatively associated with prostate cancer (GSTT1 and HOGG1-326).
Prostate Adenocarcinoma	FASN	23741342	FASN inhibition also suppressed genes involved in production of intracellular second messenger arachidonic acid and androgen hormones, both of which promote tumor progression.
Prostate Adenocarcinoma	AR	31431456	Androgen receptor splice variant-7 (AR-V7) is a constitutively active AR variant implicated in castration-resistant prostate cancers.
Prostate Adenocarcinoma	RNASEL	17407163	BACKGROUND: The Gln allele of the Arg462Gln polymorphism in RNASEL results in a threefold decrease in enzymatic activity, a reported deficiency in apoptotic response, and has been associated with prostate cancer in some high-risk family studies.
Prostate Adenocarcinoma	PTEN	23018874	Data from our group and others have shown that the genomic deletion of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor gene and the disruption of the ETS gene family have a central role in prostate cancer and are likely to be associated with Gleason grade.
Prostate Adenocarcinoma	CDK12	30993692	In addition, pathogenic mutations in DNA repair genes were found in two cases of iIDC-P (BRCA2, CHEK2, CDK12) and other known PCa-associated mutations (FOXA1, SPOP) in two cases.
Prostate Adenocarcinoma	FOXA1	30993692	In addition, pathogenic mutations in DNA repair genes were found in two cases of iIDC-P (BRCA2, CHEK2, CDK12) and other known PCa-associated mutations (FOXA1, SPOP) in two cases.
Prostate Adenocarcinoma	SPOP	30993692	In addition, pathogenic mutations in DNA repair genes were found in two cases of iIDC-P (BRCA2, CHEK2, CDK12) and other known PCa-associated mutations (FOXA1, SPOP) in two cases.
Prostate Adenocarcinoma	CHEK2	30993692	In addition, pathogenic mutations in DNA repair genes were found in two cases of iIDC-P (BRCA2, CHEK2, CDK12) and other known PCa-associated mutations (FOXA1, SPOP) in two cases.
Prostate Adenocarcinoma	BRCA2	30993692	In addition, pathogenic mutations in DNA repair genes were found in two cases of iIDC-P (BRCA2, CHEK2, CDK12) and other known PCa-associated mutations (FOXA1, SPOP) in two cases.
Prostate Adenocarcinoma	TMPRSS2	18500259	Duplication of TMPRSS2:ERG fusion was observed in seven (6%) tumors.
Prostate Adenocarcinoma	ERG	18500259	Duplication of TMPRSS2:ERG fusion was observed in seven (6%) tumors.
Prostate Adenocarcinoma	CBX8	21563192	Furthermore, EMMPRIN silencing markedly decreased the ability of PC-3 cells to form filopodia, a critical feature of invasive behavior, while it increased expression of cell-cell adhesion and gap junction proteins.
Prostate Adenocarcinoma	BSG	21563192	Furthermore, EMMPRIN silencing markedly decreased the ability of PC-3 cells to form filopodia, a critical feature of invasive behavior, while it increased expression of cell-cell adhesion and gap junction proteins.
Prostate Adenocarcinoma	TP53	9521470	Mutant p53 protein was detected in 56% of HG-PIN, 72% of prostatic adenocarcinomas, and 20% of benign prostatic glands.
Prostate Adenocarcinoma	SPDEF	23376423	RESULTS: In colorectal tumors from patients, loss of SPDEF was observed in approximately 85% of tumors and correlated with progression from normal tissue, to adenoma, to adenocarcinoma.
Prostate Adenocarcinoma	AMH	29137935	It is caused by defects in the anti-mullerian hormone (AMH) system.
Prostate Adenocarcinoma	PTEN	23867565	IMPLICATIONS: Increased expression of IL6 or OSM synergizes with loss of PTEN to promote invasive prostate cancer.
Prostate Adenocarcinoma	BRCA2	23035815	PATIENTS AND METHODS:   Ten participants from the Kathleen Cuningham Consortium for Research into Familial Breast Cancer cohort of high-risk breast cancer families were identified, with (i) a diagnosis of aggressive prostate cancer and presence of HGPIN, (ii) a pathogenic BRCA2 mutation, and (iii) access to archival prostate tissue specimens.
Prostate Adenocarcinoma	NF1	30431740	It is caused by germline mutations of the NF1 gene, which acts as tumor suppressor.
Prostate Adenocarcinoma	CRP	32329054	However, in stratification analysis by ethnicity, we found that CRP rs1205 C>T polymorphism was associated with an elevated risk of cancer in Asians (T-allele vs. C-allele, OR = 1.20, 95% CI = 1.06-1.36, pheterogeneity  = .226; TT vs. CC, OR = 1.48, 95% CI = 1.14-1.93, pheterogeneity  = .089).
Prostate Adenocarcinoma	FGFR4	16061909	Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.
Prostate Adenocarcinoma	MIR200C	32104236	The results also indicate that perturbation of the miR200c-AMACR regulatory mechanism may be involved in prostate carcinogenesis and that this may be exploited in future therapeutic approaches to prostate cancer.
Prostate Adenocarcinoma	AMACR	32104236	The results also indicate that perturbation of the miR200c-AMACR regulatory mechanism may be involved in prostate carcinogenesis and that this may be exploited in future therapeutic approaches to prostate cancer.
Prostate Adenocarcinoma	HSD3B1	17826523	The purpose of this study was to determine whether polymorphisms in HSD3B1 and UGT2B17 increase the risk of prostate cancer.
Prostate Adenocarcinoma	UGT2B17	17826523	The purpose of this study was to determine whether polymorphisms in HSD3B1 and UGT2B17 increase the risk of prostate cancer.
Prostate Adenocarcinoma	AR	25691773	RESULTS: The data herein show that (i) cabazitaxel exerts stronger cytostatic and cytotoxic response compared with docetaxel, especially in CRPC; (ii) cabazitaxel induces aberrant mitosis, leading to pyknotic and multinucleated cells; (iii) taxanes do not act through the androgen receptor (AR); (iv) gene-expression profiling reveals distinct molecular actions for cabazitaxel; and (v) tumors that have progressed to castration resistance via loss of RB show enhanced sensitivity to cabazitaxel.
Prostate Adenocarcinoma	SRD5A2	26169017	CONCLUSIONS: High 5alpha-reductase activity due to the polymorphism in SRD5A2 may contribute to resistance to ADT.
Prostate Adenocarcinoma	CDH1	11212238	We hypothesize that truncation of E-cadherin is an inactivating event that is significantly increased in localized prostate tumors and that it represents a novel molecular event that may distinguish prostate cancer from adjacent normal tissue.
Prostate Adenocarcinoma	EGFR	24595526	Activating mutations of the epidermal growth factor receptor (EGFR) confers sensitivity to tyrosine kinase inhibitors (TKIs).
Prostate Adenocarcinoma	NPEPPS	22576683	PSA was markedly detected in sera and prostate specimens of advanced PCa patients with alpha2M deficiency, and there was a negative correlation between serum alpha2M and PSA levels during the course of clinical treatment.
Prostate Adenocarcinoma	A2M	22576683	PSA was markedly detected in sera and prostate specimens of advanced PCa patients with alpha2M deficiency, and there was a negative correlation between serum alpha2M and PSA levels during the course of clinical treatment.
Prostate Adenocarcinoma	XRCC1	17486273	CONCLUSION: These results suggest that polymorphisms of XRCC1 appear to influence the risk of PCa and may modify risks attributable to environmental exposure.
Prostate Adenocarcinoma	CRP	32329054	CRP rs1205 C>T and rs2808630 T>C polymorphism may be associated with cancer risk, especially for Asians.
Prostate Adenocarcinoma	FGFR4	16061909	The Gly388Arg polymorphism in the FGFR4 gene was reported to modulate cancer cell migration in vitro and to be associated with breast, colon, and prostate cancer prognostic parameters.
Prostate Adenocarcinoma	SPOP	28805821	Cancer genome studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and prostate cancers.
Prostate Adenocarcinoma	TP53	18291508	OBJECTIVES: It has been hypothesized that abnormal p53 protein expression is associated with a worse prognosis after radiation (RT) and androgen suppression therapy (AST).
Prostate Adenocarcinoma	SRD5A2	17448593	Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Prostate Adenocarcinoma	KLK3	11876539	In the group of patients with PSA levels between 4 and 10 ng/ml, abnormal TRUS or DRE increased cancer detection rate, where neither PSA nor PSAD was capable of discriminating the patients with and without cancer.
Prostate Adenocarcinoma	TP53	30851334	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.
Prostate Adenocarcinoma	CUL3	28805821	Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants.
Prostate Adenocarcinoma	BRD3	28805821	Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants.
Prostate Adenocarcinoma	SPOP	28805821	Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants.
Prostate Adenocarcinoma	BRD2	28805821	Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants.
Prostate Adenocarcinoma	BRD4	28805821	Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants.
Prostate Adenocarcinoma	RBPJP3	17085659	Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.
Prostate Adenocarcinoma	KLK2	17085659	Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.
Prostate Adenocarcinoma	PTEN	21703421	Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.
Prostate Adenocarcinoma	TP53	21703421	Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.
Prostate Adenocarcinoma	BRCA2	18167127	Using highly metastatic prostate cancer PC-3 cells, we show that while BRCA2 depletion by small-interfering RNA promoted migration onto the extracellular matrix proteins fibronectin, laminin, and collagens, as well as invasion through the reconstituted basement membrane matrix Matrigel by more than 140%, recombinant BRCA2 overexpression decreased both phenomena by 57-80% and changed cell morphology from angular and spindle to round and compact.
Prostate Adenocarcinoma	FN1	18167127	Using highly metastatic prostate cancer PC-3 cells, we show that while BRCA2 depletion by small-interfering RNA promoted migration onto the extracellular matrix proteins fibronectin, laminin, and collagens, as well as invasion through the reconstituted basement membrane matrix Matrigel by more than 140%, recombinant BRCA2 overexpression decreased both phenomena by 57-80% and changed cell morphology from angular and spindle to round and compact.
Prostate Adenocarcinoma	WT1	7474403	It is concluded that mutations of the WT1 gene may not be involved in the formation of malignant tumors of the adult urinary tract.
Prostate Adenocarcinoma	EDN1	23200924	Moreover, its silencing altered the expression of genes involved in cell proliferation and cytoskeleton organization, as well as the endothelin-1 canonical pathway.
Prostate Adenocarcinoma	OLFM4	31241767	Furthermore, knockdown of OLFM4 gene expression was associated with enhanced epithelial-mesenchymal transition (EMT)-marker expression in RWPE immortalized normal prostate cells.
Prostate Adenocarcinoma	PSCA	21681742	These results confirm the association between variation in the promoter region of PSCA and GC risk in Caucasians and also indicate that the rs2294008 variant is a similar risk factor for both the diffuse and intestinal-types of GC.
Prostate Adenocarcinoma	RBPJP3	17085659	PURPOSE: Increased levels of serum human kallikrein-2 (hK2) and an hK2 gene (KLK2) variant are positively associated for prostate cancer, but the relationships between them remain unclear.
Prostate Adenocarcinoma	KLK2	17085659	PURPOSE: Increased levels of serum human kallikrein-2 (hK2) and an hK2 gene (KLK2) variant are positively associated for prostate cancer, but the relationships between them remain unclear.
Prostate Adenocarcinoma	CD274	27276060	Aberrant PD-L1 expression has been reported in many human cancers and is considered an immune escape mechanism for cancers.
Prostate Adenocarcinoma	DLC1	12545165	We expanded our investigations to other cancers with recurrent deletions of 8p22, and in this study examined alterations of DLC-1 in primary human breast tumors, human breast, colon, and prostate tumor cell lines.
Prostate Adenocarcinoma	BRCA2	18167127	Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9.
Prostate Adenocarcinoma	MMP9	18167127	Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9.
Prostate Adenocarcinoma	BRCA2	18167127	BRCA2 is a multifunctional tumor suppressor protein which plays critical roles in DNA repair, transcription, and cell proliferation, and the loss of which has been linked to the biology of several types of cancers.
Prostate Adenocarcinoma	MMP9	20354277	UNLABELLED: Polymorphisms Q279R, P574R and -1562 C/T of matrix metalloproteinase-9 (MMP-9) gene have been linked with the risk of cancer and with tumoral aggressiveness in various types of cancer.
Prostate Adenocarcinoma	GIT1	30417466	Specifically, upregulation of the GIT1-A splice variant and downregulation of the GIT1-C variant expressions are associated with t-NEPC patient tumors, patient-derived xenografts, and cell models.
Prostate Adenocarcinoma	MAPK1	12643788	Inhibition of ERK at a level that reduced the up-regulation of DNA repair led to the persistence of apurinic/apyrimidinic (AP) sites of DNA damage and increased cell killing.
Prostate Adenocarcinoma	PTEN	29229583	Ductal foci are enriched for cases with either a CTNNB1 hotspot mutation or a PTEN alteration, and are associated with WNT- or PI3K-pathway activation.
Prostate Adenocarcinoma	CTNNB1	29229583	Ductal foci are enriched for cases with either a CTNNB1 hotspot mutation or a PTEN alteration, and are associated with WNT- or PI3K-pathway activation.
Prostate Adenocarcinoma	AMACR	12218573	P504S, also known as alpha-methylacyl-CoA racemase, recently identified by cDNA subtraction and microarray technology, might serve as such a specific marker because it has been demonstrated to be highly expressed in prostatic adenocarcinoma, but not in benign prostatic glands.
Prostate Adenocarcinoma	DLC1	12545165	Genomic deletion of DLC-1 was observed in 40% of primary breast tumors, whereas reduced or undetectable levels of DLC-1 mRNA were seen in 70% of breast, 70% of colon, and 50% of prostate tumor cell lines To see whether DLC-1 expression affects cell growth and tumorigenicity, two breast carcinoma cell lines lacking the expression of endogenous gene were transfected with the DLC-1 cDNA.
Prostate Adenocarcinoma	TOP2A	26560244	Overexpression of TOP2A is associated with risk of systemic progression in prostate cancer patients, and higher levels of TOP2A were found in hormone-resistant cases.
Prostate Adenocarcinoma	TP53	10081877	Aberrant p53, bcl-2, CD44 and E-cadherin immunohistochemistry has been associated with aggressiveness in prostate cancer.
Prostate Adenocarcinoma	CD44	10081877	Aberrant p53, bcl-2, CD44 and E-cadherin immunohistochemistry has been associated with aggressiveness in prostate cancer.
Prostate Adenocarcinoma	CDH1	10081877	Aberrant p53, bcl-2, CD44 and E-cadherin immunohistochemistry has been associated with aggressiveness in prostate cancer.
Prostate Adenocarcinoma	PTEN	29229583	Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.
Prostate Adenocarcinoma	CTNNB1	29229583	Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.
Prostate Adenocarcinoma	MAP3K7	30333152	These include: (i) increased somatic copy number variations (SCNV), specifically deletions at 6q, 8p and 10q, which encompassed PTEN and MAP3K7 losses and gains at 3q; (ii) increased SPOP mut and ATMmut ; (iii) enrichment for mTORC1 and MYC pathways by gene expression; and (iv) increased methylation of selected genes.
Prostate Adenocarcinoma	PTEN	30333152	These include: (i) increased somatic copy number variations (SCNV), specifically deletions at 6q, 8p and 10q, which encompassed PTEN and MAP3K7 losses and gains at 3q; (ii) increased SPOP mut and ATMmut ; (iii) enrichment for mTORC1 and MYC pathways by gene expression; and (iv) increased methylation of selected genes.
Prostate Adenocarcinoma	MYC	30333152	These include: (i) increased somatic copy number variations (SCNV), specifically deletions at 6q, 8p and 10q, which encompassed PTEN and MAP3K7 losses and gains at 3q; (ii) increased SPOP mut and ATMmut ; (iii) enrichment for mTORC1 and MYC pathways by gene expression; and (iv) increased methylation of selected genes.
Prostate Adenocarcinoma	FAP	23375875	In most cases loss of DPPIV activity is connected with a higher grading scale, more aggressive tumour behaviour and higher metastatic potential.
Prostate Adenocarcinoma	PTEN	20936707	TP53 contributes significantly to the regulation of stem cell self-renewal, and we hypothesized that loss of Pten/TP53 would result in measurable changes in prostate cancer stem/progenitor cell properties.
Prostate Adenocarcinoma	TP53	20936707	TP53 contributes significantly to the regulation of stem cell self-renewal, and we hypothesized that loss of Pten/TP53 would result in measurable changes in prostate cancer stem/progenitor cell properties.
Prostate Adenocarcinoma	MIR34C	21351256	Reversely, we could also show that blocking miR-34c in vitro increases cell growth.
Prostate Adenocarcinoma	AR	17602304	The androgen receptor mutations AR(877) and AR(715) displayed a 37.5- and 5.2-fold increase in transactivation activity by progesterone and a 12.6- and 5.4-fold increase by estrogen compared to the AR(WT), respectively.
Prostate Adenocarcinoma	FGFR4	16061909	CONCLUSION: This study suggests that FGFR4 Gly388Arg polymorphism may predict prognosis in lung adenocarcinoma.
Prostate Adenocarcinoma	PEBP1	17030190	Ectopic expression of RKIP altered HCC cell proliferation and migration.
Prostate Adenocarcinoma	AURKA	22389870	We propose that alterations in Aurora kinase A and N-myc are involved in the development of NEPC, and future clinical trials will help determine from the efficacy of Aurora kinase inhibitor therapy.
Prostate Adenocarcinoma	MYCN	22389870	We propose that alterations in Aurora kinase A and N-myc are involved in the development of NEPC, and future clinical trials will help determine from the efficacy of Aurora kinase inhibitor therapy.
Prostate Adenocarcinoma	PTEN	20936707	Loss of PTEN is one of the most common mutations in prostate cancer, and loss of wild-type TP53 is associated with prostate cancer progression and castrate resistance.
Prostate Adenocarcinoma	TP53	20936707	Loss of PTEN is one of the most common mutations in prostate cancer, and loss of wild-type TP53 is associated with prostate cancer progression and castrate resistance.
Prostate Adenocarcinoma	AR	17044081	Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells.
Prostate Adenocarcinoma	TP53	30851334	TP53 mutation is associated with higher tumor-infiltrating T-cell density, which may be relevant in future clinical trials of immunotherapy in prostate cancer.
Prostate Adenocarcinoma	AR	33649102	Amongst these, point mutations in the ligand binding domain can transform antagonists into agonists, driving the disease through activation of androgen receptor (AR) signaling.
Prostate Adenocarcinoma	TXN	20955789	Our findings suggest that loss of Trx function because of oxidation and corresponding redox imbalance may play important roles in prostate cancer progression and response to therapies; and Trx1 may serve as a biomarker of subcellular redox imbalance in prostate cancer.
Prostate Adenocarcinoma	AR	16601069	Polymorphism in the length of the N-terminal glutamine (Q) tract in the human androgen receptor (AR) has been implicated in affecting aspects of male health ranging from fertility to cancer.
Prostate Adenocarcinoma	PTEN	29229583	Nine of 10 cases had mutually exclusive CTNNB1 hotspot mutations or phosphatase and tensin homolog (PTEN) alterations in the ductal component, and these were absent in the acinar foci.
Prostate Adenocarcinoma	CTNNB1	29229583	Nine of 10 cases had mutually exclusive CTNNB1 hotspot mutations or phosphatase and tensin homolog (PTEN) alterations in the ductal component, and these were absent in the acinar foci.
Prostate Adenocarcinoma	KLK3	25939393	In the 406 patients in which clinical information was available, PTEN homozygous (P = 0.009) deletion was associated with worse post-operative recurrence-free survival (number of events = 189), pre-operative prostate specific antigen (PSA) (P &lt; 0.001), and pathologic stage (P = 0.03).
Prostate Adenocarcinoma	PTEN	25939393	In the 406 patients in which clinical information was available, PTEN homozygous (P = 0.009) deletion was associated with worse post-operative recurrence-free survival (number of events = 189), pre-operative prostate specific antigen (PSA) (P &lt; 0.001), and pathologic stage (P = 0.03).
Prostate Adenocarcinoma	CTNNB1	17363566	Alterations of the Wnt/beta-catenin signaling pathway are positively associated with the development and progression of human cancer, including carcinoma of the prostate.
Prostate Adenocarcinoma	HHEX	28134934	A reduction in PRH protein levels increases the motility of normal prostate epithelial cells and conversely, PRH over-expression inhibits prostate cancer cell migration and blocks the ability of these cells to invade an extracellular matrix.
Prostate Adenocarcinoma	CADM1	12079507	These findings indicate that alteration of TSLC1 is involved in prostate cancer.
Prostate Adenocarcinoma	VDR	11789558	Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese.
Prostate Adenocarcinoma	RNASEL	20564318	The observation that a mutation predicted to completely inactivate RNASEL protein was not associated with prostate cancer, but that a missense variant was associated, suggests that the effect is due to either partial inactivation of the protein, and/or acquisition of a new protein activity.
Prostate Adenocarcinoma	PTEN	10821499	The tumor suppressor gene, PTEN/MMAC1, is also located in this region, and, in addition to other tumor types (eg, glioblastoma multiforme, endometrial, and melanoma), PTEN/MMAC1 mutations have been found in prostate cancer cell lines, xenografts, and hormone refractory prostate cancer tissue specimens.
Prostate Adenocarcinoma	TP53	30934773	Mutations in PTEN, TP53, and RB1 commonly occur in PC, particularly in metastasis and castration-resistant PC.
Prostate Adenocarcinoma	PTEN	30934773	Mutations in PTEN, TP53, and RB1 commonly occur in PC, particularly in metastasis and castration-resistant PC.
Prostate Adenocarcinoma	RB1	30934773	Mutations in PTEN, TP53, and RB1 commonly occur in PC, particularly in metastasis and castration-resistant PC.
Prostate Adenocarcinoma	HSD3B2	17823934	SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Prostate Adenocarcinoma	SRD5A2	17823934	SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Prostate Adenocarcinoma	YAP1	32313141	Dysregulation of YAP1, a key transcription coactivator of the Hippo pathway, has been related to cancer progression.
Prostate Adenocarcinoma	CLDN3	21656836	We studied whether knockdown of Cldn3 and/or Cldn4 expression using RNA interference influenced CPE-mediated cytotoxicity.
Prostate Adenocarcinoma	CLDN4	21656836	We studied whether knockdown of Cldn3 and/or Cldn4 expression using RNA interference influenced CPE-mediated cytotoxicity.
Prostate Adenocarcinoma	PKP1	20348237	Our data imply that both loss of PKP1 and up-regulation of PKP3 expression are biologically important events in prostate cancer and are associated with a more aggressive phenotype.
Prostate Adenocarcinoma	PKP3	20348237	Our data imply that both loss of PKP1 and up-regulation of PKP3 expression are biologically important events in prostate cancer and are associated with a more aggressive phenotype.
Prostate Adenocarcinoma	TP53	25295118	The abnormal level of p53 was likely associated with the prognosis of the patient; the patient succumbed to prostate carcinoma two months after the confirmation of the diagnosis.
Prostate Adenocarcinoma	ATF3	25531328	Although aberrant ATF3 expression is frequently found in human cancers, the role of ATF3 in tumorigenesis is poorly understood.
Prostate Adenocarcinoma	MIR449A	30024932	In the case of LNCaP cells, upregulated miR-449a directly downregulates c-Myc that is required to induce the cell cycle regulators Cdc25A and Cdc2/CyclinB whose inactivation blocks G2 to M phase transition.
Prostate Adenocarcinoma	CDC25A	30024932	In the case of LNCaP cells, upregulated miR-449a directly downregulates c-Myc that is required to induce the cell cycle regulators Cdc25A and Cdc2/CyclinB whose inactivation blocks G2 to M phase transition.
Prostate Adenocarcinoma	MYC	30024932	In the case of LNCaP cells, upregulated miR-449a directly downregulates c-Myc that is required to induce the cell cycle regulators Cdc25A and Cdc2/CyclinB whose inactivation blocks G2 to M phase transition.
Prostate Adenocarcinoma	CDK1	30024932	In the case of LNCaP cells, upregulated miR-449a directly downregulates c-Myc that is required to induce the cell cycle regulators Cdc25A and Cdc2/CyclinB whose inactivation blocks G2 to M phase transition.
Prostate Adenocarcinoma	OGG1	14634453	CONCLUSIONS: These results suggest that hOGG1 may have a role in the repair of 8-OH-dG adducts in prostate tissue and hOGG1 Ser326Cys polymorphism is associated with prostate cancer risk.
Prostate Adenocarcinoma	MAPK1	10492251	Immunohistochemical analysis demonstrated similar expression of ERK in cancer and normal tissues; however, phosphorylated ERK demonstrated greater intensity in the cancer specimens.
Prostate Adenocarcinoma	SPOP	28805821	Conversely, prostate cancer-specific SPOP mutations resulted in impaired degradation of BETs, promoting their resistance to pharmacologic inhibition.
Prostate Adenocarcinoma	TMPRSS2	23136568	BACKGROUND: Transmembrane protease serine 2-ETS related gene (TMPRSS2-ERG) gene fusion, the most common genetic alternation in prostate cancer, is associated with protein expression of the oncogene ERG.
Prostate Adenocarcinoma	ERG	23136568	BACKGROUND: Transmembrane protease serine 2-ETS related gene (TMPRSS2-ERG) gene fusion, the most common genetic alternation in prostate cancer, is associated with protein expression of the oncogene ERG.
Prostate Adenocarcinoma	GOLPH3	25760033	Human PC-3 and LNCaP PCa cell lines were analyzed in order to assess whether silencing of GOLPH3 expression affects cell vitality, migration and invasion, in vitro.
Prostate Adenocarcinoma	CBX8	25760033	Human PC-3 and LNCaP PCa cell lines were analyzed in order to assess whether silencing of GOLPH3 expression affects cell vitality, migration and invasion, in vitro.
Prostate Adenocarcinoma	PTEN	30934773	The loss of PTEN together with Ras activation induces partial epithelial-mesenchymal transition (EMT), which is a major mechanism that confers plasticity to cancer stem cells (CSCs) and PCSCs, which contributes to metastasis.
Prostate Adenocarcinoma	GSTP1	15649863	Although it is not yet clear at what time during carcinogenesis hypermethylation of the GSTP1 promotor occurs it seems to provide valuable information for prostate cancer screening and diagnosis.
Prostate Adenocarcinoma	ERBB2	11774175	The presence of HER-2/neu amplification was associated with high tumor volume (&gt;2.0 cm(3), P = 0.004).
Prostate Adenocarcinoma	PVT1	33430890	PVT1 knockdown followed by ChIP-qPCR showed significant epigenetic remodeling at the enhancer and promoter regions of tumor suppressor gene NOV, one of the androgen-repressed genes that were upregulated upon PVT1 silencing.
Prostate Adenocarcinoma	CCN3	33430890	PVT1 knockdown followed by ChIP-qPCR showed significant epigenetic remodeling at the enhancer and promoter regions of tumor suppressor gene NOV, one of the androgen-repressed genes that were upregulated upon PVT1 silencing.
Prostate Adenocarcinoma	CCND1	31956349	Silencing of PRPS2 resulted in the decreased expression of Bcl-2 and cyclinD1 and increased levels of Bax, cleavage of caspases-3, caspases-9 and PARP.
Prostate Adenocarcinoma	BAX	31956349	Silencing of PRPS2 resulted in the decreased expression of Bcl-2 and cyclinD1 and increased levels of Bax, cleavage of caspases-3, caspases-9 and PARP.
Prostate Adenocarcinoma	COL11A2	31956349	Silencing of PRPS2 resulted in the decreased expression of Bcl-2 and cyclinD1 and increased levels of Bax, cleavage of caspases-3, caspases-9 and PARP.
Prostate Adenocarcinoma	PTEN	9582022	Mutation or deletion of PTEN has been observed in a proportion of prostate cancer cell lines; however, primary prostate carcinomas have not been studied.
Prostate Adenocarcinoma	ERBB2	16984552	BACKGROUND: Overexpression of the HER2 receptor protein and amplification of the HER2 gene has been implicated in tumor development and progression, and has been associated with a poor prognosis in several types of cancer.
Prostate Adenocarcinoma	GSTP1	12855646	Abnormal urinary GSTP1 methylation was also detected in 7 of 21 (33%) patients without evidence of cancer on biopsy and in 4 of 6 (67%) patients diagnosed with atypia or high-grade prostatic intraepithelial neoplasia.
Prostate Adenocarcinoma	AR	12941814	Deregulation of AR activity results in inappropriate mitogenic signaling and is thought to contribute both to the initiation and progression of prostate cancers.
Prostate Adenocarcinoma	PARP1	31565603	Molecular features commonly found in prostate adenocarcinomas are now well-recognized, including defects in homologous recombination (HR) genes, like breast cancer type 2 susceptibility protein (BRCA2), leading to increased sensitivity to deoxyribonucleic acid (DNA)-damaging agents (e.g., platinum chemotherapy or poly adenosine diphosphate-ribose polymerase (PARP) inhibitors).
Prostate Adenocarcinoma	BRCA2	31565603	Molecular features commonly found in prostate adenocarcinomas are now well-recognized, including defects in homologous recombination (HR) genes, like breast cancer type 2 susceptibility protein (BRCA2), leading to increased sensitivity to deoxyribonucleic acid (DNA)-damaging agents (e.g., platinum chemotherapy or poly adenosine diphosphate-ribose polymerase (PARP) inhibitors).
Prostate Adenocarcinoma	AR	14691288	AR mutations have been infrequently reported in CaP before hormonal therapy, but in untreated, advanced tumors AR mutations are suggested to be more common.
Prostate Adenocarcinoma	AR	9377562	These results also imply that in androgen-dependent prostate cancer, increased androgen receptor (AR) activity, resulting from AR gain-of-function mutations, AR gene amplification, or AR gene overexpression, malignantly stimulates proliferation of prostatic epithelial cells and constitutes one possible mechanism of androgen-dependent tumorigenesis.
Prostate Adenocarcinoma	CCN3	33430890	Interestingly, PVT1 knockdown caused upregulation of 160 genes that were repressed by androgen, including a significantly enriched set of tumor suppressor genes, and among them FAS, NOV/CCN3, BMF, HRK, IFIT2, AJUBA, DRAIC and TNFRSF21.
Prostate Adenocarcinoma	DRAIC	33430890	Interestingly, PVT1 knockdown caused upregulation of 160 genes that were repressed by androgen, including a significantly enriched set of tumor suppressor genes, and among them FAS, NOV/CCN3, BMF, HRK, IFIT2, AJUBA, DRAIC and TNFRSF21.
Prostate Adenocarcinoma	TNFRSF21	33430890	Interestingly, PVT1 knockdown caused upregulation of 160 genes that were repressed by androgen, including a significantly enriched set of tumor suppressor genes, and among them FAS, NOV/CCN3, BMF, HRK, IFIT2, AJUBA, DRAIC and TNFRSF21.
Prostate Adenocarcinoma	HRK	33430890	Interestingly, PVT1 knockdown caused upregulation of 160 genes that were repressed by androgen, including a significantly enriched set of tumor suppressor genes, and among them FAS, NOV/CCN3, BMF, HRK, IFIT2, AJUBA, DRAIC and TNFRSF21.
Prostate Adenocarcinoma	AJUBA	33430890	Interestingly, PVT1 knockdown caused upregulation of 160 genes that were repressed by androgen, including a significantly enriched set of tumor suppressor genes, and among them FAS, NOV/CCN3, BMF, HRK, IFIT2, AJUBA, DRAIC and TNFRSF21.
Prostate Adenocarcinoma	PVT1	33430890	Interestingly, PVT1 knockdown caused upregulation of 160 genes that were repressed by androgen, including a significantly enriched set of tumor suppressor genes, and among them FAS, NOV/CCN3, BMF, HRK, IFIT2, AJUBA, DRAIC and TNFRSF21.
Prostate Adenocarcinoma	BMF	33430890	Interestingly, PVT1 knockdown caused upregulation of 160 genes that were repressed by androgen, including a significantly enriched set of tumor suppressor genes, and among them FAS, NOV/CCN3, BMF, HRK, IFIT2, AJUBA, DRAIC and TNFRSF21.
Prostate Adenocarcinoma	IFIT2	33430890	Interestingly, PVT1 knockdown caused upregulation of 160 genes that were repressed by androgen, including a significantly enriched set of tumor suppressor genes, and among them FAS, NOV/CCN3, BMF, HRK, IFIT2, AJUBA, DRAIC and TNFRSF21.
Prostate Adenocarcinoma	PCNA	15555337	CONCLUSION: The loss or decreased expression of p27 protein may be related to the genesis of benign prostate hypertrophy, but not to the development of prostate carcinoma; the overexpression of PCNA may play an important role in the malignant behavior and progression of prostate carcinoma.
Prostate Adenocarcinoma	IFI27	15555337	CONCLUSION: The loss or decreased expression of p27 protein may be related to the genesis of benign prostate hypertrophy, but not to the development of prostate carcinoma; the overexpression of PCNA may play an important role in the malignant behavior and progression of prostate carcinoma.
Prostate Adenocarcinoma	SGPL1	22784711	In human C4-2B and PC-3 cell lines, silencing SPL enhanced survival after irradiation or chemotherapy by decreasing expression of proteins involved in sensing and repairing DNA damage or apoptosis, respectively.
Prostate Adenocarcinoma	AR	15539430	Deletion of the N-terminal cyclin D1 binding site severely compromised AR activity (due to loss of FxxLF) but unmasked a repressor action through interaction with the AR C terminus.
Prostate Adenocarcinoma	CCND1	15539430	Deletion of the N-terminal cyclin D1 binding site severely compromised AR activity (due to loss of FxxLF) but unmasked a repressor action through interaction with the AR C terminus.
Prostate Adenocarcinoma	GNAS	19189654	The purpose of the present case-control study with 349 Japanese prostate cancer patients and 203 urological controls was to determine whether the GNAS1 T393C polymorphism is associated with prostate cancer risk.
Prostate Adenocarcinoma	PTEN	29851094	MYC overexpression cooperated with Pten loss to recapitulate lethal, human prostate cancer.
Prostate Adenocarcinoma	MYC	29851094	MYC overexpression cooperated with Pten loss to recapitulate lethal, human prostate cancer.
Prostate Adenocarcinoma	AR	12941814	Given these data establishing the potency of cyclin D1-mediated repression, we evaluated the ability of cyclin D1 to inhibit tumor-derived AR alleles and polymorphisms associated with tumor progression and increased prostate cancer risk.
Prostate Adenocarcinoma	CCND1	12941814	Given these data establishing the potency of cyclin D1-mediated repression, we evaluated the ability of cyclin D1 to inhibit tumor-derived AR alleles and polymorphisms associated with tumor progression and increased prostate cancer risk.
Prostate Adenocarcinoma	GSTP1	15649863	Our data support this thesis and shows that GSTP1 hypermethylation reliably distinguishes between prostate cancer and BPH .
Prostate Adenocarcinoma	SSBP2	18559593	Hypermethylation of the SSBP2 promoter and its expression were closely associated with higher stages of prostate cancer.
Prostate Adenocarcinoma	TP53	27179933	APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 protein by refolding it to wild type conformation, thus inducing apoptosis.
Prostate Adenocarcinoma	PMAIP1	27179933	APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 protein by refolding it to wild type conformation, thus inducing apoptosis.
Prostate Adenocarcinoma	PRIMA1	27179933	APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 protein by refolding it to wild type conformation, thus inducing apoptosis.
Prostate Adenocarcinoma	CALCA	8980249	Site-specific methylation changes, as revealed by the use of methylation-sensitive restriction enzymes, have been reported to occur in the promotor region of the calcitonin gene in chronic myeloid leukemia as it progresses from the chronic phase to blast crisis, in non-Hodgkin's lymphoid neoplasms and in non-lymphocytic leukemia.
Prostate Adenocarcinoma	IL10	15711248	PURPOSE: Polymorphisms in the promoter of the interleukin-10 (IL-10) gene may influence tumor development by altering the levels of IL-10 present in the serum or tumor microenvironment.
Prostate Adenocarcinoma	DAXX	31611308	The presence of ALT is strongly associated with recurrent cancer-specific somatic inactivating mutations in the ATRX-DAXX chromatin remodeling complex.
Prostate Adenocarcinoma	ATRX	31611308	The presence of ALT is strongly associated with recurrent cancer-specific somatic inactivating mutations in the ATRX-DAXX chromatin remodeling complex.
Prostate Adenocarcinoma	TP53	9180930	CONCLUSIONS: p53 mutations are uncommon in clinically localized prostatic adenocarcinoma and absent from BPH.
Prostate Adenocarcinoma	TERT	23519253	Furthermore, ablation of hTERT protein increased the sensitivity of cancer cells to CDDO-Me, whereas its overexpression rendered them resistant to CDDO-Me.
Prostate Adenocarcinoma	MAPK1	17183365	Alterations in the signaling pathways of bone morphogenetic proteins (BMPs) and activation of the ERK/MAP kinase (MAPK) pathway by growth factors have been implicated in the development and progression of prostate cancer.
Prostate Adenocarcinoma	TGFA	15355899	Blockade of the EGFR with the tyrphostin AG1478 eliminates the up-regulation XRCC1 and ERCC1 by TGF alpha or irradiation.
Prostate Adenocarcinoma	ERCC1	15355899	Blockade of the EGFR with the tyrphostin AG1478 eliminates the up-regulation XRCC1 and ERCC1 by TGF alpha or irradiation.
Prostate Adenocarcinoma	XRCC1	15355899	Blockade of the EGFR with the tyrphostin AG1478 eliminates the up-regulation XRCC1 and ERCC1 by TGF alpha or irradiation.
Prostate Adenocarcinoma	DAB2IP	23308052	Our previous studies have shown that loss of DAB2IP results in radioresistance in PCa cells primarily because of accelerated DNA double-strand break (DSB) repair kinetics, robust G(2)/M checkpoint control, and evasion of apoptosis.
Prostate Adenocarcinoma	MIR34B	26107383	Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression.
Prostate Adenocarcinoma	SOX2	26107383	Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression.
Prostate Adenocarcinoma	HSPA5	23085757	We show that in C42B prostate cancer cells, these miRNAs down-regulate GRP78 and induce apoptosis by directly targeting its 3' untranslated region.
Prostate Adenocarcinoma	SNAI1	26235627	In vitro, PEG10 promoted cell-cycle progression from G0/G1 in the context of TP53 loss and regulated Snail expression via TGF-beta signaling to promote invasion.
Prostate Adenocarcinoma	PEG10	26235627	In vitro, PEG10 promoted cell-cycle progression from G0/G1 in the context of TP53 loss and regulated Snail expression via TGF-beta signaling to promote invasion.
Prostate Adenocarcinoma	TP53	26235627	In vitro, PEG10 promoted cell-cycle progression from G0/G1 in the context of TP53 loss and regulated Snail expression via TGF-beta signaling to promote invasion.
Prostate Adenocarcinoma	KLK3	17914566	The VEGF T-460C polymorphism may have a substantial impact on both PSA recurrence after radical prostatectomy and survival in advanced prostate cancer.
Prostate Adenocarcinoma	VEGFA	17914566	The VEGF T-460C polymorphism may have a substantial impact on both PSA recurrence after radical prostatectomy and survival in advanced prostate cancer.
Prostate Adenocarcinoma	TP53	14707287	Loss of heterozygosity or mutation at the p53 tumor suppressor gene locus is frequently associated with advanced human prostate cancer.
Prostate Adenocarcinoma	GSTP1	26447830	GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress.
Prostate Adenocarcinoma	MEAF6	28427194	In this study, we identify a splice variant of the MYST/Esa1-associated factor 6 (MEAF6) gene, MEAF6-1, that is highly expressed in both t-NEPC tumor biopsies and neuroendocrine cell lines of prostate and lung cancers.
Prostate Adenocarcinoma	H3P16	19885564	Inhibition of HDACs enhanced histone acetylation and p21 gene expression, indicating that excessive HDAC activity is a requisite for deficient histone acetylation.
Prostate Adenocarcinoma	TP53	27179933	BACKGROUND: Mutation in the tumor suppressor gene TP53 is an early event in the development of high-grade serous (HGS) ovarian cancer and is identified in more than 96 % of HGS cancer patients.
Prostate Adenocarcinoma	SRD5A2	17823934	RESULTS: The SRD5A2 V89L polymorphism was not independently associated with prostate cancer risk.
Prostate Adenocarcinoma	VHL	17949520	RESULTS: In RCC, VHL gene inactivation mediates over-expression of VEGF.
Prostate Adenocarcinoma	VEGFA	17949520	RESULTS: In RCC, VHL gene inactivation mediates over-expression of VEGF.
Prostate Adenocarcinoma	TP53	9090501	The alteration of the p53 tumor-suppressor gene plays a role in a subset of advanced prostate cancer.
Prostate Adenocarcinoma	AURKA	17898866	The single-nucleotide polymorphism T91A (Phe31Ile) has been implicated in AURKA overexpression and has been suggested as a low-penetrance susceptibility allele in multiple human cancers, including prostate cancer.
Prostate Adenocarcinoma	ERG	33047739	The rearrangement of the gene encoding the transcription factor ETS-related gene (ERG) is thought to play a key role in the development of prostate cancer.
Prostate Adenocarcinoma	REXO2	24092501	Similar to vimentin, PAI-1 knockdown resulted in a modest augmentation of PC-3 cell migration inhibition by SFN.
Prostate Adenocarcinoma	SERPINE1	24092501	Similar to vimentin, PAI-1 knockdown resulted in a modest augmentation of PC-3 cell migration inhibition by SFN.
Prostate Adenocarcinoma	PCSK1	24092501	Similar to vimentin, PAI-1 knockdown resulted in a modest augmentation of PC-3 cell migration inhibition by SFN.
Prostate Adenocarcinoma	VIM	24092501	Similar to vimentin, PAI-1 knockdown resulted in a modest augmentation of PC-3 cell migration inhibition by SFN.
Prostate Adenocarcinoma	BRCA1	22252577	BRCA mutation carriers are also susceptible to other cancers, notably prostate cancer.
Prostate Adenocarcinoma	HOXB13	24722062	Recent genetic epidemiologic studies identified a germline mutation in the homeobox transcription factor, HOXB13 G84E, which is associated with markedly increased risk for prostate cancer, particularly early-onset hereditary prostate cancer.
Prostate Adenocarcinoma	HSD3B2	17823934	Stratified analyses revealed that most of the prostate cancer risk associated with the intron 3 HSD3B2 short allele was confined to the SRD5A2 89L variant subgroup and indicated that in combination these polymorphisms may be associated with increased risk of aggressive (Gleason &gt;7) disease (Gleason &gt;7).
Prostate Adenocarcinoma	SRD5A2	17823934	Stratified analyses revealed that most of the prostate cancer risk associated with the intron 3 HSD3B2 short allele was confined to the SRD5A2 89L variant subgroup and indicated that in combination these polymorphisms may be associated with increased risk of aggressive (Gleason &gt;7) disease (Gleason &gt;7).
Prostate Adenocarcinoma	REXO2	24092501	On the other hand, SFN-mediated inhibition of PC-3 and DU145 cell migration was significantly augmented by knockdown of the vimentin protein.
Prostate Adenocarcinoma	PCSK1	24092501	On the other hand, SFN-mediated inhibition of PC-3 and DU145 cell migration was significantly augmented by knockdown of the vimentin protein.
Prostate Adenocarcinoma	VIM	24092501	On the other hand, SFN-mediated inhibition of PC-3 and DU145 cell migration was significantly augmented by knockdown of the vimentin protein.
Prostate Adenocarcinoma	KDR	19908237	CONCLUSION: These findings suggest the inheritance of VEGF and VEGFR IVS6 + 54 sequence variants may jointly modify PCa susceptibility through their influence on angiogenesis.
Prostate Adenocarcinoma	VEGFA	19908237	CONCLUSION: These findings suggest the inheritance of VEGF and VEGFR IVS6 + 54 sequence variants may jointly modify PCa susceptibility through their influence on angiogenesis.
Prostate Adenocarcinoma	AR	12085963	The AR gene is amplified or a target for somatic gain-of-function mutations in metastatic prostate cancer.
Prostate Adenocarcinoma	POU5F1B	20017164	CONCLUSIONS: The over-expression of POU5F1P1 in prostatic carcinoma in addition to its genomic location and the putative function of its gene product render POU5F1P1 a good candidate to harbour functional genetic variants which modulate prostatic cancer susceptibility.
Prostate Adenocarcinoma	AR	14607214	The AR is now known to participate in tumor progression through 3 mechanisms: expression (activation and upregulation of receptor activity), point mutations, and ligand-independent activation.
Prostate Adenocarcinoma	HSD3B2	17823934	CONCLUSIONS: In Caucasians, the HSD3B2 (TG)n,(TA)n,(CA)n intron 3 length polymorphism is associated with both prostate cancer risk and aggressiveness and the SRD5A2 V89L polymorphism may modify the risk conferred by this polymorphism.
Prostate Adenocarcinoma	SRD5A2	17823934	CONCLUSIONS: In Caucasians, the HSD3B2 (TG)n,(TA)n,(CA)n intron 3 length polymorphism is associated with both prostate cancer risk and aggressiveness and the SRD5A2 V89L polymorphism may modify the risk conferred by this polymorphism.
Prostate Adenocarcinoma	IRS1	11313980	Ectopic expression of IRS-1 in LNCaP cells increases cell adhesion and decreases cell motility by an IGF-I-independent mechanism.
Prostate Adenocarcinoma	IGF1	11313980	Ectopic expression of IRS-1 in LNCaP cells increases cell adhesion and decreases cell motility by an IGF-I-independent mechanism.
Prostate Adenocarcinoma	BRCA2	31631483	Although the prevalence of BRCA2 variants in PCa is increasing in Japan, the genomic and biological implications in Japanese patients are unclear.
Prostate Adenocarcinoma	KDR	19908237	The presence of VEGF 2482T combined with VEGFR IVS6 + 54 loci were highly significant for the risk of PCa based on MDR and symbolic modeling analyses.
Prostate Adenocarcinoma	VEGFA	19908237	The presence of VEGF 2482T combined with VEGFR IVS6 + 54 loci were highly significant for the risk of PCa based on MDR and symbolic modeling analyses.
Prostate Adenocarcinoma	OLFM4	26581960	Loss of olfactomedin 4 (OLFM4) gene expression is associated with the progression of human prostate cancer, but its role and the molecular mechanisms involved in this process have not been completely understood.
Prostate Adenocarcinoma	GSK3B	18757413	These data suggest that modulation of GSK3beta activation is involved in the cell death pathway engaged by CDDO-Me in prostate cancer cells.
Prostate Adenocarcinoma	PLAC1	29138842	Furthermore, knockdown of PLAC1 expression by siRNA inhibited cell proliferation, induced apoptosis and impaired invasive ability in NSCLC cells partly via regulation of epithelial-mesenchymal transition (EMT)-related protein expression.
Prostate Adenocarcinoma	AKT1	17845997	Concomitantly, alterations in numerous signalling pathways (growth factors, Wnt-beta catenine, PI3K/Akt) are responsible for the onset of an aggressive tumor phenotype.
Prostate Adenocarcinoma	PTEN	11586263	Sequence analysis of PTEN in a limited number of lesions revealed mutations in nontumor and tumor tissue.
Prostate Adenocarcinoma	TUBA4B	30444590	Hypermethylation of genes ACSS3, TAC1, TUBA4B, ZSCAN12 not previously been shown for prostate cancer, but is characterized by the association with other cancers.
Prostate Adenocarcinoma	TAC1	30444590	Hypermethylation of genes ACSS3, TAC1, TUBA4B, ZSCAN12 not previously been shown for prostate cancer, but is characterized by the association with other cancers.
Prostate Adenocarcinoma	ZSCAN12	30444590	Hypermethylation of genes ACSS3, TAC1, TUBA4B, ZSCAN12 not previously been shown for prostate cancer, but is characterized by the association with other cancers.
Prostate Adenocarcinoma	ACSS3	30444590	Hypermethylation of genes ACSS3, TAC1, TUBA4B, ZSCAN12 not previously been shown for prostate cancer, but is characterized by the association with other cancers.
Prostate Adenocarcinoma	CD9	23575960	Our study demonstrates for the first time that ablation of Cd9 had no detectable effect on de novo primary tumour onset, but did significantly increase metastasis to the liver but not the lungs.
Prostate Adenocarcinoma	MMP9	17175378	These findings suggest that MMP9 polymorphism is an independent risk factor of PCa development and aggressiveness.
Prostate Adenocarcinoma	AR	11145738	Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
Prostate Adenocarcinoma	VEGFA	18615482	Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway.
Prostate Adenocarcinoma	AR	18559499	In summary, these data identify blockade of AR-BAF57 interaction as a novel means to target agonist-induced AR function in prostate cancer, and provide the first evidence that abrogation of SWI/SNF function can be developed as a point of therapeutic intervention in prostate cancer.
Prostate Adenocarcinoma	SMARCE1	18559499	In summary, these data identify blockade of AR-BAF57 interaction as a novel means to target agonist-induced AR function in prostate cancer, and provide the first evidence that abrogation of SWI/SNF function can be developed as a point of therapeutic intervention in prostate cancer.
Prostate Adenocarcinoma	SGPL1	22784711	Of note, the combination of SPL enforced expression with a SphK1 silencing strategy by further decreasing S1P content made prostate cancer cells even more sensitive to anticancer therapies, suggesting that a dual strategy aimed at stimulating SPL, and inhibiting SphK1 could represent a future approach to sensitize cancer cells to cancer treatments.
Prostate Adenocarcinoma	SPHK1	22784711	Of note, the combination of SPL enforced expression with a SphK1 silencing strategy by further decreasing S1P content made prostate cancer cells even more sensitive to anticancer therapies, suggesting that a dual strategy aimed at stimulating SPL, and inhibiting SphK1 could represent a future approach to sensitize cancer cells to cancer treatments.
Prostate Adenocarcinoma	TP53	8426837	These results demonstrate that abnormal p53 expression is a frequent event in prostate cancer.
Prostate Adenocarcinoma	CYP1B1	15330195	As for combined effects, the CYP1B1 polymorphisms (Leu/Val+Val/Val) together with heterozygosity for Alu in the PR were more frequent among prostate cancer patients (1.45%) than controls (0.41%), although without significance (OR, 3.99; 95%CI, 0.36-44.8).
Prostate Adenocarcinoma	PGR	15330195	As for combined effects, the CYP1B1 polymorphisms (Leu/Val+Val/Val) together with heterozygosity for Alu in the PR were more frequent among prostate cancer patients (1.45%) than controls (0.41%), although without significance (OR, 3.99; 95%CI, 0.36-44.8).
Prostate Adenocarcinoma	TP53	18552821	The rate of p53 alterations increases with prostate cancer progression.
Prostate Adenocarcinoma	TWIST1	15958559	More importantly, inactivation of TWIST suppressed migration and invasion abilities of androgen-independent prostate cancer cells, which was correlated with induction of E-cadherin expression as well as morphologic and molecular changes associated with mesenchymal to epithelial transition.
Prostate Adenocarcinoma	CDH1	15958559	More importantly, inactivation of TWIST suppressed migration and invasion abilities of androgen-independent prostate cancer cells, which was correlated with induction of E-cadherin expression as well as morphologic and molecular changes associated with mesenchymal to epithelial transition.
Prostate Adenocarcinoma	ZBED1	23575960	Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner.
Prostate Adenocarcinoma	CD9	23575960	Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner.
Prostate Adenocarcinoma	SNAI2	26540632	In PC cells, NED genes were upregulated by SOX2 overexpression and downregulated by its silencing, which also abolished SNAI2/Slug dependent NED.
Prostate Adenocarcinoma	SOX2	26540632	In PC cells, NED genes were upregulated by SOX2 overexpression and downregulated by its silencing, which also abolished SNAI2/Slug dependent NED.
Prostate Adenocarcinoma	VDR	11532853	Accordingly, we determined, in 210 prostate cancer cases, whether parameters of exposure, skin type and polymorphism in MC1R, VDR and TYR were associated with the outcome parameters, histological grade, clinical stage and presence of bone metastases.
Prostate Adenocarcinoma	MC1R	11532853	Accordingly, we determined, in 210 prostate cancer cases, whether parameters of exposure, skin type and polymorphism in MC1R, VDR and TYR were associated with the outcome parameters, histological grade, clinical stage and presence of bone metastases.
Prostate Adenocarcinoma	TP53	20332243	Abnormalities of the miR145-BNIP3 pair as part of TP53-miR145-BNIP3-AIF network may play a major role in prostate cancer pathogenesis and progression.
Prostate Adenocarcinoma	AIFM1	20332243	Abnormalities of the miR145-BNIP3 pair as part of TP53-miR145-BNIP3-AIF network may play a major role in prostate cancer pathogenesis and progression.
Prostate Adenocarcinoma	BNIP3	20332243	Abnormalities of the miR145-BNIP3 pair as part of TP53-miR145-BNIP3-AIF network may play a major role in prostate cancer pathogenesis and progression.
Prostate Adenocarcinoma	MIR145	20332243	Abnormalities of the miR145-BNIP3 pair as part of TP53-miR145-BNIP3-AIF network may play a major role in prostate cancer pathogenesis and progression.
Prostate Adenocarcinoma	TMPRSS2	17584912	Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion.
Prostate Adenocarcinoma	ERG	17584912	Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion.
Prostate Adenocarcinoma	HSP90AA1	18726985	Depletion of Hsp90 by quercetin results in decreased cell viability, levels of surrogate markers of Hsp90 inhibition (intracellular and secreted), induced apoptosis and activation of caspases in cancer cells but not in normal prostate epithelial cells.
Prostate Adenocarcinoma	TP53	27179933	Moreover, APR-246 sensitized TP53 mutant primary ovarian cancer cells, isolated from a clinically platinum-resistant patient, to cisplatin; the IC50 value of cisplatin decreased 3.6 fold from 6.5 to 1.8 muM in the presence of clinically relevant concentration of APR-246.
Prostate Adenocarcinoma	PMAIP1	27179933	Moreover, APR-246 sensitized TP53 mutant primary ovarian cancer cells, isolated from a clinically platinum-resistant patient, to cisplatin; the IC50 value of cisplatin decreased 3.6 fold from 6.5 to 1.8 muM in the presence of clinically relevant concentration of APR-246.
Prostate Adenocarcinoma	MIR195	30637589	Consistently, knockdown of CIAPIN1 phenocopied the inhibitory effects of miR-195-5p overexpression in NSCLC cell function.
Prostate Adenocarcinoma	CIAPIN1	30637589	Consistently, knockdown of CIAPIN1 phenocopied the inhibitory effects of miR-195-5p overexpression in NSCLC cell function.
Prostate Adenocarcinoma	BRAF	32639612	The presence of 2 BRAF gene rearrangements suggests that this gene fusion may be enriched in this setting, as RAF kinase fusions have been previously reported in 1-2% of prostate cancers.
Prostate Adenocarcinoma	GRPR	27542219	The knock-down of AR-V7 restores sensitivity to antiandrogens of PC cells over-expressing the GRP/GRP-R signaling pathway.
Prostate Adenocarcinoma	PTEN	19479935	Prostate tumorigenesis is associated with loss of PTEN gene expression.
Prostate Adenocarcinoma	NOTCH1	25686823	In PCa and lymph node metastasis, expression of SOX2 and NOTCH1 was highly related to that of SNAI2.In conclusion, I. SNAI2 silencing in PCa may turn-off the expression of NED markers and pluripotency genes, while turning-on that of specific metastasis-suppressors, II.
Prostate Adenocarcinoma	SNAI2	25686823	In PCa and lymph node metastasis, expression of SOX2 and NOTCH1 was highly related to that of SNAI2.In conclusion, I. SNAI2 silencing in PCa may turn-off the expression of NED markers and pluripotency genes, while turning-on that of specific metastasis-suppressors, II.
Prostate Adenocarcinoma	SOX2	25686823	In PCa and lymph node metastasis, expression of SOX2 and NOTCH1 was highly related to that of SNAI2.In conclusion, I. SNAI2 silencing in PCa may turn-off the expression of NED markers and pluripotency genes, while turning-on that of specific metastasis-suppressors, II.
Prostate Adenocarcinoma	MME	31528170	The loss of CD10 is a common early event in human prostate cancer and is seen in lower Gleason Score malignancies while increased and altered expression is seen in high Gleason Score tumors, lymph nodes and bone metastasis.
Prostate Adenocarcinoma	EGFR	33047739	The data revealed a discordant epidermal growth factor receptor (EGFR) from the separate lungs; additionally, a high frequency of point mutation on exon 9 H310P of the ERG gene was detected at the both sites of the tumor lesions.
Prostate Adenocarcinoma	ERG	33047739	The data revealed a discordant epidermal growth factor receptor (EGFR) from the separate lungs; additionally, a high frequency of point mutation on exon 9 H310P of the ERG gene was detected at the both sites of the tumor lesions.
Prostate Adenocarcinoma	TP53	20953142	While mutations of the p53 tumor suppressor gene frequently contribute to therapy resistance in other epithelial cancers, p53 mutations are relatively rare in RCC.
Prostate Adenocarcinoma	KLK3	32295536	The purpose of this study was to evaluate the association of rs16901979, rs4242382 and rs1447295 on 8q24 locus, rs2735839 (KLK3 gene) and rs721048 (EHBP1 gene) with prostate adenocarcinoma through multi-stage approach to identify the polymorphisms associated with prostate cancer and use them as screening factors.
Prostate Adenocarcinoma	EHBP1	32295536	The purpose of this study was to evaluate the association of rs16901979, rs4242382 and rs1447295 on 8q24 locus, rs2735839 (KLK3 gene) and rs721048 (EHBP1 gene) with prostate adenocarcinoma through multi-stage approach to identify the polymorphisms associated with prostate cancer and use them as screening factors.
Prostate Adenocarcinoma	CD274	28912897	TMIT was classified only for those tumor types that both PD-L1 and CD8A/CYT could prefict mutation and/or neoantigen number.
Prostate Adenocarcinoma	CD8A	28912897	TMIT was classified only for those tumor types that both PD-L1 and CD8A/CYT could prefict mutation and/or neoantigen number.
Prostate Adenocarcinoma	MTA1	23205121	Loss of E-cadherin promotes prostate cancer metastasis via upregulation of metastasis-associated gene 1 expression.
Prostate Adenocarcinoma	CDH1	23205121	Loss of E-cadherin promotes prostate cancer metastasis via upregulation of metastasis-associated gene 1 expression.
Prostate Adenocarcinoma	E2F3	16938365	We have proposed a model in which E2F3 overexpression co-operates with removal of the E2F inhibitor pRB to facilitate cancer development.
Prostate Adenocarcinoma	RB1	16938365	We have proposed a model in which E2F3 overexpression co-operates with removal of the E2F inhibitor pRB to facilitate cancer development.
Prostate Adenocarcinoma	CCDC6	8631004	The t(6;16)(p21;q22) chromosome translocation in the LNCaP prostate carcinoma cell line results in a tpc/hpr fusion gene.
Prostate Adenocarcinoma	HPR	8631004	The t(6;16)(p21;q22) chromosome translocation in the LNCaP prostate carcinoma cell line results in a tpc/hpr fusion gene.
Prostate Adenocarcinoma	PIM1	26934497	Accordingly, selective inhibition of PIM activity not only reduces cell migration, but also affects integrin-mediated cell adhesion.
Prostate Adenocarcinoma	CDH1	31485645	The silencing of MALAT1 inhibited migration, invasion and epithelial-mesenchymal transition, when epithelial (E)-cadherin expression level was increased, and neural (N)-cadherin, vimentin, Slug and Snail expression levels were decreased.
Prostate Adenocarcinoma	MALAT1	31485645	The silencing of MALAT1 inhibited migration, invasion and epithelial-mesenchymal transition, when epithelial (E)-cadherin expression level was increased, and neural (N)-cadherin, vimentin, Slug and Snail expression levels were decreased.
Prostate Adenocarcinoma	SNAI1	31485645	The silencing of MALAT1 inhibited migration, invasion and epithelial-mesenchymal transition, when epithelial (E)-cadherin expression level was increased, and neural (N)-cadherin, vimentin, Slug and Snail expression levels were decreased.
Prostate Adenocarcinoma	SNAI2	31485645	The silencing of MALAT1 inhibited migration, invasion and epithelial-mesenchymal transition, when epithelial (E)-cadherin expression level was increased, and neural (N)-cadherin, vimentin, Slug and Snail expression levels were decreased.
Prostate Adenocarcinoma	VIM	31485645	The silencing of MALAT1 inhibited migration, invasion and epithelial-mesenchymal transition, when epithelial (E)-cadherin expression level was increased, and neural (N)-cadherin, vimentin, Slug and Snail expression levels were decreased.
Prostate Adenocarcinoma	NOTCH1	19479935	Herein, we tested the hypothesis that alterations of the Notch-1 signaling pathway are present in human prostate adenocarcinoma and that Notch-1 signaling regulates PTEN gene expression in prostate cells.
Prostate Adenocarcinoma	PTEN	19479935	Herein, we tested the hypothesis that alterations of the Notch-1 signaling pathway are present in human prostate adenocarcinoma and that Notch-1 signaling regulates PTEN gene expression in prostate cells.
Prostate Adenocarcinoma	IL9	26047319	RESULTS: The minor allele (C) of rs3212227 in IL12(p40) was associated with an increased risk of total (log additive: OR = 1.30, 95%CI 1.10-1.53; P-trend = 0.0017) and lower-grade (OR = 1.36, 95%CI 1.15-1.62; P-trend = 0.0004) prostate cancer.
Prostate Adenocarcinoma	MEAF6	28427194	These findings suggest that the MEAF6-1 variant does not induce neuroendocrine differentiation of prostate cancer cells, but rather facilitates t-NEPC progression by increasing the proliferation rate of cells that have acquired neuroendocrine phenotypes.
Prostate Adenocarcinoma	SLC16A3	32212469	CONCLUSIONS: Inhibiting the expression of MCT4 can interfere with the glucose metabolism and promote the apoptosis of prostate cancer cells.
Prostate Adenocarcinoma	CCND2	17016690	Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Prostate Adenocarcinoma	BRAF	32740981	Three of five (60%) of the PIN-like ductal carcinomas showed activating mutations in the RAS/RAF pathways which are extraordinarily rare in conventional primary prostate carcinoma (<3% of cases), including an activating hotspot BRAF mutation (p.K601E), an activating hotspot mutation in HRAS (p.Q61K) and an in-frame activating deletion in BRAF (p.T488_Q493delinsK).
Prostate Adenocarcinoma	ZHX2	32740981	Three of five (60%) of the PIN-like ductal carcinomas showed activating mutations in the RAS/RAF pathways which are extraordinarily rare in conventional primary prostate carcinoma (<3% of cases), including an activating hotspot BRAF mutation (p.K601E), an activating hotspot mutation in HRAS (p.Q61K) and an in-frame activating deletion in BRAF (p.T488_Q493delinsK).
Prostate Adenocarcinoma	HRAS	32740981	Three of five (60%) of the PIN-like ductal carcinomas showed activating mutations in the RAS/RAF pathways which are extraordinarily rare in conventional primary prostate carcinoma (<3% of cases), including an activating hotspot BRAF mutation (p.K601E), an activating hotspot mutation in HRAS (p.Q61K) and an in-frame activating deletion in BRAF (p.T488_Q493delinsK).
Prostate Adenocarcinoma	BAX	11276013	This is the first study to demonstrate that Bcl-2 transfection modulates the expression of mutant p53, Bax, and PCNA in prostate cancer cells.
Prostate Adenocarcinoma	PCNA	11276013	This is the first study to demonstrate that Bcl-2 transfection modulates the expression of mutant p53, Bax, and PCNA in prostate cancer cells.
Prostate Adenocarcinoma	TP53	11276013	This is the first study to demonstrate that Bcl-2 transfection modulates the expression of mutant p53, Bax, and PCNA in prostate cancer cells.
Prostate Adenocarcinoma	FGFR4	20876804	Studies with cultured prostate carcinoma cell lines showed that the FGFR4-R388 variant, which has previously been associated with poor cancer prognosis, increased MT1-MMP-dependent collagen invasion.
Prostate Adenocarcinoma	MMP14	20876804	Studies with cultured prostate carcinoma cell lines showed that the FGFR4-R388 variant, which has previously been associated with poor cancer prognosis, increased MT1-MMP-dependent collagen invasion.
Prostate Adenocarcinoma	MYC	21779461	Alterations in chromosome 8q24 in the region of MYC have also been linked to disease aggressiveness for many years.
Prostate Adenocarcinoma	PTEN	27080984	PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.
Prostate Adenocarcinoma	NKX3-1	25360740	Nevertheless, ectopic expression of NKX3.1, which is degraded upon proinflammatory cytokine exposure in inflammation, was found to induce the degradation of beta-catenin by inhibiting Akt(S473) phosphorylation, therefore, partially rescued the disrupted beta-catenin-E-cadherin interaction as well as the cell migration in LNCaP cells upon cytokine exposure.
Prostate Adenocarcinoma	AKT1	25360740	Nevertheless, ectopic expression of NKX3.1, which is degraded upon proinflammatory cytokine exposure in inflammation, was found to induce the degradation of beta-catenin by inhibiting Akt(S473) phosphorylation, therefore, partially rescued the disrupted beta-catenin-E-cadherin interaction as well as the cell migration in LNCaP cells upon cytokine exposure.
Prostate Adenocarcinoma	CTNNB1	25360740	Nevertheless, ectopic expression of NKX3.1, which is degraded upon proinflammatory cytokine exposure in inflammation, was found to induce the degradation of beta-catenin by inhibiting Akt(S473) phosphorylation, therefore, partially rescued the disrupted beta-catenin-E-cadherin interaction as well as the cell migration in LNCaP cells upon cytokine exposure.
Prostate Adenocarcinoma	CDH1	25360740	Nevertheless, ectopic expression of NKX3.1, which is degraded upon proinflammatory cytokine exposure in inflammation, was found to induce the degradation of beta-catenin by inhibiting Akt(S473) phosphorylation, therefore, partially rescued the disrupted beta-catenin-E-cadherin interaction as well as the cell migration in LNCaP cells upon cytokine exposure.
Prostate Adenocarcinoma	PTEN	26554830	Chromosome 10q23 deletions, encompassing PTEN, and amplification of 8q24, harboring MYC, are frequently observed, and the presence of both together portends a high risk of prostate cancer-specific mortality.
Prostate Adenocarcinoma	PTEN	26554830	We hypothesized that driving combined MYC overexpression and Pten loss using recently characterized Hoxb13 transcriptional control elements that are active in prostate luminal epithelial cells would induce the development of genomic instability and aggressive disease with metastatic potential.
Prostate Adenocarcinoma	HOXB13	26554830	We hypothesized that driving combined MYC overexpression and Pten loss using recently characterized Hoxb13 transcriptional control elements that are active in prostate luminal epithelial cells would induce the development of genomic instability and aggressive disease with metastatic potential.
Prostate Adenocarcinoma	CDH1	9116756	Alterations in the E-cadherin-mediated cell-cell adhesion pathway are commonly observed in urologic malignancies.
Prostate Adenocarcinoma	SPOP	31392082	Disability or mutation of the SPOP gene has been reported to contribute to prostate cancer incidence and prognosis.
Prostate Adenocarcinoma	MME	29704385	Loss of CD10 expression appears to be associated with increasing tumour grade in carcinoma prostate and this can potentially be useful in stratification of such patients.
Prostate Adenocarcinoma	PTPA	23598299	BACKGROUND: Protein phosphatase 2A (PP2A) is a dephosphorylating enzyme, loss of which can contribute to prostate cancer (PCa) pathogenesis.
Prostate Adenocarcinoma	AKR1C3	21134280	RESULTS: Microarray and bioinformatics analysis suggested that overexpression of AKR1C3 in PC-3 cells modulates estrogen and androgen metabolism, activates insulin-like growth factor (IGF)-1 and Akt signaling pathways, as well as promotes tumor angiogenesis and aggressiveness.
Prostate Adenocarcinoma	THBD	27498545	However, the urothelial markers CK34betaE12, p63, thrombomodulin, S100P, and GATA3 were also positive in 1.8%, 0%, 0%, 3.6%, and 0% of PAC, respectively.
Prostate Adenocarcinoma	GATA3	27498545	However, the urothelial markers CK34betaE12, p63, thrombomodulin, S100P, and GATA3 were also positive in 1.8%, 0%, 0%, 3.6%, and 0% of PAC, respectively.
Prostate Adenocarcinoma	TP63	27498545	However, the urothelial markers CK34betaE12, p63, thrombomodulin, S100P, and GATA3 were also positive in 1.8%, 0%, 0%, 3.6%, and 0% of PAC, respectively.
Prostate Adenocarcinoma	CBX8	18757413	The GSK3 inhibitor lithium chloride and, more effectively, GSK3 gene silencing sensitized PC3 and DU145 prostate cancer cells to CDDO-Me cytotoxicity.
Prostate Adenocarcinoma	KLK3	10188912	The mutations in the core enhancer and promoter region probably contribute to the aberrant expression of the PSA gene in breast tumours, possibly by altering the regulation of the gene by steroid hormones.
Prostate Adenocarcinoma	SLC39A11	25900876	Four variants within ZIP11 were significantly associated with bladder cancer risk: rs11871756 (OR = 1.43, 95 % CI (1.24-1.63), p = 0.0002), rs11077654 (OR = 0.76, 95 % CI (0.68-0.85), p = 0.001), rs9913017 (OR = 0.76, 95 % CI (0.68-0.85), p = 0.002), and rs4969054 (OR = 0.78, 95 % CI (0.69-0.88), p = 0.02); the three protective variants were co-located and highly correlated.
Prostate Adenocarcinoma	LGALS3	10550525	We conclude that loss of galectin-3 expression may be associated with the progression of prostate cancer.
Prostate Adenocarcinoma	TFF2	20112343	We hypothesized that promoter methylation contributes to the regulation of trefoil factors (TFF1, TFF2 and TFF3) in human prostate cells.
Prostate Adenocarcinoma	TFF3	20112343	We hypothesized that promoter methylation contributes to the regulation of trefoil factors (TFF1, TFF2 and TFF3) in human prostate cells.
Prostate Adenocarcinoma	TFF1	20112343	We hypothesized that promoter methylation contributes to the regulation of trefoil factors (TFF1, TFF2 and TFF3) in human prostate cells.
Prostate Adenocarcinoma	ERG	21317715	ERG, an ETS family transcription factor, is known to be expressed in endothelial cells, and oncogenic ERG gene fusions occur in subsets of prostatic carcinoma, acute myeloid leukemia, and Ewing sarcoma.
Prostate Adenocarcinoma	TP53	16496070	BACKGROUND AND PURPOSE: p53 mutation and Bcl-2 overexpression is correlated with advanced prostate cancer.
Prostate Adenocarcinoma	BRCA2	33426488	Conclusions: We present the first Japanese case of a metastatic abiraterone acetate-resistant castration-resistant prostate cancer accompanied by BRCA2 mutation.
Prostate Adenocarcinoma	GRP	17372572	CONCLUSIONS: The modifications in the BBS(7-14) sequence led to a higher plasma stability while binding affinity remained unaffected.
Prostate Adenocarcinoma	GSTP1	10334105	CONCLUSIONS: GST P hypermethylation is an extremely frequent change in prostatic carcinoma which most probably precedes genome-wide hypomethylation.
Prostate Adenocarcinoma	AR	26671992	PURPOSE: The transition of prostate adenocarcinoma to a predominantly androgen receptor (AR) signaling independent phenotype can occur in the later stages of the disease and is associated with low AR expression +/- the development of small-cell or neuroendocrine tumor characteristics.
Prostate Adenocarcinoma	FGFR4	20876804	Aberrant expression and polymorphism of fibroblast growth factor receptor 4 (FGFR4) has been linked to tumor progression and anticancer drug resistance.
Prostate Adenocarcinoma	PTEN	23995785	Mutations in the PTEN tumor suppressor gene are found in a high proportion of human prostate cancers, and in mice, Pten deletion induces high-grade prostate intraepithelial neoplasia (HGPIN).
Prostate Adenocarcinoma	ERBB2	16163160	Among HER-family receptors, HER2 activation is particularly important in breast cancer, as HER2 gene amplification is associated with a distinct clinical course and response to treatment with a HER2-directed therapy (trastuzumab).
Prostate Adenocarcinoma	BRCA1	20215531	RESULTS: BRCA2 mutations were associated with a 3-fold risk of prostate cancer [odds ratio, 3.18; 95% confidence interval (95% CI), 1.52-6.66; P = 0.002] and presented with more poorly differentiated (Gleason score &gt; or =7) tumors (85% versus 57%; P = 0.0002) compared with non-BRCA-associated prostate cancer.
Prostate Adenocarcinoma	BRCA2	20215531	RESULTS: BRCA2 mutations were associated with a 3-fold risk of prostate cancer [odds ratio, 3.18; 95% confidence interval (95% CI), 1.52-6.66; P = 0.002] and presented with more poorly differentiated (Gleason score &gt; or =7) tumors (85% versus 57%; P = 0.0002) compared with non-BRCA-associated prostate cancer.
Prostate Adenocarcinoma	TP53	9803006	Since the neovascularity of prostate tumors can be attenuated by radiation and hormones, while mutant p53 may confer resistance to such treatment, it appears that p53 expression may also play an important role in addition to angiogenesis in the virulence of prostate cancer.
Prostate Adenocarcinoma	MUC1	18628787	Common variants in MUC1 and the surrounding region are not associated with risk or prognosis of prostate cancer in Swedish men.
Prostate Adenocarcinoma	KLK3	16496070	CONCLUSIONS: p53 mutation was positively correlated with serum PSA and tumor extent.
Prostate Adenocarcinoma	TP53	16496070	CONCLUSIONS: p53 mutation was positively correlated with serum PSA and tumor extent.
Prostate Adenocarcinoma	PTEN	9823969	Mutations in PTEN have been identified in cell lines derived from gliomas, melanomas and prostate tumours and from a number of tumour specimens derived from glial, breast, endometrial and kidney tissue.
Prostate Adenocarcinoma	STAT1	14656722	These data suggest that there is progressive dysregulation of nuclear factor-kappa B and STAT1 in prostate cancer cells that leads to proangiogenic production of CXC chemokines.
Prostate Adenocarcinoma	CDH1	11486167	A statically significant association between aberrant E-cadherin expression and larger tumor size was identified.
Prostate Adenocarcinoma	PTEN	27080984	We evaluated whether PTEN loss, chromosome 8q gain (MYC) and/or 8p loss (LPL) measured only on G3 cores is associated with un-sampled G4 tumor.
Prostate Adenocarcinoma	MYC	27080984	We evaluated whether PTEN loss, chromosome 8q gain (MYC) and/or 8p loss (LPL) measured only on G3 cores is associated with un-sampled G4 tumor.
Prostate Adenocarcinoma	C8orf17	17143515	RT-PCR analyses of breast and prostatic biopsies revealed MOST-1 overexpression and/or amplification in high-grade carcinomas.
Prostate Adenocarcinoma	RET	31619220	In about 75% of cases it is sporadic while, in case of RET mutation, it is associated to multiple endocrine neoplasia type 2 (25% of cases).
Prostate Adenocarcinoma	GBX2	31200836	Loss of TET2 in prostate cells resulted in greater GBX2 methylation.
Prostate Adenocarcinoma	TET2	31200836	Loss of TET2 in prostate cells resulted in greater GBX2 methylation.
Prostate Adenocarcinoma	CD8A	28912897	For the remaining tumor types, compared with TIMT II (low PD-L1 and CD8A/CYT), TIMT I (high PD-L1 and CD8A/CYT) had a significantly higher number of mutations or neoantigens in bladder urothelial carcinoma, breast and cervical cancer, colorectal, stomach and lung adenocarcinoma, and melanoma.
Prostate Adenocarcinoma	CD274	28912897	For the remaining tumor types, compared with TIMT II (low PD-L1 and CD8A/CYT), TIMT I (high PD-L1 and CD8A/CYT) had a significantly higher number of mutations or neoantigens in bladder urothelial carcinoma, breast and cervical cancer, colorectal, stomach and lung adenocarcinoma, and melanoma.
Prostate Adenocarcinoma	AR	18084622	Together, our observations provide support for the idea that the loss of p53 function in prostate cancer cells contributes to increased expression of AR.
Prostate Adenocarcinoma	TP53	18084622	Together, our observations provide support for the idea that the loss of p53 function in prostate cancer cells contributes to increased expression of AR.
Prostate Adenocarcinoma	BNIP3L	12610513	Genetic analysis of BNIP3L in 40 primary ovarian and 25 primary breast tumours identified one somatic, intronic mutation in one ovarian tumour, as well as several polymorphisms, including one resulting in an amino-acid substitution.
Prostate Adenocarcinoma	AKT1	17163422	We provide evidence that loss of PTEN expression rather than upregulated EGF/IGF1 receptor expression was responsible for increased p-Akt in neoplastic prostate cells.
Prostate Adenocarcinoma	PTEN	17163422	We provide evidence that loss of PTEN expression rather than upregulated EGF/IGF1 receptor expression was responsible for increased p-Akt in neoplastic prostate cells.
Prostate Adenocarcinoma	PTEN	11586263	PTEN mutations in microdissected morphologically normal and BPH tissue showed alterations in nontumor tissue surrounding adenocarcinoma.
Prostate Adenocarcinoma	TP53	7559095	The wild-type p53 gene has a polymorphism at codon 72 that presents the arginine (CGC) or proline (CCC) genotype, which recently has been reported to be associated with genetically determined susceptibility to smoking-related lung cancers.
Prostate Adenocarcinoma	ERBB2	7823598	Our results confirm that p53 mutations are common in breast cancer and that there is strong expression of p185erbB-2 on the membranes of a subset of breast cancers.
Prostate Adenocarcinoma	TP53	7823598	Our results confirm that p53 mutations are common in breast cancer and that there is strong expression of p185erbB-2 on the membranes of a subset of breast cancers.
Prostate Adenocarcinoma	MXI1	9458379	Due to the detection of point mutations in the retained alleles of four primary adenocarcinomas of the prostate, MXI1 gene alterations have been suggested to be involved in the development and/or the progression of prostate cancer.
Prostate Adenocarcinoma	TP53	7559095	Alterations in the p53 tumor suppressor gene appear to be important in the development of many human tumors.
Prostate Adenocarcinoma	TP53	33968663	Conclusions: Mutations in the TP53 gene can adversely affect the prognosis of prostate cancer and prostate cancer patients with mutations in some immune-related genes together have a worse prognosis.
Prostate Adenocarcinoma	MLH1	30636012	We found that DNA damage repair mutations are common in this rare subset of prostate tumours, with two of eight having bi-allelic pathogenic mutations in homologous DNA repair genes (including BRCA2 and NBN) and two of eight having bi-allelic pathogenic mutations in mismatch repair genes (including MSH2 and MLH1).
Prostate Adenocarcinoma	BRCA2	30636012	We found that DNA damage repair mutations are common in this rare subset of prostate tumours, with two of eight having bi-allelic pathogenic mutations in homologous DNA repair genes (including BRCA2 and NBN) and two of eight having bi-allelic pathogenic mutations in mismatch repair genes (including MSH2 and MLH1).
Prostate Adenocarcinoma	MSH2	30636012	We found that DNA damage repair mutations are common in this rare subset of prostate tumours, with two of eight having bi-allelic pathogenic mutations in homologous DNA repair genes (including BRCA2 and NBN) and two of eight having bi-allelic pathogenic mutations in mismatch repair genes (including MSH2 and MLH1).
Prostate Adenocarcinoma	NBN	30636012	We found that DNA damage repair mutations are common in this rare subset of prostate tumours, with two of eight having bi-allelic pathogenic mutations in homologous DNA repair genes (including BRCA2 and NBN) and two of eight having bi-allelic pathogenic mutations in mismatch repair genes (including MSH2 and MLH1).
Prostate Adenocarcinoma	CTNNB1	32758244	APC mutations associated with loss of beta-catenin degradation in the Wnt signaling pathway and result in over accumulation of beta-catenin are thought to increase mortality.
Prostate Adenocarcinoma	PTEN	26554830	Neoplastic lesions that developed with either MYC activation alone (Hoxb13-MYC) or Pten loss alone (Hoxb13-Cre Pten(Fl/Fl)) failed to progress beyond prostatic intraepithelial neoplasia and did not harbor genomic CNAs.
Prostate Adenocarcinoma	HOXB13	26554830	Neoplastic lesions that developed with either MYC activation alone (Hoxb13-MYC) or Pten loss alone (Hoxb13-Cre Pten(Fl/Fl)) failed to progress beyond prostatic intraepithelial neoplasia and did not harbor genomic CNAs.
Prostate Adenocarcinoma	AR	17189428	In contrast, the interaction of antagonist-bound or mutant AR with its target was found to be kinetically different: it was dramatically faster, occurred without chromatin remodeling, and resulted in the lack of transcriptional inhibition.
Prostate Adenocarcinoma	FGFR1	18068632	Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.
Prostate Adenocarcinoma	ERBB2	11222871	Amplification or overexpression of erbB-2 occurs in many forms of cancer, such as of the breast, colon, and prostate, and is an indicator of poor prognosis in those diseases.
Prostate Adenocarcinoma	PAWR	20724592	In contrast, specific Par-4 silencing by small-interfering RNA determined activation of CCA cell line proliferation.
Prostate Adenocarcinoma	CYP17A1	10897051	A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Prostate Adenocarcinoma	CYP17A1	10897051	We conducted a case-control study of 63 patients with untreated histologically proven prostate cancer and 126 age-matched control men with benign prostatic hyperplasia (BPH) to determine whether a polymorphism in the CYP17 gene is associated with prostate cancer risk.
Prostate Adenocarcinoma	CYP1B1	15330195	This pilot study showed that CYP1B1 and PR polymorphisms, alone or in combination, might be associated with prostate cancer risk.
Prostate Adenocarcinoma	PGR	15330195	This pilot study showed that CYP1B1 and PR polymorphisms, alone or in combination, might be associated with prostate cancer risk.
Prostate Adenocarcinoma	KLK3	21091977	CONCLUSIONS: ET-1 expression was strongly associated with ECE and, when combined with pre-operative PSA level and Gleason score, improved the predictive accuracy of pre-operative NBs.
Prostate Adenocarcinoma	EDN1	21091977	CONCLUSIONS: ET-1 expression was strongly associated with ECE and, when combined with pre-operative PSA level and Gleason score, improved the predictive accuracy of pre-operative NBs.
Prostate Adenocarcinoma	TMEM37	2208148	Two mutations were detected: an A----G transition causing a glutamine to arginine amino acid substitution at codon 61 of the Ha-ras gene in a primary prostatic duct adenocarcinoma and a G----T transversion causing a glycine to valine amino acid substitution at codon 12 of the Ha-ras gene in a prostate tumor cell line (TSU-PR1) derived from a lymph node metastasis.
Prostate Adenocarcinoma	TP53	8633403	OBJECTIVES: Mutations of the p53 tumor suppressor gene can result in unregulated cellular growth and have been implicated in numerous malignancies.
Prostate Adenocarcinoma	CDK2	20147522	Similarly, knockdown of the CDK2 substrate retinoblastoma, which causes cyclin E up-regulation, resulted in resistance to 1,25-(OH)(2)D(3)-mediated growth inhibition.
Prostate Adenocarcinoma	MIR130B	31266828	Inhibition of miR-130b modulated critical prostate cancer-related biological pathways in AA compared with EA prostate cancer patients.
Prostate Adenocarcinoma	MYH11	18796164	We have previously shown that MYH11 mutations occur in human colorectal cancer, and may also be associated with Peutz-Jeghers syndrome.
Prostate Adenocarcinoma	AMACR	15323145	The recent discovery of the overexpression of P504S/alpha-methylacyl coenzyme A racemase (AMACR) in prostate cancer is a successful example of translating an advanced molecular finding into clinical practice.
Prostate Adenocarcinoma	CDH1	11751506	PURPOSE: Prostate cancer progression is associated with deregulation of genes like E-cadherin, p21/WAF1, MMP-2, VEGF, and IGF-binding protein, 3 and 5, all of which are target genes for the transcription factor activator protein 2alpha (AP-2alpha).
Prostate Adenocarcinoma	VEGFA	11751506	PURPOSE: Prostate cancer progression is associated with deregulation of genes like E-cadherin, p21/WAF1, MMP-2, VEGF, and IGF-binding protein, 3 and 5, all of which are target genes for the transcription factor activator protein 2alpha (AP-2alpha).
Prostate Adenocarcinoma	CDKN1A	11751506	PURPOSE: Prostate cancer progression is associated with deregulation of genes like E-cadherin, p21/WAF1, MMP-2, VEGF, and IGF-binding protein, 3 and 5, all of which are target genes for the transcription factor activator protein 2alpha (AP-2alpha).
Prostate Adenocarcinoma	TFAP2A	11751506	PURPOSE: Prostate cancer progression is associated with deregulation of genes like E-cadherin, p21/WAF1, MMP-2, VEGF, and IGF-binding protein, 3 and 5, all of which are target genes for the transcription factor activator protein 2alpha (AP-2alpha).
Prostate Adenocarcinoma	MMP2	11751506	PURPOSE: Prostate cancer progression is associated with deregulation of genes like E-cadherin, p21/WAF1, MMP-2, VEGF, and IGF-binding protein, 3 and 5, all of which are target genes for the transcription factor activator protein 2alpha (AP-2alpha).
Prostate Adenocarcinoma	MYC	21435462	We verify that activation of the MYC oncogene, which is overexpressed in most human PIN and prostatic adenocarcinomas, leads to formation of enlarged nucleoli and increased nucleolar number in prostate luminal epithelial cells in vivo.
Prostate Adenocarcinoma	TP53	7879337	Importantly, most reports have demonstrated that p53 mutations detected by IHC are a late step in the progression of prostate cancer and are associated with advanced disease, dedifferentiation, and the acquisition of androgen independence.
Prostate Adenocarcinoma	NFE2L2	33101586	The present study revealed that NFE2L2 was abnormally expressed and significantly correlated with mismatch repair (MMR) gene mutation levels and DNA methyltransferase expression in human pan-cancer.
Prostate Adenocarcinoma	MMP7	20605361	PURPOSE: To evaluate whether selected high-risk matrix metalloproteinase-7 single nucleotide polymorphisms influence clinicopathologic outcomes in patients with early-stage prostate cancer.
Prostate Adenocarcinoma	TMPRSS2	17059688	These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer.
Prostate Adenocarcinoma	ERG	17059688	These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer.
Prostate Adenocarcinoma	MGP	1399132	Our findings indicate that the loss of MGP expression may be associated wih tumor progression and metastasis.
Prostate Adenocarcinoma	PEG3	30626088	Notably, we report on different genetic modifications that significantly improved PEG3 promoter's strength in PCa cells.
Prostate Adenocarcinoma	KLF6	17223258	In light of the reported functional involvement of the KLF6 gene in lung cancer and in other cancer types and to the functional nature of the rs3750861 SNP, our results suggest a potential involvement of KLF6 polymorphisms in lung cancer risk, although additional studies in large series are needed to confirm our findings and to elucidate the mechanism by which the KLF6 SNPs influence lung cancer risk.
Prostate Adenocarcinoma	STAT1	14656722	Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines.
Prostate Adenocarcinoma	NFKB1	14656722	Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines.
Prostate Adenocarcinoma	PTEN	23995785	The activation of TGFbeta signaling by Pten loss or AKT activation suggests that the same signaling events that have key roles in tumor initiation also induce the activity of a pathway that restrains disease progression.
Prostate Adenocarcinoma	AR	28253524	The presence of androgen receptor (AR) in RCC has recently been shown to be associated with higher tumour stage irrespective of gender.
Prostate Adenocarcinoma	KLK3	1691151	Most of the BPH samples contained marked amounts of an aberrant 0.9 kb mRNA, and long PSA mRNAs of 6.1 kb, 4.5 kb and 3.1 kb were found in elevated amounts in some of the CA samples.
Prostate Adenocarcinoma	TMPRSS2	33609069	Hypomethylation of TMPRSS2 promoter may not be the mechanism for TMPRSS2 overexpression in PRAD tissues and PRAD pathogenesis.
Prostate Adenocarcinoma	RALGAPA2	31058283	Silencing of RalGAPalpha2 by short hairpin RNA enhanced migration and invasion abilities of benign and malignant prostate epithelial cell lines without affecting cell proliferation.
Prostate Adenocarcinoma	AR	18701501	In addition, the continuous activation of NF-kappaB signaling in vivo by the absence of the IkappaBalpha inhibitor prevents regression of the prostate after castration by sustaining high levels of nuclear AR and maintaining differentiated function and continued proliferation of the epithelium.
Prostate Adenocarcinoma	NFKBIA	18701501	In addition, the continuous activation of NF-kappaB signaling in vivo by the absence of the IkappaBalpha inhibitor prevents regression of the prostate after castration by sustaining high levels of nuclear AR and maintaining differentiated function and continued proliferation of the epithelium.
Prostate Adenocarcinoma	TMPRSS2	29629426	Background: TMPRSS2-ERG gene fusions are frequently found in prostate cancer and are pathognomomic for prostatic origin.
Prostate Adenocarcinoma	ERG	29629426	Background: TMPRSS2-ERG gene fusions are frequently found in prostate cancer and are pathognomomic for prostatic origin.
Prostate Adenocarcinoma	MED1	22869146	We found that hypermethylation of the MIR-205 locus was strongly related with a decrease in miR-205 expression and an increase in MED1 expression in primary tumor samples (n=14), when compared with matched normal prostate (n=7).
Prostate Adenocarcinoma	CDK2	20147522	Ectopic expression of cyclin E was sufficient to overcome 1,25-(OH)(2)D(3)-mediated cytoplasmic mislocalization of CDK2 and all antiproliferative effects of 1,25-(OH)(2)D(3), yet endogenous levels of cyclin E or binding to CDK2 were not affected by 1,25-(OH)(2)D(3).
Prostate Adenocarcinoma	LYVE1	16033069	CONCLUSION: Point mutations of hAR are not necessary for metastatic prostate cancer, while alterations in the solyglutamine and polyglycine repeat region in exon 1 of the MR gene are more often found.
Prostate Adenocarcinoma	NANOG	31624231	We showed that, in one patient with pancreatic cancer, the expression of a truncated form of SPOP (p.Q360*) lacking the nuclear localization signal led to nuclear accumulation of NANOG, which promoted growth and metastasis of pancreatic cancer cells.
Prostate Adenocarcinoma	SPOP	31624231	We showed that, in one patient with pancreatic cancer, the expression of a truncated form of SPOP (p.Q360*) lacking the nuclear localization signal led to nuclear accumulation of NANOG, which promoted growth and metastasis of pancreatic cancer cells.
Prostate Adenocarcinoma	SOD2	19074884	Selenium status also modifies the effect of the mitochondrial superoxide dismutase (SOD2) SNP Ala16Val on prostate cancer risk.
Prostate Adenocarcinoma	ERG	20585344	Gene fusions prevalent in prostate cancer (CaP) lead to the elevated expression of the ERG proto-oncogene.
Prostate Adenocarcinoma	EGFR	17290443	BACKGROUND: Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in human cancers are associated with increased sensitivity to anilinoquinazoline EGFR inhibitors.
Prostate Adenocarcinoma	AR	9815849	Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer.
Prostate Adenocarcinoma	UCN	19058138	While Ucn expression in prostate cancer has been shown to be identical to non-malignant prostate tissues, we hypothesize that expression loss of CRFR2 in prostate cancer and its neovascularization contributes to prostate tumorigenesis, progression, and neoangiogenesis.
Prostate Adenocarcinoma	CRHR2	19058138	While Ucn expression in prostate cancer has been shown to be identical to non-malignant prostate tissues, we hypothesize that expression loss of CRFR2 in prostate cancer and its neovascularization contributes to prostate tumorigenesis, progression, and neoangiogenesis.
Prostate Adenocarcinoma	NFKB1	32201312	Whether CRPCa is due to aberrant AR activity or AR independence, NF-kappaB signaling is also implicated in the initiation and maintenance of CRPCa and, thus, the NF-kappaB pathway may be a promising alternative therapeutic target.
Prostate Adenocarcinoma	AR	18084622	We found that in LNCaP human prostate cancer cells that express the wild-type p53 and AR and in human normal PrECs, the activation of p53 by genotoxic stress or by inhibition of p53 nuclear export downregulated the expression of AR.
Prostate Adenocarcinoma	TP53	18084622	We found that in LNCaP human prostate cancer cells that express the wild-type p53 and AR and in human normal PrECs, the activation of p53 by genotoxic stress or by inhibition of p53 nuclear export downregulated the expression of AR.
Prostate Adenocarcinoma	TP53	1347085	Alterations of the P53 gene are associated with the progression of a human prostate carcinoma.
Prostate Adenocarcinoma	AR	10810359	Androgen receptor gene mutations do not occur in ovarian cancer.
Prostate Adenocarcinoma	THBS1	11205922	We reported recently that mutant p53 (mp53) was associated with decreased expression of an endogenous inhibitor of angiogenesis, thrombospondin-1 (TSP-1), and increased microvessel density in melanoma and breast cancer.
Prostate Adenocarcinoma	TP53	11205922	We reported recently that mutant p53 (mp53) was associated with decreased expression of an endogenous inhibitor of angiogenesis, thrombospondin-1 (TSP-1), and increased microvessel density in melanoma and breast cancer.
Prostate Adenocarcinoma	SH3PXD2A	24174371	We also manipulated the expression and activity of wild-type and mutant Src and Tks5 constructs in the LNCaP and PC-3 prostate cancer cell lines in order to ascertain the role of Src-Tks5 signaling in invadopodia development, matrix-remodeling activity, motility, and invasion.
Prostate Adenocarcinoma	SRC	24174371	We also manipulated the expression and activity of wild-type and mutant Src and Tks5 constructs in the LNCaP and PC-3 prostate cancer cell lines in order to ascertain the role of Src-Tks5 signaling in invadopodia development, matrix-remodeling activity, motility, and invasion.
Prostate Adenocarcinoma	AR	10810359	Human androgen receptor (hAR) gene mutations have been found in up to 50% of hormone-relapsed prostate cancer.
Prostate Adenocarcinoma	LYVE1	10810359	Human androgen receptor (hAR) gene mutations have been found in up to 50% of hormone-relapsed prostate cancer.
Prostate Adenocarcinoma	BRCA2	30808988	The influence of BRCA2 mutation on localized prostate cancer.
Prostate Adenocarcinoma	ELF5	26288799	CONCLUSIONS: Our in vitro experiments of cell growth and microarray analysis have demonstrated for the first time that decreased expression of period circadian protein homolog 1 due to ELF5 inhibition may induce the possibility of reacquisition of hormone sensitiveness of PCa cells.
Prostate Adenocarcinoma	PER1	26288799	CONCLUSIONS: Our in vitro experiments of cell growth and microarray analysis have demonstrated for the first time that decreased expression of period circadian protein homolog 1 due to ELF5 inhibition may induce the possibility of reacquisition of hormone sensitiveness of PCa cells.
Prostate Adenocarcinoma	TP53	10071598	Furthermore, recent evidence indicates that an apoptotic block through p53 mutations or bcl-2 overexpression may have a potential role in the poor responses seen with standard chemotherapy.
Prostate Adenocarcinoma	ALOX15B	17018618	Wild-type and mutant ANXA7 distinctly affected expression of the dexamethasone-induced 15-LOX-2 (a prostate-specific endogenous tumor suppressor) as well as the IL-4-induced 15-LOX-1.
Prostate Adenocarcinoma	ANXA7	17018618	Wild-type and mutant ANXA7 distinctly affected expression of the dexamethasone-induced 15-LOX-2 (a prostate-specific endogenous tumor suppressor) as well as the IL-4-induced 15-LOX-1.
Prostate Adenocarcinoma	ALOX5	17018618	Wild-type and mutant ANXA7 distinctly affected expression of the dexamethasone-induced 15-LOX-2 (a prostate-specific endogenous tumor suppressor) as well as the IL-4-induced 15-LOX-1.
Prostate Adenocarcinoma	SFN	15131044	Loss of 14-3-3sigma is associated with failure to arrest the cell cycle at the G(2)-M phase checkpoint after DNA damage that leads to increased G(2)-type chromosomal aberrations.
Prostate Adenocarcinoma	NAT1	21347396	RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition.
Prostate Adenocarcinoma	CDH1	21347396	RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition.
Prostate Adenocarcinoma	UBE2M	33905671	Depletion of NPRL2 or UBE2M significantly increases the niraparib sensitivity of CRPC cells and enhances niraparib-induced tumor growth inhibition in vivo.
Prostate Adenocarcinoma	NPRL2	33905671	Depletion of NPRL2 or UBE2M significantly increases the niraparib sensitivity of CRPC cells and enhances niraparib-induced tumor growth inhibition in vivo.
Prostate Adenocarcinoma	MLPH	31659808	This study provides strong evidence showing that prostate cancer risk SNP rs13426236 upregulates expression of MLPH transcript V4, which may function as a candidate oncogene in prostate cancer.
Prostate Adenocarcinoma	PTEN	20208477	Alterations in the EGFR-PTEN signaling pathway are present in a third of prostate adenocarcinomas, particularly affecting the more advanced cases.
Prostate Adenocarcinoma	YY1	16784892	The regulation of YY1 expression and activity by NF-kappaB was demonstrated by the use of the NF-kappaB inhibitor Bay 11-7085 and by the use of a GFP reporter system whereby deletion of the YY1-tandem binding site in the promoter significantly enhanced GFP expression.
Prostate Adenocarcinoma	CDKN2A	9815578	A high level of CDKN2 expression was related to abnormal RB1 in one primary tumor and in the DU145 cell line, which expressed the mutated CDKN2 allele.
Prostate Adenocarcinoma	RB1	9815578	A high level of CDKN2 expression was related to abnormal RB1 in one primary tumor and in the DU145 cell line, which expressed the mutated CDKN2 allele.
Prostate Adenocarcinoma	MST1R	19838218	The knockdown of Ron in PC-3 or DU145 cells results in a significant decrease in angiogenic chemokine production and is associated with a decreased activation of the transcription factor nuclear factor-kappaB (NF-kappaB).
Prostate Adenocarcinoma	NFKB1	19838218	The knockdown of Ron in PC-3 or DU145 cells results in a significant decrease in angiogenic chemokine production and is associated with a decreased activation of the transcription factor nuclear factor-kappaB (NF-kappaB).
Prostate Adenocarcinoma	TACSTD2	31932422	Overexpression of Trop2 induces tumor growth and metastasis while loss of Trop2 suppresses these abilities in vivo.
Prostate Adenocarcinoma	TP53	19592505	Although ERG overexpression does not cooperate with loss of the tumor suppressor p53, it does collaborate with alterations in PI3K signaling, such as Pten knockdown or AKT up-regulation, to produce a well-differentiated adenocarcinoma.
Prostate Adenocarcinoma	AKT1	19592505	Although ERG overexpression does not cooperate with loss of the tumor suppressor p53, it does collaborate with alterations in PI3K signaling, such as Pten knockdown or AKT up-regulation, to produce a well-differentiated adenocarcinoma.
Prostate Adenocarcinoma	PTEN	19592505	Although ERG overexpression does not cooperate with loss of the tumor suppressor p53, it does collaborate with alterations in PI3K signaling, such as Pten knockdown or AKT up-regulation, to produce a well-differentiated adenocarcinoma.
Prostate Adenocarcinoma	ERG	19592505	Although ERG overexpression does not cooperate with loss of the tumor suppressor p53, it does collaborate with alterations in PI3K signaling, such as Pten knockdown or AKT up-regulation, to produce a well-differentiated adenocarcinoma.
Prostate Adenocarcinoma	AURKA	25128228	When histologically similar cases with and without AURKA amplification were compared, this gene alteration was associated with larger extent of Paneth cell-like NED identified at magnification x20 (P = .015), higher percentage of Paneth cell-like NED throughout the tumor nodule (P = .033), ductal features (P = .02), and higher overall Gleason grade (P = .039).
Prostate Adenocarcinoma	AURKA	25128228	Aurora kinase A (AURKA) gene amplification has been documented in 67% of hormone-naive prostate cancer cases that progress to a highly aggressive variant of castrate-resistant disease, clinically referred to as "neuroendocrine" prostate cancer, "small cell" prostate carcinoma, or "anaplastic" prostate cancer.
Prostate Adenocarcinoma	ELAC2	14504198	Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study.
Prostate Adenocarcinoma	CDKN2A	9815578	Alteration of CDKN2 was observed in each prostate tumor cell line, including one with a missense mutation, and in one of three xenograft tumor tissues derived from primary carcinomas.
Prostate Adenocarcinoma	GPX3	25929866	Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer.
Prostate Adenocarcinoma	CDKN2A	9815578	This study demonstrates that alteration of CDKN2 is one of the most frequent genetic abnormalities in prostate cancer and may contribute to prostate carcinogenesis.
Prostate Adenocarcinoma	FBP1	31938049	Fructose-1, 6-biphosphatase (FBP1) is a key enzyme in gluconeogenesis and is implicated in human cancer due to its frequent loss in various cancer types.
Prostate Adenocarcinoma	CD274	31938049	Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Prostate Adenocarcinoma	STAT3	31938049	Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Prostate Adenocarcinoma	NFKB2	18781579	In addition, NF-kappaB2/p52 stimulates Cyclin D1 expression and knock down of Cyclin D1 expression by siRNA abolished NF-kappaB2/p52-induced cell growth in vitro.
Prostate Adenocarcinoma	CCND1	18781579	In addition, NF-kappaB2/p52 stimulates Cyclin D1 expression and knock down of Cyclin D1 expression by siRNA abolished NF-kappaB2/p52-induced cell growth in vitro.
Prostate Adenocarcinoma	ZFX	25441684	Functional analysis indicated that ZFX silencing significantly inhibited renal cell carcinoma cell proliferation and cell cycle progression, probably because of suppression of CDK4 and cyclin D1, and induced apoptosis via activation of Bax, Caspase 3, and PUMA in a p53-dependent manner.
Prostate Adenocarcinoma	BRCA1	11405179	A second breast cancer susceptibility gene (BRCA2) operates in some of the same molecular pathways as BRCA1, and mutations of this gene predispose to breast and ovarian cancer and probably to other tumor types, including prostate cancer.
Prostate Adenocarcinoma	BRCA2	11405179	A second breast cancer susceptibility gene (BRCA2) operates in some of the same molecular pathways as BRCA1, and mutations of this gene predispose to breast and ovarian cancer and probably to other tumor types, including prostate cancer.
Prostate Adenocarcinoma	BAX	10725400	Here we show that inhibition of the proteasome activity in Bcl-2-overexpressing cells accumulates the proapoptotic Bax protein to mitochondria/cytoplasm, where it interacts to Bcl-2 protein.
Prostate Adenocarcinoma	SNAI1	28768769	LGR4 knockdown impaired the migration, invasion, and colony formation of DU145 cells and reversed epithelial-mesenchymal transition (EMT), as demonstrated by up-regulation of E-cadherin and decreased expression of the EMT transcription factors ZEB, Twist, and Snail.
Prostate Adenocarcinoma	CDH1	28768769	LGR4 knockdown impaired the migration, invasion, and colony formation of DU145 cells and reversed epithelial-mesenchymal transition (EMT), as demonstrated by up-regulation of E-cadherin and decreased expression of the EMT transcription factors ZEB, Twist, and Snail.
Prostate Adenocarcinoma	LGR4	28768769	LGR4 knockdown impaired the migration, invasion, and colony formation of DU145 cells and reversed epithelial-mesenchymal transition (EMT), as demonstrated by up-regulation of E-cadherin and decreased expression of the EMT transcription factors ZEB, Twist, and Snail.
Prostate Adenocarcinoma	BRCA1	20215531	After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers.
Prostate Adenocarcinoma	BRCA2	20215531	After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers.
Prostate Adenocarcinoma	KLK3	20215531	After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers.
Prostate Adenocarcinoma	FRG1	30975102	Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.
Prostate Adenocarcinoma	AR	11803263	Due to the relationship of the androgen receptor and prostatic growth, it has been proposed that polymorphisms within the androgen receptor may play a role in an individual's susceptibility to developing prostate cancer.
Prostate Adenocarcinoma	VEGFA	23860526	VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.
Prostate Adenocarcinoma	CD82	10551326	Immunohistochemical staining showed that in one case without metastasis, loss of KAI1 mRNA was associated with invasion of the stroma by KAI1 protein-negative cancer cells.
Prostate Adenocarcinoma	TGFB1	12894225	After showing that TGFbeta upregulated p38 MAP kinase activity in PC3-M cells, we show that inhibition of p38 MAP kinase partially blocked TGFbeta-mediated increase in cell adhesion, as well as nuclear translocation of Smad3.
Prostate Adenocarcinoma	SMAD3	12894225	After showing that TGFbeta upregulated p38 MAP kinase activity in PC3-M cells, we show that inhibition of p38 MAP kinase partially blocked TGFbeta-mediated increase in cell adhesion, as well as nuclear translocation of Smad3.
Prostate Adenocarcinoma	MAPK14	12894225	After showing that TGFbeta upregulated p38 MAP kinase activity in PC3-M cells, we show that inhibition of p38 MAP kinase partially blocked TGFbeta-mediated increase in cell adhesion, as well as nuclear translocation of Smad3.
Prostate Adenocarcinoma	CBX8	12894225	After showing that TGFbeta upregulated p38 MAP kinase activity in PC3-M cells, we show that inhibition of p38 MAP kinase partially blocked TGFbeta-mediated increase in cell adhesion, as well as nuclear translocation of Smad3.
Prostate Adenocarcinoma	TFAP2A	11751506	Loss of AP-2alpha may lead to deregulation in AP-2alpha target genes that normally regulate cellular growth and differentiation.
Prostate Adenocarcinoma	MIEN1	19503095	Phosphorylation of PKB/Akt was also reduced upon C17orf37 downregulation, suggesting C17orf37 acts as a signaling molecule that increases invasive potential of prostate cancer cells by NF-kappaB-mediated downstream target genes.
Prostate Adenocarcinoma	BRCA1	23714454	There are, however, moderate to rare genetic variants, which confer a much higher risk of PrCa (e.g., BRCA1/2 and mismatch repair [MMR] repair genes).
Prostate Adenocarcinoma	TMPRSS2	18065961	Frequent presence of the TMPRSS2-ERG in index tumors suggests critical roles of ERG alterations in the onset and progression of a large subset of prostate cancer.
Prostate Adenocarcinoma	ERG	18065961	Frequent presence of the TMPRSS2-ERG in index tumors suggests critical roles of ERG alterations in the onset and progression of a large subset of prostate cancer.
Prostate Adenocarcinoma	PCSK1	19948822	Expression of TRAP-1 in nontransformed prostatic epithelial BPH-1 cells inhibited cell death, whereas silencing of TRAP-1 in androgen-independent PC3 or DU145 prostate cancer cells by small interfering RNA enhanced apoptosis.
Prostate Adenocarcinoma	TRAP1	19948822	Expression of TRAP-1 in nontransformed prostatic epithelial BPH-1 cells inhibited cell death, whereas silencing of TRAP-1 in androgen-independent PC3 or DU145 prostate cancer cells by small interfering RNA enhanced apoptosis.
Prostate Adenocarcinoma	AR	11592091	Also, androgen receptor gene amplification may be a mechanism of prostate cancer cell adaptation to hormonal therapy.
Prostate Adenocarcinoma	FOXA1	28319070	Our data strongly suggest that FOXA1 loss may play a significant role in enabling prostate cancer progression to NEPC, whereas IL-8 and MAPK/ERK pathways may be promising targets for therapeutic intervention.
Prostate Adenocarcinoma	MAPK1	28319070	Our data strongly suggest that FOXA1 loss may play a significant role in enabling prostate cancer progression to NEPC, whereas IL-8 and MAPK/ERK pathways may be promising targets for therapeutic intervention.
Prostate Adenocarcinoma	CTSB	10652560	The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Prostate Adenocarcinoma	BRAF	16721785	RAS mutations are known to occur in prostate adenocarcinomas, but little is known about BRAF mutations in these tumors.
Prostate Adenocarcinoma	MAP2K7	16721785	Constitutive activation of the kinase cascade involving RAS, RAF, MEK and ERK is common to human cancers, and mutations of KRAS and BRAF are mutually exclusive and serve as alternatives to activate the RAS/RAF/ERK signaling pathway.
Prostate Adenocarcinoma	MAPK1	16721785	Constitutive activation of the kinase cascade involving RAS, RAF, MEK and ERK is common to human cancers, and mutations of KRAS and BRAF are mutually exclusive and serve as alternatives to activate the RAS/RAF/ERK signaling pathway.
Prostate Adenocarcinoma	BRAF	16721785	Constitutive activation of the kinase cascade involving RAS, RAF, MEK and ERK is common to human cancers, and mutations of KRAS and BRAF are mutually exclusive and serve as alternatives to activate the RAS/RAF/ERK signaling pathway.
Prostate Adenocarcinoma	ZHX2	16721785	Constitutive activation of the kinase cascade involving RAS, RAF, MEK and ERK is common to human cancers, and mutations of KRAS and BRAF are mutually exclusive and serve as alternatives to activate the RAS/RAF/ERK signaling pathway.
Prostate Adenocarcinoma	KRAS	16721785	Constitutive activation of the kinase cascade involving RAS, RAF, MEK and ERK is common to human cancers, and mutations of KRAS and BRAF are mutually exclusive and serve as alternatives to activate the RAS/RAF/ERK signaling pathway.
Prostate Adenocarcinoma	ROCK1	31557128	ROCK1 up regulation was associated with androgen receptor (AR) expression, TMPRSS2:ERG fusion, genomic deletions of the PTEN tumor suppressor, as well as recurrent deletions at chromosomes 3p, 5q, 6q.
Prostate Adenocarcinoma	TMPRSS2	31557128	ROCK1 up regulation was associated with androgen receptor (AR) expression, TMPRSS2:ERG fusion, genomic deletions of the PTEN tumor suppressor, as well as recurrent deletions at chromosomes 3p, 5q, 6q.
Prostate Adenocarcinoma	AR	31557128	ROCK1 up regulation was associated with androgen receptor (AR) expression, TMPRSS2:ERG fusion, genomic deletions of the PTEN tumor suppressor, as well as recurrent deletions at chromosomes 3p, 5q, 6q.
Prostate Adenocarcinoma	CCND1	19326431	Molecular targets activated due to the loss of phosphatase and tensin homolog (PTEN) including p-Akt, cyclin D1, mammalian target of rapamycin and AR were downregulated by these agents in combination.
Prostate Adenocarcinoma	MTOR	19326431	Molecular targets activated due to the loss of phosphatase and tensin homolog (PTEN) including p-Akt, cyclin D1, mammalian target of rapamycin and AR were downregulated by these agents in combination.
Prostate Adenocarcinoma	PTEN	19326431	Molecular targets activated due to the loss of phosphatase and tensin homolog (PTEN) including p-Akt, cyclin D1, mammalian target of rapamycin and AR were downregulated by these agents in combination.
Prostate Adenocarcinoma	APEX1	25023401	APE1 T1349G polymorphism was considered to be associated with risk of cancer, but studies on the association between APE1 T1349G polymorphism and risk of prostate cancer remained inconclusive.
Prostate Adenocarcinoma	DMTN	10565303	Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression.
Prostate Adenocarcinoma	SPOP	31392082	SPOP knockdown affects DDR repair kinetics, apoptosis and cell cycle checkpoints that are induced by IR (ionizing radiation).
Prostate Adenocarcinoma	NAT1	21347396	In vivo, NAT1 knock-down cells grew with a longer doubling time compared to cells stably transfected with a scrambled RNAi or to parental HT-29 cells.
Prostate Adenocarcinoma	NPEPPS	16721785	Prostate adenocarcinomas with a BRAF mutation tended to show higher preoperative serum PSA levels, Gleason scores and tumor stages than prostate adenocarcinomas with a KRAS mutation.
Prostate Adenocarcinoma	BRAF	16721785	Prostate adenocarcinomas with a BRAF mutation tended to show higher preoperative serum PSA levels, Gleason scores and tumor stages than prostate adenocarcinomas with a KRAS mutation.
Prostate Adenocarcinoma	KRAS	16721785	Prostate adenocarcinomas with a BRAF mutation tended to show higher preoperative serum PSA levels, Gleason scores and tumor stages than prostate adenocarcinomas with a KRAS mutation.
Prostate Adenocarcinoma	AR	11592091	In addition, androgen receptor somatic mutations can result in receptors that have altered binding specificity when compared with wild-type receptors and heightened affinity for hormones other than testosterone and dihydrotestosterone.
Prostate Adenocarcinoma	HOXB13	28186998	A recurrent germline mutation (G84E) in the HOXB13 gene is associated with early onset and family history-positive prostate cancer in patients of European descent, occurring in up to 5% of prostate cancer families.
Prostate Adenocarcinoma	RBP1	15280411	CONCLUSIONS: Altered CRBP1 expression and hypermethylation are common in prostate carcinoma, although CRBP1 hypermethylation is not an early event in tumorigenesis.
Prostate Adenocarcinoma	ESR1	18952763	The purpose of our study was to investigate the effects on PC risk of polymorphisms from three steroid hormone receptor genes: the androgen (AR), and the alpha (ESR1) and beta (ESR2) estrogen receptors.
Prostate Adenocarcinoma	ESR2	18952763	The purpose of our study was to investigate the effects on PC risk of polymorphisms from three steroid hormone receptor genes: the androgen (AR), and the alpha (ESR1) and beta (ESR2) estrogen receptors.
Prostate Adenocarcinoma	COMT	17760745	We attempted to investigate whether the Val158Met polymorphism of COMT was associated with the risk of prostate cancer.
Prostate Adenocarcinoma	SH3GLB1	18824435	Loss of Bif-1 suppresses the intrinsic pathway of apoptosis and promotes tumorigenesis.
Prostate Adenocarcinoma	TP53	9471864	CONCLUSIONS: Results show that the immunohistochemical expression of gen p53 mutated protein keeps no relation to Gleason's rating index and is seen with significantly higher frequency in advanced, primarily stage D tumours.
Prostate Adenocarcinoma	SLCO1B3	27537383	Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Prostate Adenocarcinoma	ID4	24921661	Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer.
Prostate Adenocarcinoma	TP53	8998185	Several studies have shown that p53 mutations are infrequent in prostate cancer and are associated with advanced disease.
Prostate Adenocarcinoma	RNASEL	19961052	[G138A polymorphism of the RNASEL gene and its association with the development of prostate cancer.
Prostate Adenocarcinoma	KLK3	17425391	P501S labels a subset of PCa cases that are negative for PSA.
Prostate Adenocarcinoma	IGF2	9815946	Recently, a loss of IGF-II imprinting (i.e., biallelic expression) has been found in sporadic Wilm's tumors and lung carcinomas, and this molecular event may contribute to the pathogenesis of these tumors.
Prostate Adenocarcinoma	ID4	24921661	The results demonstrate that ID4 acts as a tumor suppressor in PCa, and its loss, frequently observed in PCa, promotes CRPC through constitutive AR activation.
Prostate Adenocarcinoma	TMPRSS2	18065961	TMPRSS2-ERG gene fusion leading to the androgenic induction of the ERG proto-oncogene expression is a highly prevalent oncogenic alteration in prostate tumor cells.
Prostate Adenocarcinoma	ERG	18065961	TMPRSS2-ERG gene fusion leading to the androgenic induction of the ERG proto-oncogene expression is a highly prevalent oncogenic alteration in prostate tumor cells.
Prostate Adenocarcinoma	TMPRSS2	29629426	TMPRSS2-ERG fusions were detected in six tumors that were classified as squamous carcinoma, five of which were of unknown primary site.
Prostate Adenocarcinoma	ERG	29629426	TMPRSS2-ERG fusions were detected in six tumors that were classified as squamous carcinoma, five of which were of unknown primary site.
Prostate Adenocarcinoma	FGFR4	20876804	In contrast, knockdown of the alternative FGFR4-G388 allele enhanced MT1-MMP and invasive tumor cell growth in vivo and within three-dimensional collagen.
Prostate Adenocarcinoma	MMP14	20876804	In contrast, knockdown of the alternative FGFR4-G388 allele enhanced MT1-MMP and invasive tumor cell growth in vivo and within three-dimensional collagen.
Prostate Adenocarcinoma	ERG	28186998	ETS gene expression (either ERG or ETV1/4/5) was seen in 36% (36/101) of tumors from G84E carriers compared to 68% (65/96) of the controls (p &lt; 0.0001).
Prostate Adenocarcinoma	KRAS	29942138	Conclusion: MALAT1 knockdown inhibited proliferation and migration and facilitated apoptosis by upregulating miR-1 and downregulating KRAS in androgen receptor-negative PCa cells, providing a new insight into the molecular basis of MALAT1 and a potential biomarker or therapeutic target for suppressing castration-resistant PC.
Prostate Adenocarcinoma	MALAT1	29942138	Conclusion: MALAT1 knockdown inhibited proliferation and migration and facilitated apoptosis by upregulating miR-1 and downregulating KRAS in androgen receptor-negative PCa cells, providing a new insight into the molecular basis of MALAT1 and a potential biomarker or therapeutic target for suppressing castration-resistant PC.
Prostate Adenocarcinoma	TP53	9639405	We have previously shown that the type I IFN IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21WAF1 and inhibits the cell cycle of the human prostate adenocarcinoma cell line, DU145, that carries mutations in the tumor suppressor gene products p53 and pRB.
Prostate Adenocarcinoma	IFNA1	9639405	We have previously shown that the type I IFN IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21WAF1 and inhibits the cell cycle of the human prostate adenocarcinoma cell line, DU145, that carries mutations in the tumor suppressor gene products p53 and pRB.
Prostate Adenocarcinoma	RB1	9639405	We have previously shown that the type I IFN IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21WAF1 and inhibits the cell cycle of the human prostate adenocarcinoma cell line, DU145, that carries mutations in the tumor suppressor gene products p53 and pRB.
Prostate Adenocarcinoma	CDH1	11048296	It has been shown that defective function can result from several mechanisms: mutation of the gene, alteration of transcription, post translational modifications or changes in the interaction of E-cadherin with cytoskeleton anchoring proteins: the catenins.
Prostate Adenocarcinoma	MAL	19496069	Inhibition of the molecular adaptors MyD88 and MAL by overexpression of dominant-negative mutants diminished LPS-induced activation of NF-kappaB, showing that DU-145 cells activate the NF-kappaB through MyD88-dependent signaling pathways.
Prostate Adenocarcinoma	NFKB1	19496069	Inhibition of the molecular adaptors MyD88 and MAL by overexpression of dominant-negative mutants diminished LPS-induced activation of NF-kappaB, showing that DU-145 cells activate the NF-kappaB through MyD88-dependent signaling pathways.
Prostate Adenocarcinoma	MYD88	19496069	Inhibition of the molecular adaptors MyD88 and MAL by overexpression of dominant-negative mutants diminished LPS-induced activation of NF-kappaB, showing that DU-145 cells activate the NF-kappaB through MyD88-dependent signaling pathways.
Prostate Adenocarcinoma	CYP17A1	18491956	The aim of the present study was to examine the impact of polymorphisms in prostate-specific antigen (PSA) and androgen-related genes (AR, CYP17, and CYP19) on prostate cancer (PCa) risk in selected high-risk patients who underwent prostate biopsy.
Prostate Adenocarcinoma	CYP19A1	18491956	The aim of the present study was to examine the impact of polymorphisms in prostate-specific antigen (PSA) and androgen-related genes (AR, CYP17, and CYP19) on prostate cancer (PCa) risk in selected high-risk patients who underwent prostate biopsy.
Prostate Adenocarcinoma	CDH1	30006753	E-cadherin loss of expression has been associated with poor prognosis; P-cadherin's role is still elusive.
Prostate Adenocarcinoma	LYVE1	10810359	Mutation of hAR gene is an infrequent event and therefore unlikely to be involved in the development of ovarian cancer.
Prostate Adenocarcinoma	TP53	9815901	In prostate cancer, mutation of the p53 tumor suppressor gene has been associated with locally advanced disease and hormone-resistant disease that is predominantly localized to bone.
Prostate Adenocarcinoma	CDH1	12109783	CONCLUSION: Our preliminary results indicate that, even though we could not demonstrate any significant correlation between E-cadherin staining pattern and tumour invasion and Gleason scores, aberrant staining patterns of E-cadherin may be a significant predictor for disease recurrence following radical prostatectomies if supported by large scale studies.
Prostate Adenocarcinoma	MALAT1	29942138	MALAT1 knockdown inhibited cell proliferation and migration, and promoted cell apoptosis in androgen receptor-negative DU145 and PC3 cells.
Prostate Adenocarcinoma	FADD	19955841	CONCLUSIONS: The phosphorylation status of FADD at serine 194 could strongly affect survival and invasion of prostate cancer cells via modulation of hTERT expression and telomerase activity.
Prostate Adenocarcinoma	TERT	19955841	CONCLUSIONS: The phosphorylation status of FADD at serine 194 could strongly affect survival and invasion of prostate cancer cells via modulation of hTERT expression and telomerase activity.
Prostate Adenocarcinoma	MTAP	26910893	The rate-limiting enzyme involved in this process is methylthioadenosine phosphorylase (MTAP), which, although commonly deleted in many cancers, is protected in prostate cancer.
Prostate Adenocarcinoma	CD9	17406028	Our data suggest that CD9 inactivation may play an important role in prostate cancer progression.
Prostate Adenocarcinoma	ALOX12	21225230	The presence of arachidonate 12-lipoxygenase (12-LOX) potentiates prostate cancer (PCa) progression and therefore may be a good therapeutic target and/or a potential diagnostic predictor for PCa.
Prostate Adenocarcinoma	MYC	32617978	Inhibition of KDM4B significantly inhibited prostate tumor cell growth in xenografts, and improved enzalutamide treatments through suppression of c-Myc.
Prostate Adenocarcinoma	KDM4B	32617978	Inhibition of KDM4B significantly inhibited prostate tumor cell growth in xenografts, and improved enzalutamide treatments through suppression of c-Myc.
Prostate Adenocarcinoma	OLFM4	26581960	Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway.
Prostate Adenocarcinoma	ZNRD2	16480585	CONCLUSION: In north China, p21(cip1) polymorphisms might be correlated with the susceptibility of ESCC, p27(kip1) polymorphisms might be correlated with the susceptibilities of ESCC and GCA, and they might have synergetic effect on ESCC and GCA development.
Prostate Adenocarcinoma	CDKN1A	16480585	CONCLUSION: In north China, p21(cip1) polymorphisms might be correlated with the susceptibility of ESCC, p27(kip1) polymorphisms might be correlated with the susceptibilities of ESCC and GCA, and they might have synergetic effect on ESCC and GCA development.
Prostate Adenocarcinoma	CDKN1B	16480585	CONCLUSION: In north China, p21(cip1) polymorphisms might be correlated with the susceptibility of ESCC, p27(kip1) polymorphisms might be correlated with the susceptibilities of ESCC and GCA, and they might have synergetic effect on ESCC and GCA development.
Prostate Adenocarcinoma	BRCA2	25154392	CONCLUSIONS: PDXs revealed IDC-P in patients with germline BRCA2 mutations or BRCAX classification, identifying aggressive tumours with poor survival even when the stage and grade of cancer at diagnosis were similar.
Prostate Adenocarcinoma	BRCA3	25154392	CONCLUSIONS: PDXs revealed IDC-P in patients with germline BRCA2 mutations or BRCAX classification, identifying aggressive tumours with poor survival even when the stage and grade of cancer at diagnosis were similar.
Prostate Adenocarcinoma	SLCO1B3	27537383	Loss of the drug transporter SLCO1B3 may drive taxane resistance in prostate cancer.
Prostate Adenocarcinoma	TMPRSS2	24762546	TMPRSS2:ERG fusions, in combination with deletion of the phosphatase and tensin homolog (PTEN) tumor suppressor, have been suggested to cooperatively drive tumor progression in prostate cancer.
Prostate Adenocarcinoma	PTEN	24762546	TMPRSS2:ERG fusions, in combination with deletion of the phosphatase and tensin homolog (PTEN) tumor suppressor, have been suggested to cooperatively drive tumor progression in prostate cancer.
Prostate Adenocarcinoma	ERG	24762546	TMPRSS2:ERG fusions, in combination with deletion of the phosphatase and tensin homolog (PTEN) tumor suppressor, have been suggested to cooperatively drive tumor progression in prostate cancer.
Prostate Adenocarcinoma	LRRC26	24906643	LRRC26 knockdown also increased myogenic tone over a range (40-100 mm Hg) of intravascular pressures, and reduced vasoconstriction to iberiotoxin and vasodilation to NS1619, BK channel inhibitors and activators, respectively.
Prostate Adenocarcinoma	FGF3	1552612	These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung.
Prostate Adenocarcinoma	RB1	1552612	These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung.
Prostate Adenocarcinoma	PLAU	1552612	These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung.
Prostate Adenocarcinoma	MYC	1552612	These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung.
Prostate Adenocarcinoma	TP53	1552612	These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung.
Prostate Adenocarcinoma	ERBB2	1552612	These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung.
Prostate Adenocarcinoma	KLK2	12805332	Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection.
Prostate Adenocarcinoma	NRG4	20959441	Expression of neuregulin 4 splice variants in normal human tissues and prostate cancer and their effects on cell motility.
Prostate Adenocarcinoma	CLOCK	29455641	BACKGROUND: Dysfunction of the circadian clock and single polymorphisms of some circadian genes have been linked to cancer susceptibility, although data are scarce and findings inconsistent.
Prostate Adenocarcinoma	AR	30642743	The silencing of MALAT1 inhibited dihydrotestosterone (DHT) administration-induced acceleration of proliferation and cell cycle progression, and increase of AR expression in prostate cancer cells.
Prostate Adenocarcinoma	MALAT1	30642743	The silencing of MALAT1 inhibited dihydrotestosterone (DHT) administration-induced acceleration of proliferation and cell cycle progression, and increase of AR expression in prostate cancer cells.
Prostate Adenocarcinoma	MT1G	15894685	Here, we investigated whether promoter methylation might cause MT1G silencing in prostate cancer.
Prostate Adenocarcinoma	MT1G	15894685	MT1G hypermethylation was more frequent in prostate cancer that spread beyond the prostate capsule.
Prostate Adenocarcinoma	PTEN	9458379	The newly identified putative tumor suppressor gene PTEN, located at #10q23, might be responsible for the frequently observed allelic deletions from #10q23-25 in prostate cancer.
Prostate Adenocarcinoma	AR	14739057	Amplification and mutations of the androgen receptor (AR) gene have been described as well as alterations in cofactor expression and crosstalk with other signalling pathways.
Prostate Adenocarcinoma	AR	15665279	Here, we show that BPA cooperates with androgen to activate AR-T877A as shown by both reporter assays and increased levels of prostate-specific antigen expression.
Prostate Adenocarcinoma	FRG1	30975102	To understand the mechanism, we checked expression of various cytokines and MMPs by q-RT PCR, signaling molecules by western blot, in FRG1 perturbation sets.
Prostate Adenocarcinoma	MMP1	30975102	To understand the mechanism, we checked expression of various cytokines and MMPs by q-RT PCR, signaling molecules by western blot, in FRG1 perturbation sets.
Prostate Adenocarcinoma	AR	21302606	The potential mechanisms involving the genesis and growth of androgen-independent prostate cancer include super-expression of the androgen receptor (AR), in an attempt to compensate for the low androgenic plasma levels and mutations of this specific receptor, which could determine resistance to anti-androgenic therapy.
Prostate Adenocarcinoma	COMT	17760745	The Val158Met polymorphism of the catechol-O-methyltransferase gene is not associated with the risk of sporadic or latent prostate cancer in Japanese men.
Prostate Adenocarcinoma	CLU	9415971	The testosterone-repressive prostate message-2 (TRPM-2) variant mRNA lacking the exon 5 was induced in rat primary culture hepatocytes by heat shock treatment.
Prostate Adenocarcinoma	CLU	9415971	On the other hand, in mouse cell line L929, heat shock treatment induced a variant TRPM-2 mRNA lacking only a small region located in exon 5.
Prostate Adenocarcinoma	ERG	32639612	CONCLUSIONS: ERG gene fusions are present in these rare prostate cancer variants with a close frequency to conventional prostate cancer (9/19, 47%).
Prostate Adenocarcinoma	AR	15665279	We have shown previously that a known xenoestrogen, bisphenol A (BPA), activates a tumor-derived AR mutant (T877A), leading to androgen-independent prostate cancer cell proliferation.
Prostate Adenocarcinoma	CAMKK2	30242113	They also suggest that inhibition of CAMKK2 combined with activation of AMPK would offer an efficacious therapeutic strategy in treatment of prostate cancer.
Prostate Adenocarcinoma	EPHX1	22103900	The aim of this study was to use a population-based case-control study to investigate whether or not such genetic polymorphisms in EPHX1 gene can modify the relationship between smoking status and the risk of developing prostate cancer.
Prostate Adenocarcinoma	MAPK8	11880182	Over expression of wild type JNK1 by transient transfection enhanced apoptosis in response to methionine restriction, whereas over expression of a kinase inactive mutant of JNK1 protected PC-3 human prostate cancer cells from apoptosis.
Prostate Adenocarcinoma	SPOP	29202479	Nearly 50% of prostate cancers harbor gene fusions that lead to overexpression of the transcription factor ERG, while a mutually exclusive 10% of prostate cancers harbor recurrent mutations in the gene encoding the E3 ubiquitin ligase SPOP.
Prostate Adenocarcinoma	ERG	29202479	Nearly 50% of prostate cancers harbor gene fusions that lead to overexpression of the transcription factor ERG, while a mutually exclusive 10% of prostate cancers harbor recurrent mutations in the gene encoding the E3 ubiquitin ligase SPOP.
Prostate Adenocarcinoma	MT1G	15894685	MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Prostate Adenocarcinoma	CD44	11582589	RESULTS: The correlation between the methylation status of CD44 gene and the stage progression of prostate cancer was statistically significant (P = 0.0438).
Prostate Adenocarcinoma	FHIT	15705877	Our results strongly suggest involvement of germline variations of FHIT in prostate cancer risk.
Prostate Adenocarcinoma	TP53	8627854	However, our study demonstrates that p53 alterations are found in the preponderant majority of post-radiation locally recurrent prostatic carcinoma specimens.
Prostate Adenocarcinoma	IL1B	11774033	Inhibition of IL-6 activity attenuated IL-1beta-induced promatrilysin, but not NFkappaB transactivation activity indicating that IL-6 acts downstream of NFkappaB in potentiation of IL-1beta-mediated promatrilysin expression.
Prostate Adenocarcinoma	NFKB1	11774033	Inhibition of IL-6 activity attenuated IL-1beta-induced promatrilysin, but not NFkappaB transactivation activity indicating that IL-6 acts downstream of NFkappaB in potentiation of IL-1beta-mediated promatrilysin expression.
Prostate Adenocarcinoma	PTEN	31111513	PTEN loss was significantly (P &lt; 0.05) associated with increasing GG, poorly formed glands (74% of total cases with loss vs 49% of intact), and three well-validated unfavorable pathological features: intraductal carcinoma of the prostate (IDC-P) (69% of total cases with loss vs 12% of intact), cribriform Gleason pattern 4 (38% of total cases with loss vs 10% of intact) and stromogenic PCa (23% of total cases with loss vs 6% of intact).
Prostate Adenocarcinoma	CAMKK2	30242113	Moreover, either deletion of CAMKK2 or activation of AMPK reduced cell growth in human prostate cancer cells by inhibiting de novo lipogenesis.
Prostate Adenocarcinoma	TP53	7508886	These results suggest that p53 overexpression might be associated with the known proliferative capacity of basal cells in benign hyperplastic prostate glands, and that mutations of p53 might play a role in the pathogenesis of a subset of high-grade prostate adenocarcinomas.
Prostate Adenocarcinoma	ERG	28547958	A significant proportion of these cancers have a recurrent translocation involving ETS family genes, which leads to the overexpression of ERG transcription factor.
Prostate Adenocarcinoma	SPOP	29202479	SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Prostate Adenocarcinoma	ERG	29202479	SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Prostate Adenocarcinoma	TP53	9815901	These results indicate that p53 abnormalities are associated with lymph node metastases derived from prostate cancer patients that had not undergone hormonal therapy.
